Clinical Trials on Alzheimer's Disease

Scientific program

www.ctad-alzheimer.com

November 5-7, 2015
BARCELONA
Keynote speakers

Marilyn S. Albert, PhD, is the Director of the Division of Cognitive Neuroscience in the Department of Neurology at the Johns Hopkins University School of Medicine and Director of the Johns Hopkins Alzheimer’s Disease Research Center. She is Professor of Neurology at the Johns Hopkins University School of Medicine, with joint appointments in five additional departments: (1) Neuroscience, (2) Psychiatry and Behavioral Sciences, (3) Pathology, (4) Psychology and Brain Sciences, and (5) Mental Health. Dr. Albert received her PhD in Psychology from McGill University in 1969. She joined the faculty of the Harvard Medical School in Boston in 1980 and was appointed Professor at the medical school in 1997. She was Director of the Gerontology Research Unit at Massachusetts General Hospital from 1981-2003, when she moved to the Johns Hopkins School of Medicine in Baltimore, MD. Dr. Albert served as President of the International Neuropsychological Society in 1996. She was the Chair of the Medical & Scientific Advisory Committee of the national Alzheimer’s Association in the U.S. from 2002-2005 and completed an 8-year term as member of the national Board of the Alzheimer’s Association in 2009. Her major research interests are in the area of cognitive change with age, disease-related changes of cognition (with a particular focus on the early diagnosis of Alzheimer’s disease). Her research has focused on the relationship of cognitive change to brain structure and function, as assessed through imaging, cerebrospinal fluid and other biomarkers. She has authored over 220 peer-reviewed publications. She is the recipient of three awards for her research in Alzheimer’s disease: (1) the Ronald and Nancy Reagan Institute Award, given in 2006, (2) the Leon Thal Award from the Lou Ruvo Brain Institute, given in 2008, and (3) the Zaven Khatchaturian Award from the Alzheimer’s Association, given in 2010.

Suzanne B. Hendrix, PhD, has spent the last 24 years as a statistician focusing on clinical trial research in many different indications. She has extensive experience designing clinical trials, writing statistical analysis plans, running analyses, writing statistical reports, interacting with the FDA and preparing manuscripts for publication. She is experienced at communicating statistical concepts in an understandable way, and has helped develop software for graphically understanding large complex datasets. For the past 8 years, she has focused on statistical issues in Alzheimer’s disease such as identifying appropriate outcomes, addressing measurement issues, demonstrating disease modification and optimizing clinical trial design and analysis. She has been on multiple advisory boards and expert panels, convened to address current issues in Alzheimer’s disease, and has interacted with the division of Neurology products at the FDA and with the EMA through scientific advice regarding these issues. She currently heads up Pentara, a company that provides data management and statistical consultation to the pharmaceutical industry, academic groups and non-profits, primarily supporting clinical trial design and optimization in neurological indications, particularly Alzheimer’s disease. She has researched methods for discerning disease modification of treatments, and has proposed novel approaches to this problem.

Simon Lovestone, PhD, MRCPsych is Professor of Old Age Psychiatry and Neuroscience at the Institute of Psychiatry, King’s College London. He has made significant contributions to several areas of Alzheimer’s disease research, particularly his work concerning the role of glycogen synthase kinase 3 which provides a potential route to novel therapeutic agents. Professor Lovestone has also worked on biomarkers for Alzheimer’s where he has shown that peripheral blood could provide useful biomarkers of disease. He has been a significant contributor to the UK-USA genetics collaboration that has made important discoveries in recent years in genetic susceptibility to Alzheimer’s. Besides these laboratory contributions he has also investigated the burden experienced by carers responsible for Alzheimer’s patients and the effects of pre-morbid personality on age of onset.
Ronald C. Petersen, Ph.D., M.D. is Professor of Neurology, Cora Kanow Professor of Alzheimer’s Disease Research, and he is currently the Director of the Mayo Alzheimer’s Disease Research Center and the Mayo Clinic Study of Aging and has authored over 600 peer-reviewed articles on memory disorders, aging, and Alzheimer’s disease. He has edited five books, Memory Disorders, Mayo Clinic on Alzheimer’s Disease, Mild Cognitive Impairment: Aging to Alzheimer’s Disease, FMayo Clinic Guide to Alzheimer’s Disease and Mayo Clinic on Alzheimer’s Disease (2013)ii. Dr. Petersen is one of the recipients of the 2004 MetLife Award for Medical Research in Alzheimer’s Disease and the 2005 Potamkin Prize for Research in Picks, Alzheimer’s and Related Disorders of the American Academy of Neurology. Dr. Petersen also received the inaugural Ronald and Nancy Reagan Research Institute Award in 2004 from the Alzheimer’s Association and the inaugural Leon Thal Prize of the Lou Ruvo Brain Institute in 2007. In 2012 he received the Khachaturian Award of the Alzheimer’s Association and the Henry Wisniewski Lifetime Achievement Award in 2013. In 2011 he was appointed by the Secretary of Health and Human Services, Kathleen Sebelius, to serve as the Chair of the Advisory Committee on Research, Care and Services for the National Alzheimer’s Project Act. Recently, he was appointed to the World Dementia Council by the UK government.

Philip Scheltens, MD, PhD is Professor of Cognitive Neurology and Director of the Alzheimer Centre at the VU University Medical Center in Amsterdam, as well as Honorary Professor of Neurology at University College London. From 2011 onwards he is also scientific director of the Dutch Pearlsring Institute (PSI). In 2013 he was appointed vice-chair of the board of the Dutch “Deltaplan Dementie”. His main clinical and research interests are dementia in the broadest sense, from basic research to care and translational research. He is active in the field of biomarkers and clinical trials and has been the (inter) national PI for many studies, including Phase I–III multicentre clinical trials. He is founder of, and has directed since 2000, the VUmc Alzheimer Center, which during this time has produced over 50 PhD theses. He also founded the Alzheimer Research Center, a center dedicated to and specialised in Alzheimer clinical trials, of which he is now scientific adviser and member of the Board of Trustees. Dr Scheltens is an active member of several societies, including the Dutch Society for Neurology, the AAN, the Alzheimer Imaging Consortium, the ISTAART Consortium, and the ECNP. He has been instrumental in organising several national and international conferences, including the Imaging Symposium attached to ICAD. He is past chair of the dementia panel of the EFNS. He was Associate Editor of the Journal of Neurology, Neurosurgery and Psychiatry until 2010. He was Chief Editor of the official journal of the Dutch Society of Neurology until November 2008. He is co-editor-in-chief of Alzheimer’s Research & Therapy and acts as an ad hoc reviewer of scientific articles for all of the major journals. He has authored >665 peer reviewed papers and >50 book chapters. Dr Scheltens co-edited the books, Magnetic Resonance in Dementia (Springer), Neuroimaging in dementia (Springer) and Functional Magnetic Resonance Imaging: Clinical Applications (Oxford University Press). He was one of the founding fathers of, and has acted as Treasurer of the International Society for Vascular Behavioural and Cognitive Disorders (Vas-Cog), until 2011. He was elected member of the Royal Academy of Arts and Sciences in 2011 and act as secretary of the Medicine Section since 2012.

Eric Siemers, M.D. is a Distinguished Medical Fellow of the Alzheimer’s Disease Global Development Team at Eli Lilly and Company. He earned his MD with highest distinction from the Indiana University School of Medicine in 1982. After an internship in the Department of Internal Medicine at the Indiana University School of Medicine, he completed his residency in the Department of Neurology in 1986. Prior to joining Lilly, he founded and headed the Indiana University Movement Disorder Clinic; his previous research included investigations of Parkinson’s disease and Huntington’s disease, and he established one of the first centers for surgical PD treatments in the US. Dr. Siemers currently directs late stage clinical research efforts at Lilly concerning investigational treatments for Alzheimer’s disease, and is more broadly involved with other neurological indications such as Parkinson’s disease. Major research interests include the use of biomarkers in investigational drug research and the development of trial designs that broadly characterize the effects of investigational drugs on chronic diseases. Dr. Siemers is a founding member of the Alzheimer’s Association Research Roundtable and is currently serving as Chair. He is a member of the Steering Committee for the Alzheimer’s Disease Neuroimaging Initiative (ADNI), which is funded by the National Institute on Aging and a consortium of pharmaceutical companies. He served as the chair of the Industry Scientific Advisory Board for ADNI in 2007 and previously served as a member of the Resource Allocation Request Committee. Dr. Siemers is a current member of the New York Academy of Sciences Alzheimer’s Disease Leadership Counsel. He participated as a member of the NIA working group that proposed criteria for preclinical Alzheimer’s disease in 2011. He is a past member of the Board of Directors of the American Society of Experimental Neurotherapeutics.
# Program at a glance

## Thursday, November 5th

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00 - 8.30 am</td>
<td>WELCOME BY THE ORGANIZING COMMITTEE AND THE LOCAL BARCELONA COMMITTEE</td>
</tr>
<tr>
<td>8.30 - 9.00 am</td>
<td><strong>KEYNOTE 1</strong>&lt;br&gt;Blood-based biomarkers for AD clinical trials</td>
</tr>
<tr>
<td>9.00 - 10.00 am</td>
<td><strong>ORAL COMMUNICATIONS</strong>&lt;br&gt;Hot topics in AD clinical trials</td>
</tr>
<tr>
<td>10.30 - 12.00 pm</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
</tr>
<tr>
<td>12.00 - 12.30 pm</td>
<td><strong>PRESENTATION AND PANEL DISCUSSION</strong></td>
</tr>
<tr>
<td>12.30 - 1.00 pm</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
</tr>
<tr>
<td>2.00 - 3.00 pm</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
</tr>
<tr>
<td>3.00 - 3.30 pm</td>
<td><strong>KEYNOTE 2</strong>&lt;br&gt;The BIOCARD Study: Lessons for Clinical Trials in Preclinical AD</td>
</tr>
<tr>
<td>3.30 - 4.15 pm</td>
<td><strong>ORAL COMMUNICATIONS</strong>&lt;br&gt;Hot topics in AD clinical trials</td>
</tr>
<tr>
<td>4.15 - 5.00 pm</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
</tr>
<tr>
<td>5.30 - 6.00 pm</td>
<td><strong>KEYNOTE 3</strong>&lt;br&gt;Drug development in AD: point of view from the industry</td>
</tr>
<tr>
<td>6.00 - 7.00 pm</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong></td>
</tr>
</tbody>
</table>
## Friday, November 6th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>7.45 - 8.00 am</td>
<td>LATE BREAKING ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td>8.00 - 8.30 am</td>
<td>KEYNOTE 4</td>
</tr>
<tr>
<td></td>
<td>Speeding up drug development: using sensitive biological measure</td>
</tr>
<tr>
<td>8.30 - 9.30 am</td>
<td>Symposium 1</td>
</tr>
<tr>
<td></td>
<td>Prospective Readiness Cohorts, Internet-based Registries and Matching Services for Alzheimer’s Disease Clinical Trials</td>
</tr>
<tr>
<td>9.30 - 10.15 am</td>
<td>ORAL COMMUNICATIONS SESSION</td>
</tr>
<tr>
<td>10.15 - 11.00 am</td>
<td>ORAL COMMUNICATIONS</td>
</tr>
<tr>
<td></td>
<td>Hot topics in AD clinical trials</td>
</tr>
<tr>
<td>11.30 - 1.00 pm</td>
<td>LATE BREAKING ORAL COMMUNICATIONS (2)</td>
</tr>
<tr>
<td></td>
<td>Lunch Break and poster sessions 2 - Gaudi Mezzanine Level</td>
</tr>
<tr>
<td>1.30 - 3.00 pm</td>
<td>Symposium 2</td>
</tr>
<tr>
<td></td>
<td>The Lancet and The Lancet Neurology Symposium on Clinical Research in Dementia: Increasing Value and Reducing Waste</td>
</tr>
<tr>
<td>3.00 - 4.30 pm</td>
<td>ORAL COMMUNICATIONS SESSION</td>
</tr>
<tr>
<td></td>
<td>Poster sessions 2 and coffee break - Gaudi Mezzanine Level</td>
</tr>
<tr>
<td>5.00 - 5.30 pm</td>
<td>KEYNOTE 5</td>
</tr>
<tr>
<td></td>
<td>MCI as a Drug Target: Acceptable or Too Late?</td>
</tr>
<tr>
<td>5.30 - 6.30 pm</td>
<td>Symposium 3</td>
</tr>
<tr>
<td></td>
<td>Utility of multi-modal biomarker-endpoint trials in high-risk persons to identify candidate agents for AD prevention trials</td>
</tr>
<tr>
<td>6.30 - 7.00 pm</td>
<td>ORAL COMMUNICATIONS SESSION</td>
</tr>
</tbody>
</table>

## Saturday, November 7th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8.00 - 8.30 am</td>
<td>KEYNOTE 6</td>
</tr>
<tr>
<td></td>
<td>Construction of cognitive composites for early-stage clinical trials</td>
</tr>
<tr>
<td>8.30 - 9.30 am</td>
<td>Symposium 4</td>
</tr>
<tr>
<td></td>
<td>Observational cohorts and global initiatives for the prevention of Alzheimer’s disease</td>
</tr>
<tr>
<td>9.30 - 10.15 am</td>
<td>ORAL COMMUNICATIONS SESSION</td>
</tr>
<tr>
<td>10.15 - 11.15 am</td>
<td>Symposium 5</td>
</tr>
<tr>
<td></td>
<td>Tau Spread, PET Tracers and Immunotherapy</td>
</tr>
<tr>
<td>11.45 - 1.00 pm</td>
<td>ORAL COMMUNICATIONS SESSION</td>
</tr>
</tbody>
</table>
Welcome by the Organizing Committee - Paul Aisen, Jacques Touchon, Bruno Vellas, Mike Weiner - Catalunya

Presentation of the CiAD Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research to Dr. Professor Gordon K Wilcock, DM, FRCP, (Hon) DSc Emeritus Professor of Gerontology University of Oxford, Oxford - UK

KEYNOTE 1
Introduction: Mike Weiner
Blood-based biomarkers for AD clinical trials
Simon Lovestone MD, PhD, University of Oxford, Oxford, UK

OC1 - Magnitude of delay in Aβ-related memory decline in APOE ε4 non-carriers: Implications for clinical trials in preclinical Alzheimer’s disease
Paul Maruff (1,2), Yen Ying Lim (1), Simon M. Laws (3), Victor L. Villenmagne (1), David Ames (1), Christopher Fowler (1), Christopher C. Rowe (1), Colin L. Masters (1)
(1) The University of Melbourne, Parkville, Victoria, Australia; (2) CogState Ltd., Melbourne, Victoria, Australia; (3) Centre of Excellence for Alzheimer’s Disease Research and Care, Edith Cowan University, Perth, Australia

OC2 - The active vaccine AADvac1 against pathological tau displays an excellent safety and immunogenicity profile in the phase 1 study
Petr Novak, MD, PhD (1), Matej Ondrus, MD (1), Reinhold Schmidt, Prof., MD, PhD (2), Stanislav Katina, Assoc. Prof., PaedDr., RNDr., PhD (1), Eva Kontsekova, Prof., RNDr., PhD, DrSc. (1), Michal Novak, Prof., MVD, PhD, DrSc. (1)
(1) AXON Neuroscience SE, Bratislava, Slovakia; (2) Department of Neurology, Medical University of Graz, Austria

OC3 - A Phase II trial of AAV2-NGF in Mild to Moderate Alzheimer’s Disease
Michael S. Rafii, MD, PhD (1,2), Ronald G. Thomas (1,2), Sarah Walter (3), Mark Tuszynski (2), PS Aisen (3) for the ADCS
(1) Alzheimer’s Disease Cooperative Study (ADCS), (2) Department of Neuroscience, University of California, San Diego, (3) Alzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego

OC4 - Efficacy and safety of gantenerumab from the Phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD
Robert Lasser, MD, MBA (1), Susanne Ostrowitzki, MD (2), Philip Scheltens, MD, PhD (3), Mercè Boada, MD, PhD (4), Bruno Dubois, MD (5), Ernest Dorflinger, MD (7), Bogdan Balas, MD (1), Tania Nikolcheva, MD, PhD (2), Dietmar Volz, PhD (1), Elizabeth Ashford, BSc (6), Sylvie Retout, PhD, Chris Edgar, PhD (6), George Garibaldi, MD (7), Paulo Fontoura, MD, PhD (1), Luca Santarelli, MD (2)
(1) F. Hoffmann-La Roche Ltd, Basel, Switzerland; (2) Roche Pharmaceutical Research & Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland; (3) Department of Neurology and Alzheimer Center, VU University Medical Center, MB Amsterdam, the Netherlands; (4) Memory Clinic of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; (5) Institut de la Mémoire et de la Maladie d’Alzheimer and INSERM, Hôpital La Salpêtrière, UPMC University, Paris, France; (6) Roche Products Limited, Welwyn Garden City, UK; (7) Formerly of F. Hoffmann-La Roche Ltd, Basel, Switzerland

OC5 - CSF and amyloid PET biomarker data from the Phase 3 SCarlet RoAD trial, a study of gantenerumab in patients with prodromal AD
Tania Nikolcheva, MD, MBE (1), Robert Lasser, MD, PhD (1), Susanne Ostrowitzki, MD (1), Philip Scheltens, MD, PhD (3), Mercè Boada, MD, PhD (4), Bruno Dubois, MD, PhD (5), Ernest Dorflinger, MD (6), Dietmar Volz, PhD (2), Udo Eichenlaub, MEng, PhD (7), Christina Rabe, PhD (7), Tobias Bittner, PhD (7), Markus Schmitz, PhD (7), Chris Edgar, PhD (8), George Garibaldi, MD (6), Paulo Fontoura, MD, PhD (2), Luca Santarelli, MD (1)
(1) Roche Pharmaceutical Research & Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland; (2) F. Hoffmann-La Roche Ltd, Basel, Switzerland; (3) Department of Neurology and Alzheimer Center, VU University Medical Center, MB Amsterdam, the Netherlands; (4) Memory Clinic of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; (5) Institut de la Mémoire et de la Maladie d’Alzheimer and INSERM, Hôpital La Salpêtrière, UPMC University, Paris, France; (6) Formerly of F. Hoffmann-La Roche Ltd, Basel, Switzerland; (7) Roche Diagnostics GmbH, Penzberg, Germany; (8) Roche Products Limited, Welwyn Garden City
**CTAD 2015 Program**

**Thursday, November 5th**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.45 am</td>
<td><strong>LATE BREAKING COMMUNICATION</strong></td>
</tr>
<tr>
<td></td>
<td><strong>OC6 - Sembragiline in moderate Alzheimer’s disease dementia: results of a phase 2 trial (Mayflower RoAD)</strong></td>
</tr>
<tr>
<td></td>
<td>Stephane Nave (1), Rachelle S. Doody (2), Mercè Boada Rovira (3), Timo Grimmer (4), Juha Savola (1), Paul Delmar (1), Meike Pauly-Evers (1), Tania Nikitcheva (1), Christian Czech (1), Edilvio Borrioni (1), Bénédicte Ricci (1), Emma Moran (6), Marie Mannino (5), Irene Gerlach (1), Paolo Fontoura (1), Luca Santarelli (1), Sembragiline study group</td>
</tr>
<tr>
<td></td>
<td>(1) Roche Pharma Research &amp; Early Development, Roche Innovation Center Basel, F.Hoffmann-La Roche Ltd, Switzerland; (2) Alzheimer’s Disease and Memory Disorders Center, Department of Neurology, Baylor College of Medicine, Houston, USA; (3) Memory Clinic of Fundación ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; (4) Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technische Universität München, Munich, Germany; (5) Roche Safety Risk Management, Licensing &amp; Early Development, F.Hoffmann-La Roche Ltd, New York, USA; (6) Roche Products Limited, Roche Innovation Center Welwyn, Welwyn Garden City, UK</td>
</tr>
<tr>
<td>11.00 am</td>
<td><strong>OC7 - Prevention of Dementia by Intensive Vascular Care (preDIVA) – preliminary findings from a randomised controlled trial</strong></td>
</tr>
<tr>
<td></td>
<td>Edo Richard (1,2), Eric Moll van Charante (3), Lisa Eurelings (1), Jan-Willem van Dalen (1), Suzanne Ligthart (3), Marieke Hoevenaar-Blom (1), Willem A. van Gool (1)</td>
</tr>
<tr>
<td></td>
<td>(1) Dept of neurology, Academic Medical Center, University of Amsterdam, the Netherlands; (2) Dept of neurology, Radboud University Medical Center, Nijmegen, the Netherlands; (3) Dept of primary care, Academic Medical Center, University of Amsterdam, the Netherlands</td>
</tr>
<tr>
<td>11.15 am</td>
<td><strong>LATE BREAKING COMMUNICATION</strong></td>
</tr>
<tr>
<td></td>
<td><strong>OC8 - Randomized, Placebo-Controlled, Phase 1b Study of the Anti-β-Amyloid Antibody Aducanumab (BILB037) in Patients With Prodromal or Mild Alzheimer’s Disease: Interim Results From a Subpopulation of Patients With Early Alzheimer’s Disease Meeting Phase 3 Study Entry Criteria</strong></td>
</tr>
<tr>
<td></td>
<td>Vissia Violetta, MD, PhD (1); Xiaopeng Mao, PhD (1); Tianle Chen, PhD (1); John O’Gorman, PhD (1); Leslie Williams, DVM, MPH (1); Yan Ling, MD (1); Jeff Sevigny, MD (1) (1) Biogen, Cambridge, MA, USA</td>
</tr>
<tr>
<td>11.30 am</td>
<td><strong>OC9 - FINGER - A Multidomain Two-Year Randomised Trial to Prevent Cognitive Decline</strong></td>
</tr>
<tr>
<td></td>
<td>Miia Kivipelto for the FINGER Study Group</td>
</tr>
<tr>
<td>11.45 am</td>
<td><strong>OC10 - Imaging Dementia—Evidence for Amyloid Scanning (IDEAS): A Study to Evaluate the Clinical Utility of Amyloid PET in U.S. Medicare Beneficiaries</strong></td>
</tr>
<tr>
<td></td>
<td>Gil D. Rabionovic MD, (1) Bruce E. Hilner MD, (2) Rachel A. Whitmer PhD, (3) Maria C. Carrillo PhD, (4), Constantine A. Gatsonis PhD, (5), Barry A. Siegel MD, (6), James A. Hendrix, PhD (4)</td>
</tr>
<tr>
<td></td>
<td>(1) Memory and Aging Center and Dept. of Neurology, University of California San Francisco, USA; (2) Dept. of Internal Medicine, Virginia Commonwealth University, Richmond, VA, USA; (3) Kaiser Permanente Division of Research, Oakland, CA, USA; (4) Alzheimer’s Association, Chicago, IL, USA; (5) Department of Biostatistics, Brown University School of Public Health, Providence, RI, USA; (6) Mailman School of Public Health, New York, USA</td>
</tr>
<tr>
<td>12.00 pm</td>
<td><strong>PRESENTATION AND PANEL DISCUSSION</strong></td>
</tr>
<tr>
<td></td>
<td><strong>OC11 - A combined measure of cognition and function for clinical trials: The Integrated Alzheimer’s Disease Rating Scale</strong></td>
</tr>
<tr>
<td></td>
<td>Aliette Wessels (1), Eric Siemers (1), Peng Yu (1), Scott Andersen (1), John Sims (1), Yaakov Stern (2),loreine Renz (3), Bruno Dubois (4), Roy Jones (5), Jeffrey Cummings (6), Paul Aisen (7)</td>
</tr>
<tr>
<td></td>
<td>(1) Eli Lilly and Company, Indianapolis, IN, USA; (2) Department of Neurology, Columbia University Medical Center, New York, NY, USA; (3) United States, (4) Department of Neurology, Massachusetts General Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, (5) Centre des Maladies Cognitives et Compromissantes (IMDA), Institut du Cerveau et de la Moelle épineure (ICM), UMR-S975, Université Pierre et Marie Curie- Paris - Hôpital de la Salpêtrière - Paris, France, (5) RICE (The Research Institute for the Care of Older People), Bath, UK, (6) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada, USA, (7) University of Southern California, CA, USA</td>
</tr>
<tr>
<td>12.30 pm</td>
<td><strong>OC12 - Using all your data: Combining Area Under the Curve and Multidomain Composite Endpoints in Efficacy Analyses</strong></td>
</tr>
<tr>
<td></td>
<td>Allirea Atri MD, PhD (1,2)</td>
</tr>
<tr>
<td></td>
<td>(1) Ray Dolby Brain Health Center, California Pacific Medical Center, and Sutter Health, San Francisco, CA, USA; (2) Harvard Medical School, Boston, MA, USA</td>
</tr>
<tr>
<td>12.45 pm</td>
<td><strong>LATE BREAKING COMMUNICATION</strong></td>
</tr>
<tr>
<td></td>
<td><strong>OC13 - Assessment of plasma Aβ markers to estimate dichotomous amyloid PET among cognitively healthy people</strong></td>
</tr>
<tr>
<td></td>
<td>Pedro Pesini, PhD (1), Virginia Pérez-Grijalba, BS (1), Noelia Fandos, BS (1), Salvador Olmos, PhD (2), Matías Bossa, PhD (2), Colin Masters, MD, PhD (3), Victor Villemagne, MD, PhD (4), James Doecke, PhD (5), Chris Fowler, MD, PhD (3), Alan Rembach MD, PhD (3), Manuel Sarasa, PhD (1) and the AIBL research group (6)</td>
</tr>
<tr>
<td></td>
<td>(1) Araclon Biotech, Zaragoza, Spain; (2) Aragon Institute of Engineering Research, University of Zaragoza, Spain; (3) The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, VIC, Australia; (4) Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia; (5) The Australian E-Health Research Centre, Royal Brisbane and Women’s Hospital, Herston, QLD, Australia; (6) <a href="http://www.aibl.csiro.au/">http://www.aibl.csiro.au/</a></td>
</tr>
<tr>
<td>1.00 pm</td>
<td><strong>Lunch and poster sessions 1</strong></td>
</tr>
<tr>
<td></td>
<td>Gaudi Mezzanine Level</td>
</tr>
</tbody>
</table>
## CTAD 2015 Program

### Thursday, November 5th

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.00 pm</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong> - Catalunya</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> Carole Dufouil, Mike Rafi</td>
<td></td>
</tr>
<tr>
<td>2.00 pm</td>
<td><strong>OC14</strong> - Hippocampus volume loss in Alzheimer’s disease patients: effect of treatment with choline alphascerate in addition to cholinesterase inhibitor</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Enea Traini, PhD (1), Anna Carotenuto, PhD (1, 2), Angiola Maria Fasanaro, MD (1, 2), Raffaele Rea, PhD (1, 2), Francesco Amenta, MD (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1) Centre for Clinical Research, Telemedicine and Telepharmacy, University of Camerino, Camerino, Italy; (2) Alzheimer Evaluation Unit, National Hospital, “A. Cardarelli”, Naples, Italy</td>
<td></td>
</tr>
<tr>
<td>2.15 pm</td>
<td><strong>OC15</strong> - Short-interval MRI atrophy rates and implications for clinical trial design</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alexander J. McFaulkes, MRCP, DPhel (1), Jennifer M. Nicholas, PhD (1, 2), Ian B. Malone, PhD (1), Chris Frost, MA, DipStat (1, 2), Nick C. Fox, MD, FRCP, FMedSci (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1) Dementia Research Centre, UCL Institute of Neurology, London, UK; (2) London School of Hygiene and Tropical Medicine, London, UK</td>
<td></td>
</tr>
<tr>
<td>2.30 pm</td>
<td><strong>OC16</strong> - Impact of a multi-domain intervention on brain atrophy rate: the MAPT MRI ancillary study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carole Dufouil, PhD (1), Jean-François Mangin, PhD (2), Ali Bouyahia, MD (3), Michèle Allard, MD (4), Frédéric Ricolfi, MD (5), Dominique Dubois, MD (6), Marie Paule Bonecour Martel, MD (7), François Cotton, MD (8), Alain Bonafé, MD (9), Stéphane Chanalet, MD (10), Franoise Hugon, MD (11), Fabrice Bonneville, MD (12), Christophe Cognard, MD (12), François Chollet, MD (12), Isabelle Carrie, PhD (13), S. Gillette-Guyonnel, PhD (13), Sandrine Andrieu, MD PhD (13), Stéphane Leheuricy, MD PhD (14), Marie Chupin, PhD (3), Bruno Vellas, MD PhD (13)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1) INSERM Center U897, CIC-E7, Bordeaux University, Department of Public Health of CHU Bordeaux, Bordeaux, France; (2) CATI, NeuroSpin, CEA-Saclay Center, Gif-sur-Yvette, France; (3) INSERM U1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Institut du Cerveau et la Moelle épineire, ICM, Inria Paris-Rocquencourt, Paris, France; (4) Neuroimaging department, CHU Bordeaux, Bordeaux, France; (5) Neuroimaging department, CHU Dijon, Dijon, France; (6) Neuroimaging department, CHU Foix, Foix, France; (7) Neuroimaging department, CHU Limoges, Limoges, France; (8) Neuroimaging department, CHU Lyon, Lyon, France; (9) Neuroimaging department, CHU Montpellier, Montpellier, France; (10) Neuroimaging department, CHU Nice, Nice, France; (11) Neuroimaging department, CHU Tarbes, Tarbes, France; (12) Neuroimaging department, CHU Bordeaux, Bordeaux, France; (13) Génopôle, Department of Genetistics, CHU Toulouse, Purpan University Hospital, Toulouse, France; (14) Institut du Cerveau et de la Moelle épineire, Centre de Neuroimagerie de Recherche (CENIR), InstiCRI, UPMC, UPMC/Inserm U975, CNRS 7225, Hôpital Pitié Salpêtrière, Paris, France</td>
<td></td>
</tr>
<tr>
<td>2.45 pm</td>
<td><strong>OC17</strong> - The Down Syndrome Biomarker Initiative (DSBI) Pilot: Proof of Concept for Deep Phenotyping of AD Biomarkers in DS</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Michael S. Rafi (1), Hannah Wishnek (1), James B. Brewer (1), Michael C. Donohue (1), Seth Ness (2), William C. Mobley (1), Paul S. Aisen (3), Robert A. Rissman (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1) Alzheimer’s Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, CA, USA; (2) Janssen Research and Development LLC, Titusville, New Jersey - USA; (3) Alzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego</td>
<td></td>
</tr>
<tr>
<td>3.00 pm</td>
<td><strong>KEYNOTE 2</strong> - Catalunya</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Introduction:</strong> Bruno Vellas</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>The BIOCARD Study: Lessons for Clinical Trials in Preclinical AD</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marilyn S. Albert, PhD, The Johns Hopkins Hospital, Baltimore, MD, USA</td>
<td></td>
</tr>
<tr>
<td>3.30 pm</td>
<td><strong>ORAL COMMUNICATIONS SESSION</strong> - Hot topics in AD clinical trials - Catalunya</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Moderators:</strong> Audrey Gabelle, Mary Sano</td>
<td></td>
</tr>
<tr>
<td>3.30 pm</td>
<td><strong>OC18</strong> - Two phase Ib trials of S 38093 in Alzheimer’s Disease patients at mild to moderate stage</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Roy Jones (1), Bruno Vellas (2), Serge Gauthier (3), Bénédicte Cognet (4), Anthony Bauraud (5), Hans-Martin Schneble (4), Annette Merdes (5)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1) RICE - Research Institute for the Care of Older People, Bath, United Kingdom; (2) C.H.U. Toulouse, France; (3) McGill Centre for Studies in Aging, Montréal, Canada; (4) Institut de Recherches Internationales Servier, Suresnes, France; (5) Servier Forschung und Pharma-Entwicklung, München, Germany</td>
<td></td>
</tr>
<tr>
<td>3.45 pm</td>
<td><strong>OC19</strong> - Randomized, Placebo-Controlled, Phase 1b Study of the Anti–Beta-Amyloid Antibody Aducanumab (BIIB037) in Patients with Prodomal or Mild Alzheimer’s Disease: Interim Results</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jeff Sevigny, MD (1); Ping Chiao, PhD (1); Leslie Williams, DVM, MPH (1); Tiantie Chen, PhD (1); Yan Ling, MD, PhD (1); John O’Gorman, PhD (1); Christoph Hock, MD (2); Roger M Nitsch, MD, PhD (2); Alfred Sandrock, MD, PhD (1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1) Biogen, Cambridge, MA, USA; (2) Neuimmune Holding AG and University of Zurich, Zurich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>4.00 pm</td>
<td><strong>OC20</strong> - ELND005 for agitation and aggression in Alzheimer’s Disease (HARMONY-AD Study): Phase 2/3 design and clinical outcomes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Anton P. Porsteinsson MD (1), Susan Abushakra, MD (2), Merce Boada (3), Ira Goodman (4), Giovanni Marotta (5), Aleksandra Pastrak, MD, PhD (2), Eearvin Liang, PhD (2), Rachelle Doody MD, PhD (6), Bruno Vellas (7), Constantine Lyketsos MD, PhD (8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(1) University of Rochester School of Medicine and Dentistry, Rochester, NY, USA; (2) Transition Therapeutics Ireland Limited, Dublin, Ireland; (3) Foundation ACE, Barcelona Alzheimer Treatment &amp; Research Center, Barcelona, Spain; (4) Compass Research, Orlando, FL, USA; (5) Centre for Memory and Aging, Gerontion Research, Toronto, Canada; (6) Department of Neurology, Baylor College of Medicine, Houston TX, USA; (7) University of Toulouse, Alzheimer’s Disease Research Center, Toulouse, France; (8) Department of Psychiatry, Johns Hopkins University, Baltimore, MD, USA</td>
<td></td>
</tr>
</tbody>
</table>
4.15 pm

**ORAL COMMUNICATIONS SESSION - Catalunya**

4.15 pm

**OC21 - A new plasma metabolomics panel predicts preclinical to clinical Alzheimer’s disease transition**

Massimo S. Fiandaca, MD, MBA (1,2), Xiaogang Zhong, PhD (3), Amrita K. Cheema, PhD (4), Michael H. Orquiza, MD (2), Swathi Chidambaram, BS (5), Ming T.Tan, PhD (3), Mike A.Nalls, PhD (6), Mark Mapstone, PhD (7), Howard J.Federoff, MD, PhD (1,2) (1) Neurology Department, Georgetown University Medical Center, Washington, DC, USA; (2) Neuroscience Department, Georgetown University Medical Center, Washington, DC, USA; (3) Department of Bioinformatics, Biostatistics and Biomathematics, Georgetown University Medical Center, Washington, DC, USA; (4) Departments of Oncology and Biochemistry, Georgetown University Medical Center, Washington, DC, USA; (5) School of Medicine, Georgetown University, Washington, DC, USA; (6) Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA; (7) Neuroscience Department, University of Rochester Medical Center, Rochester, NY, USA

4.30 pm

**OC22 - The incremental diagnostic value of 18F Florbetapir imaging in naturalistic patients with cognitive impairment: final results from the INDIA-FBP study**

Boccardi Marina, PhD (1), Altomare Daniele, MS (1), Festari Cristina, MS (1), Tarallo Anna, MS (1), Guerra Ugo Paolo, MD (2), Paghera Barbara, MD (3), Pizzocaro Claudio, MD (4), Pasqualettis Patrizio, MS (4), Muscio Cristina, MS (1,5), Pievani Michela, PhD (1), Padovani Alessandro, MD (6), Frisoni Giovanni Battista, MD (1,7), and the INDIA-FBP Working Group*. (1) Laboratory of Alzheimer’s Neuroimaging and Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; (2) Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy; (3) Nuclear Medicine, University of Brescia and Spedali Civili di Brescia, Brescia, Italy; (4) Fatebenefratelli Hospital of Isola Tiberina, Roma, Italy; (5) European Foundation Biomedical Research (FERB), Center of Excellence Alzheimer, Ospedale Broiliini di Gazzania, Bergamo, Italy; (6) Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy; (7) Memory Clinic and LANHIVE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

4.45 pm

**OC23 - CSF biomarkers for Amyloid Related Imaging Abnormalities (ARIA) in immunotherapy trials of Alzheimer’s disease and Cerebral Amyloid Angiopathy: report from the iCAB International Network.**

Fabrizio Piazza, PhD (1), on behalf of The Inflammatory Cerebral amyloid angiopathy and Alzheimer’s disease Biomarkers (iCAB) International Network* ** MAIN NETWORK CO-INVESTIGATORS: Steven M. Greenberg, MD, PhD,Bengt Winblad, MD, PhD(3), Nick Fox, MD (4), Alberto Lleo, MD, PhD(5), Fabrizio Tagliavini, MD(6), Ricardo Nitrini, MD(7), Hideya Sakaguchi, MD(8), Masafumi Iihara, MD(9), Massimo Caudo, MD (10), Antonio Uccini, MD(10), Mehdi Touat, MD, MD(11), Richard Levy, MD, PhD(11), Martina Longoni, MSc(1), Jacopo C. DiFrancesco, MD, PhD (1) (1) Department of Surgery and Translational Medicine, Milan Center for Neuroscience (NeuroMI), University of Milano-Bicocca, Monza, Italy; (2) Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; (3) Department of Neurobiology, Care Sciences and Society (NVS), Karolinska Institutet, Center for Alzheimer Research, Division of Neurogenetics, Huddinge, Sweden; (4) Dementia Research Centre, Institute of Neurology, Queen Square, London; (5) CIBERNED, IIB-SantPau, Barcelona, Spain; (6) IRCCS Foundation «Carlo Besta» Neurological Institute, Milano, Italy; (7) Department of Neurology, University of Sao Paulo, Sao Paulo, Brazil; (8) Department of Neurology, Kumamoto University, Kumamoto, Japan; (9) Division of Neurology, Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Osaka, Japan; (10) Department of Neurosciences and Imaging, University “G. d’Annunzio”, Chieti, Italy; (11) INSERM & Neurology Department, Hospital Saint Antoine, APHP, Paris, France

5.00 pm

**Poster sessions 1 and coffee break - Gaudì Mezzanine Level**

5.30 pm

**KEYNOTE 3 - Catalunya**

Introduction: Rachelle Doody

Drug development in AD: point of view from the industry

Eric Siemers, MD, Eli Lilly and Company, Indianapolis, IN - USA

6.00 pm

**ORAL COMMUNICATIONS SESSION - Catalunya**

Moderators: Howard Feldman, Isabel Hernández

6.00 pm

**OC24 - Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment With Aducanumab (BIB037) in Patients With Early Alzheimer’s Disease: Phase 3 Study Design**

Vissia Violetta, MD, PhD (1); John O’Gorman, PhD (1); Leslie Williams, DVM, MPH (1); Rachel Doody, MD, PhD (2); Stephen Salloway, MD, MS (3); Frederik Barkhof, MD, PhD (4); Bruno Vellas, MD, PhD (5); Mary Sano, PhD (6); Paul Aisen, MD (7); Jeffrey Sevigny, MD (1)

(1) Biogen, Cambridge, MA, USA; (2) Baylor College of Medicine, Houston, TX, USA; (3) Department of Health and Social Care, Brown University, Providence, RI, USA; (4) VU University Medical Center, Amsterdam, Netherlands; (5) Toulouse University Hospital, Toulouse, France; (6) John Scott Research Institute, Alzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego

6.15 pm

**OC25 - Tolerability and preliminary pharmacodynamics after single doses of MEDI1814, a Beta-Amyloid 42 (Aβ42)-specific antibody, in mild-moderate Alzheimer’s disease**

Laura Rosen, MD, PhD (1), Michael Pomfret, BSc (2), Andrew Billinton PhD (2), Iain Chessell, PhD (2), Tharani Chessell, PhD (2), Alan Kugler, PhD1, Eva Lindqvist MSc (3), Mary McFarlane PhD (2), Maria Groves, PhD (4), Rajesh Narwal PhD (6), Keith Tan, PhD (5), Manasa Tatipalli, MSc (6), Amanda Dudley, PhD (2)

(1) Neuroscience Innovative Medicines, AstraZeneca, Cambridge, MA, USA; (2) Neuroscience Innovative Medicines, MedImmune, Cambridge, UK; (3) Personalised Healthcare & Biomarkers, AstraZeneca, Molndal, SE; (4) Antibody Design and Protein Engineering, MedImmune, UK; (5) Translational Sciences, MedImmune, UK; (6) Translational Sciences, Gaithersburg, MD, USA
OC26 - Additive and independent effect of vascular and amyloid pathology on structural connections in mild cognitive impairment

Moira Marizzoni, PhD (1), Jorge Jovicich, PhD (2), Flavio Nobili, MD (3), Mira Didic, MD (4,5), David Bartrés-Faz, MD (6), Ute Fiedler (7), Peter Schonknecht, MD (8), Pierre Payoux, MD (9,10), Alberto Beltramello, MD (11), Andrea Soricelli, MD (12,13), Lucilla Parnetti, MD (14), Magda Tsalaki, MD (15), Paolo Maria Rossini, MD (16,17), Philip Scheltens, MD (18), Pieter Jelle Visser, MD (18), Gianluigi Forloni, PhD (19), Regis Bordet, MD (20), Olivier Blin, MD (21), Giovanni Battista Frisoni, MD (1,22); on behalf of the PharmaCog Consortium

1. Laboratory of Neuroimaging and Alzheimer’s Epidemiology, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; 2. Center for Mind/Brain Sciences, University of Trento, Trento, Italy; 3. Department of Neurosciences, Ophthalmology, Genetics and Mother–Child Health (DINOGM), University of Genova, Genova, Italy; 4. APHM, CHU Timone, Service de Neurologie et Neuropsychologie, Marseille, France; 5. Aix-Marseille Université, INSERM U 1106, Marseille, France; 6. Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain; 7. LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany; 8. Department of Psychiatry, University of Leipzig, Leipzig, Germany; 9. INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU Purpan, Place du Dr Baylac, Toulouse Cedex 9, France; 11. Department of Neuroradiology, General Hospital, Verona, Italy; 12. IRCCS S. Anna, Naples, Italy; 13. University of Naples Parthenope, Naples, Italy; 14. Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy; 15. 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece; 16. Dept. Geriatrics, Neuroscience & Orthopaedics, Catholic University, Policlinic Gemelli, Rome, Italy; 17. IRCCS S. Raffaele Pisana, Rome, Italy; 18. Alzheimer Centre and Department of Neurology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands; 19. Neurosciences Department, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy; 20. Department of Pharmacology, EA1046, University of Lille Nord de France, 59045 Lille Cedex, France; 21. Pharmacology, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University-CNRS UMR 7289, Marseille, France; 22. Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

OC27 - Effect of Insulin Sensitizer Metformin on AD Biomarkers (NCT01965756): Initial Findings of a Randomized Placebo Controlled Crossover Pilot Study of Metformin Effects on Biochemical, Neurophysiological and Cognitive Biomarkers of Amnestic MCI and Mild AD

Steven E. Arnold, MD1,2,3*, David A. Wolk, MD1,3, Dawn Mechanic-Hamilton, PhD1,2, Aaron M. Koenig, MD1,2, Sharon X. Xie, PhD4, Anne R. Cappola, MD5, Martha F. Combs, MS1,2, Natalia Louneva, PhD2

1. Penn Memory Center, University of Pennsylvania, Philadelphia, PA, USA; 2. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; 3. Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; 4. Department of Epidemiology & Biostatistics, University of Pennsylvania, Philadelphia, PA, USA; 5. Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA. *Current affiliation: Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
### CTAD 2015 Program

**Friday, November 6th**

#### 7.45 am ORAL COMMUNICATIONS SESSION - Catalunya

**OC28** - A Phase Ib Study of AZD0530 (Saracatinib) and the transition to a Phase IIa Proof of Concept study for Alzheimer’s Disease

Haakon B. Nygaard, MD, PhD (1), Kewei Chen, PhD (2), Eric M. Reiman, MD (2), Stephen M. Strittmatter, MD, PhD (3), Christopher H. van Dyck, MD (3)

(1) The University of British Columbia, Vancouver, BC, Canada; (2) Banner Alzheimer’s Institute, Phoenix, AZ, USA; (3) Yale University School of Medicine, New Haven, CT, USA

---

#### 8.00 am KEYNOTE 4 - Catalunya

**Introduction:** Paul Aisen

Speeding up drug development: using sensitive biological measure

Phil Scheltens MD, PhD, Alzheimercentrum Vumc, Amsterdam, The Netherlands

---

#### 8.30 am SYMPOSIUM 1 - Catalunya

Prospective Readiness Cohorts, Internet-based Registries and Matching Services for Alzheimer’s Disease Clinical Trials

Moderators: Michael Weiner and Jessica Langbaum

1. Alzheimer’s Association TrialMatch

   Maria C. Carrillo, Ph.D. (1), Keith Fargo, Ph.D. (1), Beth Kallmyer, MSW (1)

   (1) Alzheimer’s Association National Organization, USA

2. Alzheimer’s Prevention Registry

   Jessica B. Langbaum, PhD (1), Nellie High, MA (1), Paul S. Aisen, MD (2), Marilyn S. Albert, PhD (3), Meryl Corner (4), Jeffrey L. Cummings, MD, PhD (5), Jennifer J. Manly, PhD (6), Ronald C. Petersen, MD PhD (7), Reisa A. Sperling, MD (8), Gabrielle Strobel (9), Michael W. Weiner, MD (10), Eric M. Reiman, MD (1), Pierre N. Tariot, MD (1)

   (1) Banner Alzheimer’s Institute, Phoenix, AZ, USA; (2) Alzheimer’s Therapeutic Research Institute (ATRI) University of Southern California (USC) at San Diego; (3) Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; (4) Geoffrey Beene Foundation Alzheimer’s Initiative, Washington, DC, USA; (5) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; (6) Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY, USA; (7) Department of Neurology, Mayo Clinic, Rochester, MN, USA; (8) Department of Neurology, Harvard Medical School, Boston, MA, USA; (9) Alzforum, Cambridge, MA, USA; (10) Department of Radiology and Biomedical Engineering, University of California San Francisco, San Francisco, CA, USA

3. Brain Health Registry

   Michael W. Weiner, MD

   University of California San Francisco (UCSF), San Francisco, CA, USA

4. Cognitive Health in Ageing Register: Investigational, Observational and Trial studies in dementia research – Prospective Readiness cOhort (CHARIOT-PRO)

   Michael T. Ropacki, PhD (1,2), H. Michael Arrighi, PhD (1), Robert Perneczky, MD (3), Josip Car, MD (3), Lefkos Middleton, MD (3)

   (1) Janssen R&D, Fremont, CA, USA; (2) Loma Linda University School of Medicine, Neurology, Loma Linda, CA, USA; (3) School of Public Health, Imperial College London, London, UK

---

#### 9.30 am ORAL COMMUNICATIONS SESSION - Catalunya

**Introduction:** Rafael Blesa, Kostas Lyketsos

**OC29** - A case-control cohort study to define a threshold for the Tau/Abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer’s disease

Michael F. Egan, MD (1), Yi Mo, PhD (1), Julie Stromswold, RN, BSN (1), Kimberly Wilson, MS (1), Daniel E. Holder, PhD (1), Cyrille Sur, PhD (1), Omar Laterza, PhD (1), Mary J. Savage, PhD (1), Arie Struyk, MD, PhD (1), Philip Schelten, MD (2), Charlotte E. Teunissen, MD (2), James Burke, MD, PhD (3), S. Lance Macaulay, PhD (4), Geir Bråthen, MD, PhD (5), Sigrid Botne Sando, MD, PhD (5), Linda White, PhD (5), Christy Weiss, BS (6), Arturo Cowes, BS (6), Michele M. Bush, BA (6), Ganga DeSilva, BS (6), Johan Luthman, PhD (1), David Michelson, MD (1)

(1) Merck & Co, Inc., Kenilworth, NJ, USA; (2) VU University Medical Center, Amsterdam, Netherlands; (3) Duke Neurology, Duke University, Durham, NC, USA; (4) Commonwealth Scientific and Industrial Research Organization, Parkville, Victoria, Australia; (5) Department of Neuroscience, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway; (6) Luminex, Austin, TX, USA

---

#### 9.45 am OC30 - Aerobic Exercise Reduces Phosphorylated Tau Protein in Cerebrospinal Fluid in Older Adults with Mild Cognitive Impairment

Laura D Baker, PhD (1), Jeannine Skinner, PhD (2), Suzanne Craft, PhD (1), Brenna Cholterson, PhD (3), Maureen Callaghan, MD (4), Angela Hanson, MD (4), Kaycee M Sink, MD (1), Valerie M Wilson, MD (1)

(1) Department of Internal Medicine – Geriatrics, Wake Forest School of Medicine, Winston-Salem NC, USA; (2) Vanderbilt School of Medicine, Memory and Alzheimer’s Center, Nashville TN, USA; (3) Department of Psychiatry, University of Washington Health Sciences, Seattle WA, USA; (4) Geriatric Research, Education, and Clinical Center, VA Puget Sound, Seattle WA, USA
**CTAD 2015 Program**

**Friday, November 6th**

10.00 am **OC31 - Data-driven enrichment strategies for predicting Aβ positivity in an older adult cohort from the Brain Health Registry**
Rachel L. Nosheny (1), PhD, Philip S. Insel (1), MS, Diana Truran (1), Derek Flemniken (1), Shannon Finley (1), Monica Camacho (1), R. Scott Mackin, PhD (1,2,3), Michael W. Weiner, MD (1,2,4)

1. Center for the Imaging of Neurodegenerative Diseases, San Francisco Veteran's Administration Medical Center; 2. Department of Psychiatry, University of California, San Francisco; 3. Mental Health Service, Department of Veteran’s Affairs Medical Center, San Francisco, CA; 4. Department of Radiology, University of California, San Francisco

10.15 am **ORAL COMMUNICATIONS SESSION: Hot topics in AD clinical trials - Catalunya**

10.15 am **OC32 - Fornix Deep Brain Stimulation for Stimulation of Alzheimer’s Disease: Results of the Multi-center ADvance Trial**
Constantine G. Lyketsos (3), Kathryn B. Holroyd (1), Lisa Fosdick (2), Gwenn Smith (3), Jeannie-Marie Leoutsakos (3), Cynthia Munro (3), Esther Oh (3), Kristen Drake (2), Paul B. Rosenberg (1,3), William S. Anderson (3), Stephen Salloway (9), Cara Pendergrass, Anna Burke, David A. Wolk (7), David F. Tang-Wai (4,6), Francisco A. Ponce (8), Wael F. Assaad (10), Marwan Sabbagh, Michael S. Okun, Gordon Baltuch, Kelly D. Foote, Steve Targum (2), Andres M. Lozano (4)

1. Johns Hopkins University School of Medicine; 2. Functional Neuromodulation Ltd., Minneapolis, MN; 3. Johns Hopkins University Memory and Alzheimer’s Treatment Center and Alzheimer’s Disease Research Center, Baltimore MD; 4. Departments of Neurology and Neurosurgery, University of Toronto, Toronto, Ontario Canada; 5. Departments of Neurology and Neurosurgery, University of Florida Center for Movement Disorders and Neurorestoration, Gainesville FL; 6. University Health Network Memory Clinic, University of Toronto, Division of Neurology, Toronto ON Canada; 7. Penn Memory Center, Department of Neurology, University of Pennsylvania, Philadelphia PA; 8. Division of Neurosurgical Sciences, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ; 9. Departments of Neurology, Butler and Rhode Island Hospital and the Alpert Medical School of Brown University; 10. Departments of Neurosurgery, Rhode Island Hospital and the Alpert Medical School of Brown University

10.30 am **OC33 - MAPT (Multi-Domain Alzheimer’s Prevention Trial): Clinical, Biomarkers results and lessons for the future**
Vellas B (1,2,3), Voisin T, Dufoiul C, Carrie I (1), Gillette-Guyonnet,S (1,2,3), Gabelle, A (4), Touchon J (4), Dantoine T (5), Dartigues J-F (6), Buffa M-N (7), Bordes, S (8), Gasnier Y (8), Robert, P (9), Boril, L (10), Rouaud O (11), Desclaux F (12), Sudres K (13), Bonnefoy M (14), Pesce A (15), Fougeron (1), B Delrieu. J (11), Faisant C (1), Lafa F (1), Dupuy C (1,2), Canet C (1,2,3), N Coley (2,3), Belleville S (18), Willis S (19), Weiner (20), M W Ousset, PJ (1,2,3), Andreu S (1,2,3), (1) CHU Toulouse, Purpan University Hospital, Toulouse, France; (2) INSERM UMR 1027, Toulouse, France; (3) University of Toulouse III, Toulouse, France; (4) Memory Research Resource Center for Alzheimer’s Disease, University Hospital of Montpellier, Montpellier, France; (5) Memory Research Resource Center, University Hospital of Limoges, Limoges, France; (6) INSERM U897, Memory Research Resource Center for Alzheimer’s Disease, University Hospital of Bordeaux, Bordeaux, France; (7) Geriatrie de Montréal, Montréal, Canada; (8) University of Washington, Washington, USA; (9) Center for Alzheimer’s Disease, University Hospital of Bordeaux, Bordeaux, France; (10) Departments of Neurology, Butler and Rhode Island Hospital and the Alpert Medical School of Brown University; (11) Departments of Neurosurgery, Rhode Island Hospital and the Alpert Medical School of Brown University; (12) CHU Toulouse, Toulouse, France

10.45 am **OC34 - Improving the sensitivity of cognitive composite scores to abnormal amyloid burden in preclinical Alzheimer’s disease:**
Paul Maruff (1,2), Yen Ying Lim (1), Peter J. Snyder (3), Victor L. Villemagne (1), David Ames (1), Christopher C. Rowe (1), Colin Maters (1)

1. The University of Melbourne, Parkville, Victoria, Australia; 2. Cogstate Ltd., Melbourne, Victoria, Australia; 3. Department of Neurology, Warren Allen School of Medicine, Brown University, Providence, RI, USA

11.00 am **Poster sessions 2 and coffee break - Gaudi Mezzanine Level**

11.30 am **PARALLEL SESSIONS - Catalunya AB**

**ORAL COMMUNICATIONS SESSION**
Moderator: Dr. Robert Rissman

11.30 am **OC35 - Neuroinflammation in Alzheimer’s disease: role in pathogenesis and prospects for therapeutic intervention**
Richard Margolin, MD (1) CereSpir, Inc., New York, NY, USA

**LATE BREAKING COMMUNICATIONS**
Moderators: Nicola Coley, Merce Boada

LB1 - Evaluating the clinical relevance of a composite cognitive outcome measure: an analysis of 1414 participants from a 5-year Alzheimer’s disease prevention trial
Nicola Coley, PhD (1,2,3), Adeline Gallini, PharmD, PhD (1,2,3), Bruno Vellas, MD, PhD (1,2,4), Sandrine Andrieu, MD, PhD (1,2,3), for the GuidAge study group

1. Inserm UMR1027, Toulouse, France; 2. University Toulouse III, Toulouse, France; 3. CHU Toulouse, Department of Epidemiology and Public Health, Toulouse, France; 4. Gérontopôle, CHU Toulouse, Department of Geriatric Medicine, Toulouse, France
11.45 am

**OC36 - Evaluation of the Phase 2b safety of azeliragon (TTP488) 20mg/day and 5 mg/day in support of Phase 3 dose selection**

Marwan N Sabbagh, M.D. (1), Aaron Burstein, PharmD (2), Imogene Grimes, PhD (2), Carmen Valcarce, PhD (2), Rachelle S Doody, MD, PhD (3), Lon S Schneider, MD (4) and Douglas Galasko, MD (5)

(1) Barrow Neurological Institute, Phoenix, AZ, USA; (2) vTv Therapeutics, High Point, NC, USA; (3) Baylor College of Medicine, Houston, TX, USA; (4) Keck School of Medicine of USC, Los Angeles, CA, USA; (5) UC San Diego / VA San Diego Healthcare System, San Diego, CA, USA

**LB2 - Cross-Cultural Validation and Normative Study of a Neuropsychological Battery Used in the Determination of Clinical Endpoints to Delay Onset of MCI Due to AD**

Kathleen A. Welsh-Bohmer, PhD (1,2), Heather R. Romero, PhD (1,2), Kathleen M. Hayden, PhD (1,2), Brenda L. Plassman, PhD (1,2), Alexandra S. Atkins, PhD (3), Nicole M. Turcotte, MA (3), Richard S.E. Keefe, PhD (2,3), Oksana A. Makeeva, MD, PhD (4), Natalia G. Zhukova, MD, PhD (4), Andreas U. Monsch, PhD (5), Giovanni B. Frisoni, MD (6,7), Zara Melikyan, PhD (8), Shyama Brewster, BSc(Hon) (8), Carl Chiang, PhD (8), Yuka Maruyama, DVM (8), Janet O’Neil, MBA (9), Dominic Fitzsimmons, BSc (Hon) (9), Grant Runyan, PhD (9), Stephen Crawford, PhD, MHS,(10) Toyoko Oguri (10), Mark Atkinson, PhD (10), Kumar Budur, MD, MS (9), Daniel K. Burns, PhD (8), Allen D. Roses, MD (1,8) for the TOMMORROW Study Investigators

(1) Joseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC, USA (2) Department of Psychiatry, Duke University Medical Center, Durham, NC, USA (3) NeuroCog Trials, Durham, NC, USA (4) Center for Clinical Trials, Nebbiolo LLC, Tomsk, RU (5) University Center for Medicine of Aging Basel, Felix Platter Hospital, Basel, CH (6) IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, IT (7) University Hospitals and University of Geneva, Geneva, CH (8) Zinfandel Pharmaceuticals Inc., Chapel Hill, NC, USA (9) Takeda Development Center Americas, Inc., Deerfield, IL, USA (10) Covance Inc, Princeton, NJ, USA

12.00 pm

**LATE BREAKING COMMUNICATIONS**

**LB3 - ORY-2001, an epigenetic drug for the treatment of cognition defects in Alzheimer’s Disease and other neurodegenerative disorders**

Tamara Maea, PhD (1), Elena Carceller, PhD (1), Fernando Cavallanti, PhD (1), Cristina Mascaro, PhD (1), César Molinero, MD, PhD (1), Alberto Ortega, David Rotillant, PhD (1), Carlos Buesa, PhD (1)

(1) Oryzon Genomics S.A. Barcelona, Spain

12.15 pm

**OC38 - MK-8931 treatment suppresses amyloid plaque progression in aged post-plaque Tg2576 mice without increased microhemmorhage**

Matthew E. Kennedy (1), Stephanie Villarreal (2), Fuqiang Zhao (6), Lynn Hyde (3), Daniel Holder (5), Thomas Forest (4), Marie Sondy (3), Xia Chen (3), Cyrille Sur (6), Eric Parker (3)

(1) Early Discovery Neuroscience, Merck Research Labs, Boston MA USA, (2) Early Discovery Neuroscience, Merck Research Labs, West Point PA USA, (3) Pharmacology, Merck Research Labs, Kenilworth NJ USA, (4) Safety Assessment and Laboratory Animal Research, Merck Research Labs West Point PA USA, (5) Biostatistics, Merck Research Labs, West Point PA USA (6) Imaging, Merck Research Labs, West Point PA USA

**LB4 - sAPPα is a Potent Endogenous Inhibitor of BACE1**

Varghese John (1), Clare Peters-Libeu (2), Jesus Campagna (1), Patricia Spillman (1), Karen Pocksay (2), Dale E. Brederes (1,2)

(1) Geffen School of Medicine, UCLA, Los Angeles, CA, USA; (2) Buck Institute for Research on Aging, Novato, CA, USA

12.00 pm

**ORAL COMMUNICATIONS SESSION: Animal models/preclinical section**

 chaired by Robert Rissman, MD

**OC37 - CRF Receptor 1 Antagonism as a Disease-Modifying Treatment for AD: Preclinical Efficacy and Safety Data**

Robert A. Rissman, PhD, Alzheimer’s Disease Cooperative Study, Department of Neurosciences, University of California, San Diego, La Jolla, CA - USA
CTAD 2015 Program
Friday, November 6th

12.30 pm

OC39 - Modulating Gamma-Secretase Activity Reverses Endosomal Phenotypes Induced by Increased APP Dose in Down Syndrome Model Neurons
William C. Molley, MD, PhD (1), Matthew Pearn, MD (1), Mariko Sawa, PhD (1), Nishant Singhal, PhD (1), Orlangie Natera, PhD (1), Xu Chen PhD (1), Chengbiao Wu, PhD (1), Steven Wagner, PhD (1) (1) Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA

12.45 pm

OC40 - Vitamin D improves cognition and neurogenesis, reduces amyloid burden and inflammation in a mouse model of Alzheimer’s disease
P. Millet (1,2,3), V. Landel (1), M. Morello (1,4), F. Féron (1) (1) Aix Marseille Université, CNRS, NICN UMR 7259, Marseille, France; (2) CMRR, G.H. Lariboisière-Fd.股指al, Paris, France; (3) Inserm UMR-S942, Paris, France; (4) University of Rome Tor Vergata, Clinical Biochemistry, Human Nutrition, Faculty of Medicine, Italy

1.30 pm

SYMPOSIUM 2
The Lancet and The Lancet Neurology Symposium on Clinical Research in Dementia: Increasing Value and Reducing Waste
Moderator: Prof Lon S. Schneider, University of Southern California, USA

1. Towards valuable research design, conduct, and analysis
Malcolm Macleod, Professor of Neurology and Translational Neuroscience, University of Edinburgh, UK

2. Tackling waste in the regulation and management of clinical trials
Rustam Al-Shahi Salman, Professor of Clinical Neurology, University of Edinburgh, UK

3. Aims and priorities of the IMI2 Alzheimer's Disease Research Platform
Elisabetta Vaudano, Principal Scientific Manager & Coordinator, Innovative Medicines Initiative, Brussels, Belgium

LATE BREAKING COMMUNICATIONS
Moderators: José Luis Molinuerto, Pierre-Jean Ousset

2.00 pm

LB5 - Robust and sustained efficacy of tramiprosate in APOE4/4 homoyogous patients with Mild and Moderate AD: combined data sets from two 78-week Phase 3 trials
A Porsteinsson (1), J.Cummings (2), M.Kipvelto (3), J.A.Hey (4), J.Y.Yu (4), A.Power (4), M.Bairu (5), M.Tolar (4), S.Abushakra (4) (1) University of Rochester, Rochester NY USA; (2) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, Nevada and Cleveland, USA; (3) Karolinska Institutet Alzheimer Disease Research Center, Stockholm, Sweden; (4) Alzheon Inc., Boston, MA, USA; (5) Serenus Biotherapeutics, Inc., San Francisco, CA, USA

1.00 pm

Lunch and poster sessions 2 - Gaudi Mezzanine Level

1.00 pm

LB6 - Plasma exchange with albumin and immunoglobulin in Alzheimer’s disease patients: interim analysis of the AMBAR trial
M.Boada, MD (1,2,3), O.López, MD (4,5), L.Núñez (6), M.Torres (6), N.Afonso (6), A.Páez, MD (6), and the investigators of the AMBAR Clinical Trial Study Group (1) Fundació ACE, Barcelona, Spain; (2) Hospital General Universitari Vall d’Hebron, Barcelona, Spain; (3) AMBAR clinical trial, National Coordinator of Spain; (4) University of Pittsburgh School of Medicine, Pittsburgh, USA; (5) AMBAR clinical trial, National Coordinator of USA; (6) Grifols, Barcelona, Spain

2.15 pm

LB7 - Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease: implications for clinical trials
Daniel Alcolea, MD (1), Pablo Martínez-Lage, MD, PhD (2), Pascual Sánchez-Juan, MD, PhD (3), Javier Olazarán, MD, PhD (4,8), Carmen Antúnez, MD, PhD (5), Andrea Izagirre, RN (2), Mirian Ecay-Torres, MSc (2), Ainara Estanga, MSc (2), Montserrat Clarijón, PhD (2), Mª Concepción Guisasola, PhD (1), María Carmona-Iragui, MD (1), Estrella Morenas-Rodríguez, MD (1), Eloy Rodríguez-Rodríguez, MD, PhD (3), José Luis Vázquez Higuera, MD, PhD (3), Juan Fortea, MD, PhD (1), Alberto Lleó, MD, PhD (1) (1) Hospital Sant Pau, Barcelona, Spain; (2) Fundación CITIA-alzheimer Fundación, San Sebastián, Spain; (3) Hospital Universitario Marqués de Valdecilla, Santander, Spain; (4) Hospital General Gregorio Marañón, Madrid, Spain; (5) Instituto de Salud Carlos III, CIBERNED, Madrid, Spain; (6) Fundación CIEN - Fundación Reina Sofia, Madrid, Spain; (7) Instituto de Salud Carlos III, CIBERNED, Madrid, Spain; (8) Fundación CIEN - Fundación Reina Sofia, Madrid, Spain - Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain. The SIGNAL study

2.15 pm

LB8 - A ratio of synaptic CSF biomarkers as potential correlate for cognitive decline in Alzheimer’s disease
A.De Vos, PhD (1), H.Struyfs,MSc (2), D.Jacob, MD (1), E.Fransen,PhD (3), D.Smeets,PhD (4), W.Maes, PhD (5), S.Engelborghs,MD,PhD (2,6), E.Vanmechelen,PhD (1) (1) ADx NeuroSciences NV, Ghent, Belgium; (2) University of Antwerp, Antwerp, Belgium; (3) StatUa Center for Statistics, U of Antwerp, Antwerp, Belgium; (4) icomEtrix NV, Leuven, Belgium; (5) PharmAbx, The KU Leuven Antibody Center, Leuven, Belgium; (6) Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium
SYMPOSIUM 2 continued

Panel Discussion:
Moderator: Lon S. Schneider
Jose Luis Molinuevo (Hospital Clinic, Barcelona, Spain), Rachel J. Schindler (VP, Neurosciences Area, Pfizer, New York, NY, USA), Sabine Kleinert (Executive Editor, The Lancet, London, UK), Elena Becker-Barroso (Editor, The Lancet Neurology, London, UK)

2.30 pm
LB9 - The challenge of interpreting longitudinal change in CSF tau in therapeutic trials of amyloid positive subjects
John R Sims (1), Peng Yu (1), Jeffrey L Dage (1), Yun-Fei Chen (1), Peter Castelluccio (2), Robert A Dean (1)
(1) Lilly Research Laboratories, Indianapolis, IN, USA; (2) Bucher & Christian Consulting, Inc., Indianapolis, IN, USA

2.45 pm
LB10 - Discovery, Preclinical Development, and Clinical Trial Approach for NPT088, a General Amyloid Interaction Motif (GAIM)-Immunoglobulin Fusion
Jonathan Solomon, PhD (1), Ram Krishnan, PhD (1), Kim Gannon, PhD (1), Jonathan Levenson, PhD (1), Haim Tsubery, PhD (1), Ming Proschtsiky, PhD (1), Eva Asp, PhD (1), Jenna Carroll, PhD (1), Valerie Cullen, PhD (1), Myra Gartner, MS (1), Sharon Gilead, PhD (1), Michal Lulu, MS (1), Sally Schroeter, PhD (1), Jason Wright, PhD (1), Charlotte Chung, PhD (1), Peter Davis, PhD (2), Jonathan Waltho, PhD (2), E. Rockenstein (3), E. Masliah (3), Beka Solomon, PhD (4), Michelle Gray, MS (1), Franz Hefit, PhD (1), Michael Grundman, MD, MPH (5)
(1) NeuroPhage Pharmaceuticals, Cambridge, MA, USA; (2) Molecular Biology and Biotechnology, University of Sheffield, Sheffield, United Kingdom; (3) Neurosciences, UC San Diego, San Diego, USA; (4) Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel; (5) Global R&D Partners, San Diego, CA, USA

3.00 pm
ORAL COMMUNICATIONS SESSION
Moderators: Serge Gauthier, Reisa Sperling

ORAL COMMUNICATIONS SESSION

3.00 pm
OC41 - Innovative mass spectrometry quantification of cerebrospinal fluid tau and phospho tau in Alzheimer’s disease patients
C. Hirtz (1)*, N. Barthelemy (1), A. Gabelle (1,3), F. Fenaille (2), N. Sergeant (4), J. Vialaret (1), S. Schraen-Maschke (3), P. Bros (1), L. Tiers (1), C. Delaby (1), C. Junot (2), J. Touchon (3), L. Buée (4), F. Becher (2), S. Lehmann (1)
(1) CHRU de Montpellier and Université de Montpellier, IRMB, Laboratoire de Biochimie Protéomique Clinique, Montpellier, France; (2) CEA, iBiTec-S, Service de Pharmacologie et d’Immunoanalyse, Gif-sur-Yvette, France; (3) Centre Mémoire Ressources Recherche Languedoc-Roussillon, CHU de Montpellier, hôpital Gui de Chauliac, Montpellier, and Université de Montpellier; Montpellier, France; (4) CHU de Lille, Centre de Biologie Pathologie; Université Lille-Nord de France, INSERM U837; Lille, France

LATE BREAKING COMMUNICATIONS

LB11 - Evaluation of Serum Plasmalogens and their Associations with Cognition and Alzheimer’s disease Across Four Studies
Dayan B. Goodenowe, PhD (1), Vijitha Senanayake, PhD (1), Mitchel A. Kling, MD (2), Jon B. Toledo, MD (3), Tara Smith, PhD (1), Asuka Mochizuki, MS (1), Jessica Tenenbaum, PhD (4), Emily Burke, BS (4), Xianlin Han, PhD (5), Rebecca Baillie, PhD (6), Joseph Lucas, PhD (4), Munir Doraismwamy, MBBS (7), John Q. Trojanowki, MD, PhD (3), Leslie M. Shaw, PhD (3), Sungun Kim, PhD (8), Andrew J. Saykin, PsyD (8), Rima Kaddurah-Daouk, PhD (7), and the Alzheimer Disease Metabolomics Consortium
(1) Phenomenome Discoveries Inc., Saskatoon, Saskatchewan, Canada; (2) Department of Psychiatry, (3) Department of Pathology & Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; (4) Duke University Medical Center, Durham, NC; (5) Sanford-Burnham Medical Research Institute, Orlando, FL; (6) Rosa & Co. LLC, San Carlos, CA; (7) Duke Institute for Brain Sciences, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC; (8) Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN
CTAD 2015 Program
Friday, November 6th

PARALLEL SESSIONS - Catalunya AB

3.15 pm
OC42 - Measuring Cognitive Processes Affected by Alzheimer’s Disease Using Markov Models
Gregory E. Alexander, MS (1), William H. Batchelder, Ph.D (1), William R. Shankle, MS, MD (1,2,3), Ronald Petersen, MD, PhD (4)
(1) Department of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA; (2) Medical Care Corporation, Newport Beach, CA, USA; (3) Hoag Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA, USA; (4) Mayo Clinic, Rochester, MN, USA

3.30 pm
OC43 - Optimized Cognitive function composites related to Biomarkers to look for SNAP and Prodromal AD on AB255 study
Ana Espinosa, MSc (1), Montserrat Alegret PhD (1), Pedro Pesini PhD (2), Sergi Valero PhD (1,3), Asunción Lafuente MD (1), Mar Buendia (1), Virginia Pérez-Grijalba Msc (2), Itziar San José Msc (2), Marta Ibarria Msc (1), Miguel A Tejero (4), Joan Giménez MD (4), Susana Ruiz (1), Isabel Hernández MD (1), Josep Munuera MD (5), Javier Arbizu MD (6), Lluís Tàrraga MSc (1), Agustín Ruiz MD, PhD (1), Oscar Sotolongo-Grau PhD (1), Manuel Sarasà PhD (2), Mercè Boada MD, PhD (1)
(1) Alzheimer Research Center and Memory Clinic: Fundación ACE. Institut Català de Neurociències Aplicades. Barcelona, Spain; (2) Aracion Biotech S.L.; Zaragoza, Spain; (3) Department of Psychiatry. Hospital Universitari Vall d’Hebron, CIBERSAM. Universitat Autònoma de Barcelona. Barcelona, Spain; (4) Clinica Corachán. Barcelona, Spain; (5) Unitat RM Badalona, Institut de diagnòstic Per la imatge. Badalona, Spain; (6) Clinica Universitaria de Pamplona, Pamplona, Spain

3.45 pm
OC44 - Vitamin D Status Predicts Rates of Cognitive Decline in a Multi-Ethnic ADC Cohort of Older Adults
John M. Olchnev, MD (1), Joshua W. Miller, PhD (2,4), Danielle J. Harvey, PhD (3), Laurel A. Beckitt, PhD (3), Ralph Green, MD, PhD (4), Sarah, Farias, PhD (1), Bruce R. Reed, PhD (1), Dan M. Mungas, PhD (1), Charles DeCarli, MD (1)
(1) Neurology, University of California, Davis, CA (SF, BRR, JMO, DMM, CSD); (2) Nutritional Sciences, Rutgers University, New Brunswick, NJ (JWM); (3) Public Health Sciences, Division of Biostatistics, University of California, Davis, CA (DJIH, LAB); (4) Medical Pathology and Laboratory Medicine, University of California, Davis, CA (JWM, RG)

4.00 pm
OC45 - Reduction of amyloid-b with gantenerumab for treatment of prodromal Alzheimer’s disease – post hoc analyses from the Phase 3 SCarlet RoAD trial
Juergen Dukart, Dipl.-Psych., PhD (1), Fabio Sambataro, MD, PhD (2), Robert Lasser, MD, MBA (2), Tania Nikolicheva, MD, PhD (1), Susanne Ostrowski, MD, PhD (1), Luca Santarelli, MD (1), Dietmar Volz, PhD (2), Paolo Fontoura, MD, PhD (2) Alessandro Bertolino, MD, PhD (1)
(1) Roche Pharmaceutical Research & Early Development. F. Hoffmann-La Roche Ltd, Basel, Switzerland; (2) F. Hoffmann-La Roche Ltd, Basel, Switzerland

PARALLEL SESSIONS - Catalunya C

LB12 - Kinetic modeling of the tau PET tracer [18F]AV1451
O.Barret, PhD (1), D.Alagille, PhD (1), S.Sanabria, PhD (2), R.Comley, PhD (3), R.Weimer, PhD (2), E.Borroni, PhD (3), N.Seneca, PhD (4), A.Joshi,PhD (5), M.Devous, PhD (5), M.A. Mintun, MD (5), D.Jennings, MD (1), K.Marek, MD (1), J.P. Seibyl, MD (1), G.D. Tamagno, PhD (1)
(1) Molecular NeuroImaging LLC, New Haven, CT, USA; (2) Genentech Research and Development, Genentech, South San Francisco, CA, USA; (3) Pharma Research and Early Development. F. Hoffmann-La Roche, Basel, Switzerland; (4) Product Development, F. Hoffmann-La Roche, Basel, Switzerland; (5) Avid Radiopharmaceuticals, Philadelphia, PA, USA

LB13 - The importance of understanding the variable rate of progression among Alzheimer’s disease patients: data from the gantenerumab program
Sylvie Retout, PhD (1), Ronald Gieschke, MD, MSc (1), Cornelia Weber, PhD (1), Jean-Eric Charoin, PharmD (1), Dietmar Volz, PhD (2), Robert Lasser, MD, MBA (2), Nicolas Frey, PharmD (1), Carsten Hofmann, PhD (1)
(1) Roche Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Basel, Switzerland; (2) F. Hoffmann-La Roche Ltd, Basel, Switzerland

LB14 - Using Run-in Data in Secondary Prevention Cognitive Endpoint Trials
Jason Hassenstab, PhD (1,2), Suzanne Hendrix, PhD (3), Noel Elliott, MS (3), Yakeel T. Quiroz, PhD (4,5), Daniel C. Aguine, PhD (4), Eliana Henoa, MA (4), Victoria Tirado MA (4), Claudia Muñoz, MA (4), Jennifer Smith, PhD (1), Francisco R. Lopera, MD, PhD (4), John C. Morris, MD (1), Randall Bateman, MD (1), and the Distinguishly-Inherited Alzheimer Network (DIAN)
(1) Washington University in St. Louis, St. Louis, MO USA; (2) Washington University in St. Louis, St. Louis, MO USA; (3) Penlava Corporation, Salt Lake City, UT USA; (4) Universidad de Antioquia, Medellín, Colombia; (5) Massachusetts General Hospital, Boston, MA USA

LB15 - Sex Differences in Neuropsychiatric Symptoms in Patients with Alzheimer’s Disease
Cynthia A Munro, PhD (1), Ye Tao, BA (1), Matthew E. Peters, MD (1), Lea T.Drye, PhD (2), Davangere P.Devanand, MD (3), Jacobo E.Mintzer, MD (4), Bruce G.Pollock, MD, PhD (5), Anton P.Porsteinsson, MD (6), Paul B.Rosenberg, MD (7), Antonio P.Porsteinsson, MD (6), Paul B.Rosenberg, MD (7), David M.Shade, JD (2), Daniel Weintraub, MD (7), Jerome Yesavage, MD (8), Constantine G. Lyketsos, MD, MHS (1); For the CTAD Research Group
(1) Johns Hopkins University School of Medicine, (2) Johns Hopkins Bloomberg School of Public Health, (3) Columbia University Medical Center, (4) Medical University of South Carolina, Clinical Biotechnology Research Institute-Roper St. Francis Healthcare, Ralph H. Johnson VA Medical Center, (5) University of Toronto, (6) University of Rochester School of Medicine, (7) University of Pennsylvania School of Medicine, (8) Stanford University School of Medicine
CTAD 2015 Program
Friday, November 6th

4.15 pm
**OC46** - Statistical modeling of biomarker profiles for the prediction of rapid cognitive decline in MCI and mild AD subjects
Robin Wolz, PhD (1,2), Katherine R. Gray, PhD (1,2), Maria Rosa, PhD (1), Derek Hill, PhD (1)
(1) IXICO Plc, London, UK; (2) Imperial College London, London, UK

**LB16** - Cholesterol-metabolizing enzyme cytochrome P450 46A1 (CYP46A1) as a new therapeutic target for Alzheimer’s disease
Irina A. Pikuleva, PhD, Natalia Mast, PhD, James Constans, MD, and Ana Valencia-Olvera, PhD
Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH, USA

4.30 pm
**Poster sessions 2 and coffee break** - Gaudi Mezzanine Level

4.45 pm
**OC47** - Consistent Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Across Diverse Neurological Etiologies
Joan Siffert, MD (1), Paul Shin (1), Andrea Formella (1)
(1) Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA

5.00 pm
**KEYNOTE 5 - Catalunya**
Introduction: Jacques Touchon
MCI as a Drug Target: Acceptable or Too Late?
Ronald C. Petersen, MD, PhD, Mayo Clinic, Rochester, MN - USA

5.30 pm
**SYMPOSIUM 3 - Catalunya**
Utility of multi-modal biomarker-endpoint trials in high-risk persons to identify candidate agents for AD prevention trials
Moderator: Marilyn Albert, PhD. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA

1. Study design and cross-sectional analyses of multiple biomarkers in aging persons at high risk of symptomatic AD
John C, S. Breitner, MD, MPH, Douglas Hospital Research Center and McGill University Faculty of Medicine, Montreal, QC, Canada
Judes Poirier, PhD (1,2), Pierre E. Etienne, MD (1,2), Pedro Rosa-Neto, MD, PhD (1,2,3), Jennifer Tremblay-Mercier, MS (1) (1) Douglas Hospital Research Centre, (2) McGill University Faculty of Medicine, (3) McGill Centre for Studies on Aging, Montreal, QC, Canada

2. Genetic, CSF and longitudinal results from PREVENT-AD suggest measurable pre-clinical AD progression susceptible to attenuation
Judes Poirier, PhD, Douglas Hospital Research Centre & McGill University Faculty of Medicine, Montreal, QC, Canada
John C. S. Breitner, MD (1,2), Pierre E. Etienne, MD (1,2), Pedro Rosa-Neto, MD, PhD (1,2,3), Jennifer Tremblay-Mercier, MS (1) (1) Douglas Hospital Research Centre, (2) McGill University Faculty of Medicine, (3) McGill Centre for Studies on Aging, Montreal, QC, Canada

3. Item Response Theory latent variable models may summarize multi-modal biomarker results to measure progress of pre-clinical AD
Jeannie-Marie S. Leoutsakos, PhD, Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
Alden L. Gross, PhD (1), Marilyn Albert, PhD (2), John C. S. Breitner, MD, MPH (3,4) (1) Department of Neurology, Johns Hopkins University School of Medicine, (2) Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, (3) Douglas Hospital Research Centre, (4) McGill University Faculty of Medicine, Montreal, QC, Canada

6.30 pm
**ORAL COMMUNICATIONS SESSION - Catalunya**
Moderator: Giovanni Frisoni

6.30 pm
**OC47** - Consistent Effectiveness of Dextromethorphan/Quinidine for Pseudobulbar Affect Across Diverse Neurological Etiologies
Joan Siffert, MD (1), Paul Shin (1), Andrea Formella (1)
(1) Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA

6.45 pm
**OC48** - Update on FDA qualification of low baseline hippocampal volume as a prognostic biomarker in Alzheimer’s disease clinical trials, for the Coalition Against Major Diseases
Richard Meibach (1), Laurel Beckett (2), Robert Berman (3), Marina Boccardi (4), Maria Carrillo (5), Patricia Cole (6), Giovanni Frisoni (7), Katherine Gray (8), Mark Forrest Gordon (8), James Hendrix (5), Suzanne Hendrix (10), Derek Hill (8), Kaori Ito (11), Jorge Jovicich (12), Paul Maguire (1), Gerald Novak (13), David Raunig (14), Alberto Redolfi (4), Klaus Romero (15), Mahesh N. Santani (13), Rachel Schindler (11), Joyce Suhy (17), Brian Willis (16), Robin Wolz (8), Peng Yu (16), Steve Arneric (15), Diane Stephenson (15)
(1) Novartis, East Hanover, NJ, USA; (2) University of California, Davis, CA, USA; (2) Biohaven Medical Services, New Haven, CT, USA; (3) IRCSS Fatebenefratelli, Italy; (4) Alzheimer’s Association, Chicago, IL, USA; (5) Takeda Development Center Americas, Deerfield, IL, USA; (6) University Hospital of Geneva & University of Geneva; (7) IXICO PLC., London, UK; (8) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; (9) Pentara Corporation, Salt Lake City, USA; (10) Pfizer, Groton, CT, USA; (11) University of Trento, Italy; (12) Janssen Research and Development, Titusville, USA; (13) ICON, Lansdale, PA, USA; (14) Coalition Against Major Diseases, Critical Path Institute, Tucson, AZ, USA; (15) Eli Lilly, Indianapolis, IN, USA; (16) BioClinica, Fremont, CA, USA; (17) BioClinica, Fremont, CA, USA
CTAD 2015 Program
Saturday, November 7th

8.00 am  KEYNOTE 6 - Catalunya
Introduction: Sandrine Andrieu
Construction of cognitive composites for early-stage clinical trials
Suzanne Hendrix, PhD, Pentara Corporation, Salt Lake City, UT, USA

8.30 am  SYMPOSIUM 4 - Catalunya
Observational cohorts and global initiatives for the prevention of Alzheimer’s disease
Moderators: José L Molinuevo, MD (1,2); Jacques Touchon, MD, PhD (3)
(1) BarcelonaBeta Research Centre, Pasqual Maragall Foundation, Barcelona, Spain (2) Alzheimer’s disease and other cognitive disorders unit, IDIBAPS, Hospital Clinic i Universitari, Barcelona; (3) INSERM U1061 Neuropsychiatry: epidemiological and clinical research, Montpellier, France

1. The ALFA and ALFA+ study: cohorts based studies aiming to identify the beginning of AD
José L Molinuevo, MD, PhD (1,2), Juanjo Gispert (1), Karine Fauria (1), Nina Gramunt (1)
(1) BarcelonaBeta Brain Research Centre, Pasqual Maragall Foundation Barcelona, Spain, (2) Alzheimer’s disease and other cognitive disorders unit, IDIBAPS, Hospital Clinic i Universitari, Barcelona

2. Moving from PREVENTion cohorts to interventional studies like the European Prevention of Alzheimer’s dementia project (EPAD)
Craig Ritchie, M.D. on behalf of the EPAD project, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
Karen Ritchie, MD, PhD (1); Katie L Wells, MD, PhD (2,3), Isabelle Carrière (1) (1) INSERM Neuropsychiatry (U1061) Montpellier, France, (2) The Centre for Mental Health, Imperial College London, London, UK, (3) West London Cognitive disorders Treatment and Research unit, West London Mental Health NHS Trust, London, UK

3. US initiatives for prevention of Alzheimer’s disease
Reisa Sperling, MD on behalf of the USPAD
(1) Harvard Medical School, Boston, MA, USA, (2) Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital and Massachusetts General Hospital, Boston, MA, USA

4. Canadian initiatives to prevent AD
Howard Feldman MD (1,2), Howard Chertkow MD (3,4)
(1) University of British Columbia, Vancouver, British Columbia, Canada, (2) UBC Hospital Clinic for Alzheimer’s disease and Related Disorders, Vancouver, British Columbia, Canada, (3) McGill University, Montreal, Quebec, Canada, (4) Canadian Consortium of Neurodegeneration and Aging, Jewish General Hospital, Montreal, Quebec, Canada

9.30 am  ORAL COMMUNICATIONS SESSION - Catalunya
Moderator: Matthieu Ceccaldi

9.30 am  OC49 - RVT-101: review of the preclinical and clinical results and status of the development program
Lawrence T. Friedhoff, MD, PhD, FACP (1), Ilise Lombardo, MD (1), Geetha Ramaswamy, MD (1), Stephen C. Piscitelli, PharmD (2) (1) Axovant Sciences, Inc, New York, NY, USA (2) Roivant Sciences, Inc, New York, NY, USA

9.45 am  OC50 - New Exploratory Alzheimer’s Drug ANAVEX 2-73: Assessment of Safety and Cognitive Performance in a Phase 2a Study in mild-to-moderate Alzheimer’s Patients
Steve Macfarlane, MD (1), Paul Maruff, PhD (2), Marco Cecchi, PhD (3), Dennis Moore, PhD (3), Anastasios Zografidis, PhD (4), Christopher Missling, PhD (4)
(1) Caulfield Hospital, Melbourne, Australia; (2) Cogstate, Melbourne, Australia; (3) Neuronetrix, KY, USA; (4) Anavex Life Sciences, Corp., New York, NY, USA

10.00 am  OC51 - Rationale for the Development of low doses of ITI-007 for the Treatment of Behavioral Disturbances Associated with Dementia
Robert E. Davis, PhD (1), Kimberly E. Vanover, PhD (2), Cedric O’Gorman, MD (2), Jelena Saillard (2)
Sharon Mates, PhD (2)
(1) 3-D Pharmaceutical Consultants, Inc, San Diego, CA, USA; (2) Intra-Cellular Therapies, Inc, New York, NY, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Authors</th>
<th>Institutions</th>
</tr>
</thead>
</table>
| 10.15 am  | SYMPOSIUM 5 - Catalunya | Tau Spread, PET Tracers and Immunotherapy | Molecular Mechanism of Tau Spread and Target Regions for Immunotherapy  
Khalid Iqbal, Ph.D.; Chunling Dai, MD, Ph.D.; Wen Hu, M.D., Ph.D.; Fei Liu, Ph.D.  
New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA  
Characterization and Development of Novel Tau PET Tracers for the assessment of Tau spreading in Alzheimer’s disease  
(1) AC Immune, Lausanne, Switzerland; (2) Piramal Imaging, Berlin Germany  
Two sides of one coin – efficacy and safety in pre-clinical studies on tau immunotherapeutics  
Michal Novak, Axon Neuroscience, Bratislava, Slovak Republic | Chair: Khalid Iqbal, PhD  
New York State Institute for Basic Research in Developmental Disabilities, Staten Island, New York, USA  
New York State Institute for Basic Research in Developmental Disabilities Staten Island, New York, USA |
| 11.15 am  | Poster sessions 3 and coffee break - Gaudi Mezzanine Level | | | |
| 11.45 am  | ORAL COMMUNICATIONS SESSION - Catalunya | | | Moderators: Jeffrey Cummings, Bruno Dubois |
| 11.45 pm  | OC52 | Clinical Trial in MCI Reducing Hippocampal Overactivity: HOPE4MCI | Michela Gallagher (1,2), Marilyn Albert (3), Sharon Rosenzweig-Lipson (2)  
(1) Department of Psychological and Brain Sciences, Johns Hopkins University, Baltimore, MD - USA; (2) AgeneBio, Inc. Baltimore, MD USA; (3) Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD - USA |  
OC53 | Effects of Regular and Long-Acting Insulin on Cognition and AD Biomarkers in MCI and AD: A Pilot Study | Suzanne Craft, PhD (1), Laura D. Baker, PhD (1), Amy Claxton, PhD (2), Angela Hanson, MD (2,3), Hector Hernandez Saucedo, BS (1), Deborah Dahl, RN (1), Bryan Neth, BS (1), Joseph Maldjian, MD (1)  
(1) Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA; (2) Geriatric Research, Education, and Clinical Center, VA Puget Sound, Seattle, WA, USA; (3) Department of Medicine-Geriatrics, University of Washington, Seattle, WA, USA |  
OC54 | NPI Agitation/Aggression Domain as a Useful Clinical Trial Measure: Validity and Correlation with Other NPI and Global Outcomes | Jeffrey Cummings, MD (1), Sanjay Dubé, MD (2,3,4,5), Harry Cui (2), Joao Siffert, MD (2)  
(1) Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA (2) Avarin Pharmaceuticals, Inc., Aliso Viejo, CA, USA (3) Stanford University School of Medicine, Palo Alto, CA, USA (4) Indiana University School of Medicine, Indianapolis, IN, USA (5) University of Pittsburgh School of Medicine, Pittsburgh, PA, USA |  
OC55 | Effect of active Aβ immunotherapy on cellular death pathways in Alzheimer’s disease brain | Claire Paquet MD (1,2,3), Seth Love FRCPath (4), James AR Nicoll FRCPath (5,6), Clive Holmes MRCPsych (5,6), Jacques Hugon MD (1,2,3), Delphine Doche PhD (5)  
(1) INSERM, U942, Paris, France; (2) University of Paris Diderot, Sorbonne Paris Cité, UMR 942, Paris, France; (3) Centre Memoire de Ressources et de Recherche Paris Nord Ile de France AP-HP, Hôpital Lariboisière, Paris, France; (4) Department of Neuropathology, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, UK; (5) Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton UK; (6) Memory Assessments and Research Centre, Moorgreen Hospital, Southern Health Foundation Trust, Southampton UK |  
OC56 | Longitudinal plasma biomarker changes in middle-aged individuals at risk for Alzheimer Disease | Anne M. Fagan PhD (1), Virginia Pérez-Grijalba BS (2), Noelia Fandos BS (2), Pedro Pesini PhD (2), Salvador Olmos PhD (3), Matias Bossa PhD (3), Manuel Sarasà PhD (2), and the ACS research group (1)  
(1) Knight Alzheimer’s Disease Research Center, Department of Neurology, Washington University, St Louis, MO, USA; (2) Araction Biotech, Zaragoza, Spain; (3) Aragon Institute of Engineering Research, University of Zaragoza, Spain |  
| 12.00 pm  | OC52 | Clinical Trial in MCI Reducing Hippocampal Overactivity: HOPE4MCI | Michele Gallagher (1,2), Marilyn Albert (3), Sharon Rosenzweig-Lipson (2)  
(1) Department of Psychological and Brain Sciences, Johns Hopkins University, Baltimore, MD - USA; (2) AgeneBio, Inc. Baltimore, MD USA; (3) Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD - USA |  
OC55 | Effect of active Aβ immunotherapy on cellular death pathways in Alzheimer’s disease brain | Claire Paquet MD (1,2,3), Seth Love FRCPath (4), James AR Nicoll FRCPath (5,6), Clive Holmes MRCPsych (5,6), Jacques Hugon MD (1,2,3), Delphine Doche PhD (5)  
(1) INSERM, U942, Paris, France; (2) University of Paris Diderot, Sorbonne Paris Cité, UMR 942, Paris, France; (3) Centre Memoire de Ressources et de Recherche Paris Nord Ile de France AP-HP, Hôpital Lariboisière, Paris, France; (4) Department of Neuropathology, Institute of Clinical Neurosciences, School of Clinical Sciences, University of Bristol, Bristol, UK; (5) Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton UK; (6) Memory Assessments and Research Centre, Moorgreen Hospital, Southern Health Foundation Trust, Southampton UK |
POSTER PRESENTATIONS

POSTER SESSION 1: Thursday, November 5th ............................. p. 21
   P1-1 to P1-70

POSTER SESSION 2: Friday, November 6th ................................. p. 29
   P2-1 to P2-61

POSTER SESSION 3: Saturday, November 7th .............................. p. 37
   P3-1 to P3-27
POSTER SESSION 1: Thursday, November 5th

THEME 1: Clinical Trials Methodology

P1-1 VALIDATING THE PGSA (PLACEBO GROUP SIMULATION APPROACH) USING DATA FROM A COMPANY-SPONSORED MCI DRUG TRIAL
René Spiegel PhD1, Andreas U. Monsch PhD1, André Miseriez MD2, Manfred Berres PhD3
(1) Felix Platter Hospital, University Center for Medicine of Aging Basel, Switzerland; (2) Diagene Laboratories Inc., Reinach, Switzerland; (3) University of Applied Sciences Koblenz, RheinAhrCampus, Remagen, Germany

P1-2 COMPARATIVE TRADITIONAL PSYCHOMETRICS OF COGNITIVE AND FUNCTIONAL ENDPOINTS IN A PRODROMAL ALZHEIMER’S DISEASE POPULATION
Chris Edgar, PhD (1), Angela J Rylands, PhD, CPsychol (1), Dietmar Volz, PhD (2), Michaela Mertes (2), Elisabeth Grunendi, PhD (2), Paulo Fontoura, MD, PhD (2), Luca Santarelli, MD (2), Robert Lasser, MD, MBA (2)
(1) Roche Products Limited, Welwyn Garden City, UK; (2) F. Hoffmann-La Roche Ltd, Basel, Switzerland

P1-3 DESIGNING A FIRST INTERVENTIONAL PHASE 2A TRIAL IN FTD-GRN WITH AN HDAC INHIBITOR (FRM-0334)
Hans J Moebius, MD, PhD (1), Nancy Dgetluck, MS (1), Gordon Loewen, PhD (1), Holger Patzke, PhD (1), Adam L Boxer, MD, PhD (2), Dana C Hilt, MD (1)
(1) FORUM Pharmaceuticals Inc, Waltham, MA, USA; (2) Neurosciences Clinical Research Unit, University of California, San Francisco, CA, USA

P1-4 CAUSAL ANALYSIS WITH TRUNCATION BY DEATH IN RANDOMIZED AND NON-RANDOMIZED CLINICAL TRIALS
Xiao-Hua Zhou (1,2,3), Linbo Wang (1)
(1) Department of Biostatistics, University of Washington, Seattle, WA, USA; (2) National Alzheimer’s Coordinating Center (NACC), University of Washington, Seattle, WA, USA; (3) Biostatistics Unit, U.S. Department of Veterans Affairs Seattle Medical Center, Seattle, WA, USA

P1-5 EXPERIENCES AND PERSPECTIVES OF STUDY PARTNERS INVOLVED IN DEMENTIA RESEARCH
Betty S. Black, PhD (1), Holly A. Taylor, PhD (2), Peter V. Rabins, MD (3), Jason Karlawish, MD (4)
(1) Department of Psychiatry & Behavioral Sciences, Johns Hopkins School of Medicine and the Johns Hopkins Berman Institute of Bioethics, Baltimore, MD, USA; (2) Department of Health Policy & Management, Johns Hopkins School of Public Health and the Johns Hopkins Berman Institute of Bioethics, Baltimore, MD, USA; (3) Department of Psychiatry & Behavioral Sciences, Johns Hopkins School of Medicine and the Johns Hopkins Berman Institute of Bioethics, Baltimore

P1-6 FUNDACIÓ ACE HEALTHY BRAIN INITIATIVE (FACEHBI): A LONGITUDINAL STUDY OF BIOMARKERS AND COGNITION IN INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE
O. Rodríguez-Gómez (1) MD, A. Sanabria (1) MS, A. Pérez-Cordón (1) MS , S. Ruiz (1), M. Tarragona (1), D. Sánchez-Ruíz (1) MD, S. Moreno-Grau (1) MS, J. Pavia (2) PhD, F. Campos (2) MS, A. Vivas (3) MD, M. Gómez (3) MD, M. Tejero (3) RT, M. Alegret (1) PhD, A. Espinosa (1) MS, G. Ortega (1) PhD, C. Abdelnour (1) MD, M. Rosende-Roca (1) MD, A. Boada (1) MD, L. Vargas (1) MD, E. Martín (1) MS, S. Valero (1) PhD, O. Sotolongo-Grau (1) PhD, A. Ruiz (1) MD PhD, I. Hernández (1) MD, Ph. J. Giménez (3) MD, F. Lomeña (2) MD, L. Tárraga (1) MS, M. Boada (1) MD PhD
(1) Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; (2) Servei de Medicina Nuclear, Hospital Clínic i Provincial. Barcelona, Spain; (3) Departament de Diagnòstic per la Imatge, Clínica Corachan, Barcelona, Spain

P1-7 DEVELOPMENT OF A COGNITIVE SAFETY INDEX FOR MONITORING ADVERSE EVENTS IN INDIVIDUALS TAKING PART IN CLINICAL TRIALS OF ANTI-AMYLOID DRUGS
Paul Maruff, Yen Ying Lim (1,2), Peter J. Snyder (2), Victor L. Villemagne (1,6,7), David Ames (8,9), Christopher C. Rowe (6,7), Robert Pietrzak, Colin L. Masters (1)
(1) The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; (2) Department of Neurology, Warren Alport School of Medicine of Brown University & Lifespan Hospital System, Providence, RI, USA; (3) Centre of Excellence for Alzheimer’s Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia; (4) Sir James McCusker Alzheimer’s Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia; (5) Co-operative Research Centre for Mental Health, http://www.mentalhealthcrc.com; (6) Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia; (7) Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia; (8) Academic Unit for Psychiatry of Old Age, St. Vincent’s Health, The University of Melbourne, Kew, Victoria, Australia; (9) National Ageing Research Institute, Parkville, Victoria, Australia; (10) CogState Ltd., Melbourne, Victoria, Australia

P1-8 SIMAMCI: A RANDOMIZED CONTROLLED TRIAL OF SIMVASTATIN IN AMNESTIC MCI PATIENTS FOR THE PREVENTION OF CONVERSION TO ALZHEIMER’S DEMENTIA
Brigitte Haas, PhD, Arne Klostermann, Oliver Peters, MD, Isabella Heuser, MD, PhD
Department of Psychiatry, Charité University Medicine Berlin, Berlin, Germany
### POSTER PRESENTATIONS

**POSTER SESSION 1: Thursday, November 5th**

**P1-9**

**ANALYSING TIME TO EVENT DATA IN DEMENTIA PREVENTION TRIALS: THE EXAMPLE OF THE GUIDAGE STUDY OF EGB761®**

SCHERRER B (1), ANDRIEU S (2,3,4,5), OUSSET P-J (7), DUBOIS B (8), PASQUIER F (9), PIETTE F (10), ROBERT P (11), TOUCHON J (12), GARNIER P (13), MATHIEX-FORTUNET H (13), VELLAS B (2,3,4), and the GuidAge Study Group*

(1) Bruno Scherrer Conseil, Saint-Arnoult en Yvelines, France; (2) INSERM, U1027, Toulouse, France; (3) University of Toulouse III, Toulouse, France; (4) Gerontopole, Toulouse University Hospital, Toulouse, France; (5) Department of Epidemiology and Public Health, Toulouse University Hospital, Toulouse, France; (6) Clinical Gerontology Department, Nantes University Hospital, Nantes, France; (7) INSERM U897, University of Bordeaux II, Bordeaux, France; (8) Department of Neurology and Alzheimer Institute, Salpêtrière University Hospital, Paris, France; (9) University Lille Nord de France, UDSL EA1046, Centre Hospitalier Universitaire, Lille, France; (10) Gerontology Department, Charles Foix Hospital, Pierre and Marie Curie University, Ivry-sur-Seine, France; (11) Memory Center–EA CoBeTKe Centre Hospitalier Universitaire, University of Nice Sophia Antipolis, Nice, France; (12) Neurology Department, INSERM U1061, Montpellier University Hospital, Montpellier, France; (13) Ipsen, Boulogne, France

**P1-10**

**INFLAMMATORY MARKERS IN ALZHEIMER’S DISEASE WITH VARIOUS DEGREES OF DEMENTIA SEVERITY**

Tatyana Klyushnik, Lyubov Androsova, Natalia Mikhailyova, Svetlana Zozulya, Alexander Dupin, Svetlana Gavrilova

FSGI “The Mental Health Research Centre”, Moscow, Russia

**P1-11**

**STATISTICAL PROPERTIES OF COMPOSITE SCALES**

Hong Liu-Seifert, PhD (1), Scott Andersen, MS (1), Michael Case, MS (1), JonDavid Sparks, PhD (1), Suzanne Hendrix, PhD (2), Paul Aisen, MD (3), Eric Siemers, MD (1)

(1) Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; (2) Pentara Corporation, Salt Lake City, UT, USA; (3) Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA

**P1-12**

**APPLICATION OF NEUROCIRCUITRY-BASED ASSESSMENTS USING EEG/ERP AND FMRI TO ASSESS NOVEL MOLECULES IN EARLY PHASE CLINICAL DEVELOPMENT FOR BEHAVIOURAL AND PSYCHIATRIC SYMPTOMS ASSOCIATED WITH DEMENTIA**

Brett A. English, PharmD, PhD (1,2), Jack Johnstone, PhD (3), Alex Korb, PhD (4), Lev Gertsik, MD (5), Lovingly Q. Park, PhD (5), Niki Osmo (1), Larry Ereshefsky, PharmD (1,6)

(1) PAREXEL International Glendale, CA; (2) Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN; (3) Q-Metrix, Glendale, CA; (4) Department of Psychiatry, University of California, Los Angeles; (5) California Clinical Trials Medical Group, Glendale, CA; (6) University of Texas College of Pharmacy, Austin, TX; Glendale, CA

**P1-13**

**ENHANCING CLINICAL TRIAL RECRUITMENT IN ALZHEIMER’S DISEASE RESEARCH THROUGH MOBILE CLINICAL TRIAL UNIT**

Jill Smith, MA, CCRC (1); Amanda Smith, MD (1), Dave Morgan, PhD (1)

(1) USF Health Byrd Alzheimer’s Institute, University of South Florida, Tampa FL USA

**P1-14**

**A METHODOLOGY FOR EVALUATING CLINICAL TRIAL SITES AND RATERS BASED ON PERFORMANCE DATA**

Miller, D (1), Feaster, T (1), Allen, S (1), Gratkowski, H (1), Butler, A (1)

(1) Bracket, Wayne, PA, USA

**P1-15**

**EFFICIENCY OF TELEPHONE PRESCREENING FOR THE A4 TRIAL**

Kristine Lipowski (1), Oikkes Kuybu (1), Carly Oboudiyat (1), Raj C. Shah (2), Neelum T. Aggarwal (2), Sandra Weintraub (1)

(1) Northwestern University Cognitive Neurology and Alzheimer’s Disease Center, Chicago, IL; (2) Rush Alzheimer’s Disease Center, Chicago, IL

**P1-16**

**ASSESSING ELIGIBILITY FOR PRODROMAL AND PRECLINICAL AD TRIALS USING THE LUMOSITY BRAIN PERFORMANCE TEST AND THE BRAIN HEALTH REGISTRY**

Rachel L Nosheny PhD (1), Derek Flenniken (1), Philip S Insel (1), R Scott Mackin PhD (1,2), Shannon Finley (1), Monica Camacho (1), Diana Truran (1), Glenn Morrison PhD (3), Nicole Ng (3), Daniel Sternberg PhD (3), Michael W Weiner MD (1,4)

(1) Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, CA; (2) UCSF Department of Psychiatry, San Francisco, CA; (3) Lumos Labs. Inc. San Francisco, CA; (4) UCSF Department of Radiology and Biomedical Imaging, San Francisco, CA

**P1-17**

**DEVELOPMENT OF AD CLINICAL RESEARCH: EXAMPLE OF THE NORTH OF FRANCE MEMORY CLINICS NETWORK “MEOTIS3RC”**

Catherine Adnet-Bonte, MD (1), Laetitia Breuilh, PhD (2,3), Florence Pasquier, MD, PhD (2,3)

(1) Meotis, Centre Hospitalier Regional Universitaire de Lille, France; (2) Neurology Department, Centre Hospitalier Regional Universitaire de Lille, France; (3) Excellence Laboratory DISTALZ
POSTER SESSION 1: Thursday, November 5th

THEME 2: Clinical Trials Results

P1-18  EFFECTS OF MULTIMODAL COGNITIVE ENHANCEMENT THERAPY (MCET) FOR PEOPLE WITH MILD COGNITIVE IMPAIRMENT AND EARLY STAGE DEMENTIA: A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, CROSS-OVER TRIAL

- Ji Won Han, MD (1), Hyegong Lee, MD (2), Joo Young Kong, MD (1), Tae Hyeon Kim, MD (1) , Hyun-Jin Byun, MD (1), Seung-Ho Ryu, MD, PhD (3), Kangjin Lee, MD, PhD (4), Nam-Jin Lee, MD (5), Ki Woong Kim, MD, PhD (1,6,7)
- Department of Neuropsychiatry, Seoul National University Bundang Hospital, Seongnam, Korea; (2) Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Korea; (3) Department of Neuropsychiatry, Kyunggi Provincial Hospital for the Elderly, Yongin, Korea; (4) Department of Psychiatry, School of Medicine, Konkuk University, Konkuk University Medical Center, Seoul, Korea; (5) Department of Psychiatry, Jeonju City Welfare Hospital for the Elderly, Jeonju, Korea; (6) Department of Brain and Cognitive Science, Seoul National University College of Natural Sciences, Seoul, Korea; (7) Department of Psychiatry, Seoul National University College of Medicine, Seoul, Korea

P1-19  AN INTELLIGENT SYSTEM FOR MONITORING PEOPLE WITH DEMENTIA

- Edgar Batista, Frederic Borras, Antonio Martinez-Ballesta, Agusti Solanas
- Smart Health Research Group, Universitat Rovira i Virgili, Tarragona, Catalonia, Spain

P1-20  PHASE I STUDIES EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE-RISING DOSES OF BI 409306 IN YOUNG AND ELDERLY HEALTHY VOLUNTEERS

- Glen Wunderlich, PhD (1), Wolfgang Timmer, MD (2), Grit Andersen, MD (3), Anja Hoch (4), Viktoria Moschetti, MD (5), Katja Boland, PhD (4), Heike Zimdahl-Gelling, PhD (4), Andreas Botta MD, PhD (4), Michael Sand PhD, MPH (6)
- (1) Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada; (2) CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany; (3) Profil Institut für Stoffwechselfororschung GmbH, Neuss, Germany; (4) Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany; (5) Boehringer Ingelheim Pharmaco GmbH & Co. KG, Ingelheim am Rhein, Germany; (6) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA

P1-21  CUMULATIVE CLINICAL Efficacy OF Idalopidine, A 5-Ht6 Antagonist IN ADVANCED DEVELOPMENT FOR TREATMENT OF Alzheimer's Disease

- Alireza Ataj, MD, PhD (1), Kristian Windfeld, PhD (2), Benoit Rive, PhD (3)
- (1) Ray Dolby Brain Health Center, California Pacific Medical Center, San Francisco, CA; Dept. of Neurology, Massachusetts General Hospital; and Harvard Medical School, Boston MA, USA; (2) H. Lundbeck A/S, Valby, Denmark; (3) Lundbeck SAS, Issy-les-Moulineaux, France

P1-22  THE ROSAS STUDY: A LONG-TERM, LONGITUDINAL, MULTI-PARAMETRIC AND COMPARATIVE EVALUATION OF ALZHEIMER'S DISEASE PROGRESSION IN A UNIQUE COHORT OF PATIENTS

- Pierre-Jean Ousset, MD (1), Maria Pueyo, MD (2), Ph.D, Maria Soto, MD (1), Ph.D, Vera Kiyasova, MD, PhD (2), PhD, Isabelle Guignot, MS (2), Eva Bouguen, MSc (2), Stéphane Galtier, MSc (2), Fabrice Bonneville, MD (1), PhD, Françoise Lala, MD (1), Nathalie Sastre, MD (1), Julien Delrieu, MD (1), Bruno Vellas, MD (1), PhD
- (1) Gerontopôle, INSERM U 1027, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, France; (2) Institute de Recherches Internationales SERIEV, Suresnes, France

P1-23  PHARMACOKINETICS AND TARGET ENGAGEMENT PROFILE OF RESTERATOL IN HUMAN BLOOD: IMPLICATIONS FOR AD CLINICAL TRIALS

- Louise Mont, MS (1, 2), Darren Insko, PhD (1, 2), Paula Desplats, PhD (2), Paul S. Asien, MD (1, 2), R. Scott Turner, MD, PhD (3), Robert A. Rissman, PhD (1, 2)
- (1) Alzheimer's Disease Cooperative Study; (2) Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA; (3) Department of Neurology, Georgetown University, Washington, DC, USA

P1-24  COGNITIVE AND FUNCTIONAL EFFICACY OF TRANIMPROSE IN APOE4+ PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE: SUBGROUP ANALYSES OF THE PHASE 3 NORTH AMERICAN AND EUROPEAN TRIALS

- John A. Hey (1), Jeremy Yu (1), Martin Tolar (1), Menghis Bairu (2), John Sampalis (3)
- (1) Alzheon, Inc., Framingham, MA, USA; (2) Serenus Biotherapeutics, Inc., San Francisco, CA, USA; (3) JSS Medical Research, Inc., St. Laurent, QC, Canada & McGill University, Montreal, QC, Canada

P1-25  DISEASE-MODIFYING EFFECT OF B-VITAMINS ON BRAIN ATROPHY AND COGNITIVE DECLINE IN MCI IS ENHANCED BY OMEGA-3 FATTY STATUS

- A.D. Smith (1), A. Oulhaj (2), F. Jerneren (1), H. Refsum (1, 3), C.A. de Jager (4)
- (1) OPTIMA, Department of Pharmacology, University of Oxford, Oxford, United Kingdom; (2) Institute of Public Health, College of Medicine and Health Sciences, United Arab Emirates University; United Arab Emirates; (3) Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway; (4) Division of Geriatric Medicine, Department of Medicine, University of Cape Town, Cape Town, South Africa

P1-26  HEALTHY AGING THROUGH INTERNET COUNSELING IN THE ELDERLY (HATICE) – A LARGE PREVENTION TRIAL

- Academic Medical Center, dept of Neurology, Amsterdam; INSERM U1027, University of Toulouse III; Dept. of Epidemiology and Public Health and Gerontopôle, Toulouse University Hospital; Dept. of Neurology, University of Eastern Finland, Kuopio; Dept. of Public Health and Primary Care, Institute of Public Health, Cambridge, UK; NOVAPTE; Aging Research Center, Dept. of Neurobiology, Health Care Sciences and Society, Karolinska Institute, Stockholm; Dept. of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki; VitalHealth Software; Academic Medical Center, dept of primary care, Amsterdam
POSTER PRESENTATIONS

POSTER SESSION 1: Thursday, November 5th

P1-27 PHARMACOKINETIC AND PHARMACODYNAMIC (PK/PD) ASSESSMENT AND COVARIATE ANALYSIS FOR ADUCANUMAB (BIIB037) IN PATIENTS WITH PRODROMAL OR MILD ALZHEIMER’S DISEASE: INTERIM RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 1B STUDY
Yaming Hang (1), PhD, Ping Chiao (1), PhD, Jeff Sevigny (1), MD, Leslie Williams (1), DVM, MPH, Xiaopeng Miao (1), PhD, John O’Gorman (1), PhD, Alyx Mikulskis (1), Kate Leitermann (1), James Ferrero (1), PhD
(1) Biogen, Cambridge, MA, USA

P1-28 COMPARATIVE EFFICACY AND SAFETY OF ANTIDEPRESSIVE MONO- AND MULTIMODAL THERAPY IN ELDERLY PATIENTS WITH DEPRESSION IN PSYCHOGERIATRIC HOSPITAL
Y.B. Kalyn, T.P. Safarova, V.S. Sheshenin, S.I. Gavrilova
FSGI “The Mental Health Research Centre”, Moscow, Russia

P1-29 COGNITIVE RESPONSE TO METFORMIN IS ASSOCIATED WITH PRE-TREATMENT CSF Aβ1-42 LEVELS: SECONDARY ANALYSIS OF DATA FROM PILOT STUDY OF METFORMIN’S EFFECTS ON BIOMARKERS OF ALZHEIMER’S DISEASE
Aaron M. Koenig MD (1,2,5), David A. Wolk MD (1,3), Dawn Mechanic-Hamilton PhD (1,2), Sharon X. Xie PhD (4), Martha F. Combs MS (1,2), Steven E. Arnold MD (1,2,3,6)
(1) Penn Memory Center, University of Pennsylvania, Philadelphia, PA, USA; (2) Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; (3) Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA; (4) Department of Epidemiology & Biostatistics, University of Pennsylvania, Philadelphia, PA, USA; (5) Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA (Current affiliation); (6) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA (Current affiliation)

P1-30 PREVENTION OF COGNITIVE DECLINE AND IMPROVEMENT OF INNATE IMMUNITY IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT BY OMEGA-3 FATTY ACID AND ANTI-OXIDANT SUPPLEMENTATION
M. Fiala, M.D
Surgery Department, UCLA, Los Angeles, CA, USA

P1-31 ACCELERATING PATIENT RECRUITMENT IN EARLY ALZHEIMER’S DISEASE
Hans Chr. Hoeck, MD, PhD (1), Mette Skaksen (2), Tue K. Rasmussen, MD, PhD (2), Peter Alexandersen, MD, DMSc (3), Line M. Lindgren MD (4), Anthony Frankland (1), Roger Bullock, MD (1)
(1) CCBR, Stans, NW, Switzerland; (2) CCBR, Aalborg, Denmark; (3) CCBR, Vejle, Denmark; (4) CCBR, Copenhagen, Denmark

THEME 5: Clinical Trials and Cognitive Endpoints

P1-32 EFFICIENCY OF COGNITIVE REHABILITATION IN ALZHEIMER’S DISEASE: A ONE YEAR FOLLOW-UP STUDY
Sophie Germain, PhD (1,2), Vinciane Wojtasik (1), Françoise Lekeu PhD (1), Anne Quittre (1), Catherine Olivier (1), Vinciane Godichard MA (1), Eric Salmon, MD, PhD (1,3)
(1) Memory Clinic, Department of Neurology, C.H.U. Liège, Belgium; (2) Neuropsychology Unit, Department of Psychology: Cognition and Behavior, University of Liège, Belgium; (3) Cyclotron Research Centre, University of Liège, Belgium

P1-33 CLINICAL CORRELATES OF COGNITIVE SCALES USED AS PRIMARY ENDPOINTS IN PRODROMAL ALZHEIMER’S DISEASE CLINICAL TRIALS
Steven D. Edland (1,2)
(1) Department of Neurosciences, University of California San Diego, La Jolla, CA, USA; (2) Division of Biostatistics, Department of Family & Preventive Medicine, University of California San Diego, La Jolla, CA, USA

P1-34 DAILY FUNCTIONING BENEFITS OF ADDING MEMANTINE TO STABLE CHOLINESTERASE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE ALZHEIMER’S DISEASE: A POST HOC POOLED FACTOR ANALYSIS
Gustavo Alva, MD (1), Noel Ellison, MS (2), Biplob Dass, PhD (3), Suzanne Hendrix, PhD (2)
(1) ATP Clinical Research, Costa Mesa, CA, USA; (2) Pentara Corporation, Salt Lake City, UT, USA; (3) Prescott Medical Communications Group, Chicago, IL, USA

P1-35 IMPROVEMENT IN VISION, COGNITION, AND NEUROPSYCHIATRIC SYMPTOMS FOLLOWING CATARACT SURGERY IN SUBJECTS WITH DEMENTIA
Alan J. Lerner (1,4), Sara M. Debanne (2), Julie K. Belkin (3,4), Jonathan H. Lass (3,4), Paula K. Ogrocki (1,4), Tatiana M. Riedel (6), Susie A. Sami (4), Thomas L. Steinemann (3,5), Grover C. Gilmore (6)
(1) Department of Neurology, Case Western Reserve University, Cleveland, OH, USA; (2) Epidemiology and Biostatistics Case Western Reserve University, Cleveland, OH, USA; (3) Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH, USA; (4) Department of Neurology, University Hospitals Case Medical Center, Cleveland, OH, USA; (5) Department of Ophthalmology, MetroHealth Medical Center, Cleveland, OH, USA; (6) Jack, Joseph and Morton Mandel School of Applied Social Sciences, Case Western Reserve University, Cleveland, OH, USA

P1-36 THE ADAS-COG NAME ITEM: MORE TROUBLE THAN IT IS WORTH?
Selam Negash (1), Christopher Weber (1), Lori Garzio (1), Christopher Randolph (1,2)
(1) MedAvante, Inc, (2) Loyola University Medical Center
POSTER SESSION 1: Thursday, November 5th

P1-37 MEASURING EXECUTIVE FUNCTION USING A SIMPLE, CULTURE- AND EDUCATION-FREE TASK
Michael D. Lee, PhD, (1), Melinae Abramyan, (1), William R. Shankle, MS MD, (1,2,3)
(1) Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA; (2) Medical Care Corporation, Irvine, CA, USA; (3) Hoag Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA USA

P1-38 AN INNOVATIVE COGNITIVE INTERVENTION GROUP PROGRAM FOR PATIENTS WITH MILD COGNITIVE IMPAIRMENT: TRAIN YOUR BRAIN
YanHong Dong, PhD, (1,2), Kim A. Granland, MSci (2,3)
(1) Psychological Medicine, National University Hospital, Singapore, (2) Memory Ageing and Cognition Center, Pharmacology, National University Health System, Singapore, Singapore, (3) James Cook University, Singapore Campus, Singapore

P1-39 IMPACT OF EXPERT DATA REVIEW AND CENTRALIZED SCORING ON TEST-TEST RELIABILITY OF THE ADASCOG
Alexandra S Atkins, PhD, (1), Ioan Strenciu, PhD, (1), Vicki G. Davis, DrPH, (1), Tiffany Williamson, BA, (1), Kelley Boyd, BS, (1), Lyn Harper Mozley, PhD, (2), Tiffini Voss, MD, (2), Kerry Budd-McMahon, Dr, (2), Richard SE Keefe, PhD, (1,3)
(1) NeuroCog Trials, Durham, NC, USA, (2) Merck & Co, Inc., Kenilworth, NJ, USA, (3) Duke University Medical Center, Durham, NC, USA

P1-40 CREATION OF A MOBILE RESEARCH TEAM TO ALLOW EQUAL OPPORTUNITY FOR PATIENTS WITH ALZHEIMER DISEASE
Emilie Chrétien, PhD, (1); Jing Xie, MD, (1); Christelle Mouchoux, MD, (1); Pierre Krolak-Salmon, MD, (1)
(1) CRC VCF, Hôpital des Charpennes, Villeurbanne, France

P1-41 EFFECT OF CIRCADIAN RHYTHM ON COGNITION TESTING IN A PHASE 2B MILD/MODERATE ALZHEIMER’S DISEASE (AD) STUDY4
Dana C Hilt MD, (1), Nancy Dgetluck, MS, (1), Stephen Sainati, MD, (1), Hans J Moebius, MD, PhD (1)
FORUM Pharmaceuticals, Waltham MA, USA

P1-42 THE IMPACT OF ELECTRONIC ADMINISTRATION OF THE ADAS-COG, MMSE AND CDR ON CLINICAL TRIAL DATA QUALITY
David Miller, MD, MA, (1), Todd Feaster, PsyD, (1), Antonio Hernandez, PsyD, (1), Jessie He, MD, (2), Alan Kott, MUDr, (3)
(1) Bracket, Wayne, PA, USA, (2) F. Hoffmann-La Roche, Shanghai, China, (3) Bracket, Prague, Czech Republic

P1-43 THE INFLUENCE OF THE SUBCORTICAL ISCHEMIA AND COGNITIVE PATTERNS AND THEIR CHANGES IN NORMAL HOSPITAL VISITED ELDERLY
Sang Joon Ahn, MD, (1), Bon D. Ku, MD, (2), Hye-Yoon Kim, MD, (2), Min Sung Koo, MD, PhD (3)
(1) Neurology Department, Seoul National University, Seoul, South Korea; (2) Neurology Department, Catholic Kwandong University, Incheon, South Korea; (3) Psychiatry Department, Catholic Kwandong University, Incheon, South Korea

P1-44 RELATIONSHIP BETWEEN SUBJECTIVE AND OBJECTIVE MEMORY IMPAIRMENT IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND NORMAL AGING
Montserrat Alegrat, PhD, (1), Octavio Rodriguez, MD, (1), Ana Espinosa, MSc, (1), Gemma Ortega, PhD, (1), Angela Sanabria, MSc, (1), Sergio Valero, PhD, (1,2), Isabel Hernandez, MD, PhD, (1), Maitè Rosende-Roca, MD, (1), Liliana Vargas, MD, (1), Carla Abdelnour, MD, (1), Ana Mauleón, MD, (1), Anna Gaihajanet, MSc, (1), Elvira Martín, MSc, (1), Lluís Tarragà, MSc, (1), Dorene M. Rentz, PsyD, (3,4), Rebecca E. Amarioglio, PhD, (3,4), Agustín Ruiz, MD, PhD, (1), Mónica Boada, MD, PhD (1)
(1) Alzheimer Research Center and Memory Clinic of Fundació ACE. Institut Català de Neurociències Aplicades, Barcelona, Spain; (2) Psychiatry Department. Hospital Universitari Vall d’Hebron, CIBERSAM. Universitat Autònoma de Barcelona, Spain; (3) Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women’s Hospital, Boston, MA, USA; (4) Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

P1-45 REGIONAL WHITE MATTER DISRUPTIONS OF CINGULUM IN MILD COGNITIVE IMPAIRMENT DEFINED BY FUNCTIONAL AND COGNITIVE CRITERIA
Yu-Ling Chang, PhD, (1,2), Yu-Shuan Yen, MS, (1), Pei-Cing Chen, MS, (1), Chia-Hua Lin, BS, (1), Yi-Yuan Zhuo BS, (1), Ta-Fu Chen, MD (3), Sui-Hsing Yan, MD, (4), Wen-Yih Isaac Tseng, MD, PhD, (2,5,6,7)
(1) Department of Psychology, National Taiwan University, Taipei, Taiwan; (2) Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan; (3) Department of Neurology, National Taiwan University Hospital, Taipei, Taiwan; (4) Section of Neurology, Renai Branch, Taipei City Hospital, Taipei, Taiwan; (5) Graduate Institute of Medical Devices and Imaging System, National Taiwan University, Taipei, Taiwan; (6) Graduate Institute of Brain and Mind Sciences, National Taiwan University, Taipei, Taiwan; (7) Department of Medical Imaging, National Taiwan University Hospital, National Taiwan University, Taipei, Taiwan

P1-46 Δ SCORES PREDICT AD CONVERSIONS FROM MCI. CASE-SELECTION FOR EARLY INTERVENTIONS
Donald R. Royall, MD, (1-4), Raymond F. Palmer, PhD (3)
(1) Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA; (2) Department of Medicine, UTHSCSA, San Antonio, Texas, USA; (3) Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA; (4) South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA
P1-47  DIFFERENTIAL EFFECTS OF VASCULAR AND AMYLOID PATHOLOGY ON COGNITIVE FUNCTIONS IN MILD COGNITIVE IMPAIRMENT

Elena Rolandi (1), Moira Marizzoni (1), Samantha Galluzzi (1), Jorge Jovicich (2), Flavio Nobili (3), Mira Didic (4,5), David Bartre-Faz (6), Ute Fiedler (7), Peter Schonknecht (8), Pierre Payoux (9), Alberto Beltramello (11), Andrea Soricelli (12,13), Lucilla Parnetti (14), Magda Tsolaki (15), Paolo Maria Rossini (16,17), Philip Scheltens (18), Gianluigi Forloni (19), Regis Bordet (20), Olivier Blin (21), Giovanni Battista Frisoni (1,22); on behalf of the PharmaCog Consortium

(1) Laboratory of Neuroimaging and Alzheimer’s Epidemiology, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; (2) Center for Mind/Brain Sciences, Dept. of Cognitive and Education Sciences, University of Trento, Trento, Italy; (3) Department of Neuroscience, Ophthalmology, Genetics and Mother–Child Health (DINOGMI), University of Genoa, Genoa, Italy; (4) APHM, CHU Timone, Service de Neurologie et Neuropsychologie, Marseille, France; (5) Aix-Marseille Université, INSERM U 1106, Marseille, France; (6) Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain; (7) LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany; (8) Department of Neuroradiology, University Hospital Leipzig, Leipzig, Germany; (9) INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France; (10) Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France; (11) Department of Neuroradiology, General Hospital, Verona, Italy; (12) IRCSS S.Raffaele, Milano, Italy; (13) University of Naples Parthenope, Naples, Italy; (14) Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy; (15) 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece; (16) Dept. Geriatrics, Neuroscience & Orthopaedics, Catholic University, Policlinic Gemelli, Rome, Italy; (17) IRCSS S. Raffaele Pisana, Rome, Italy; (18) Alzheimer Centre and Department of Neurology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; (19) Neuroscience Department, IRCCS Istituto di Ricerche Farmacologiche «Mario Negri», Milano, Italy; (20) Department of Pharmacology, EA1046, University of Lille Nord de France, Lille Cedex, France; (21) Pharmacology, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University- CNRS UMR 7289, Marseille, France; (22) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

P1-48  ACEMOBILE – UTILIZING AN APP PLATFORM TO SUPPORT DEMENTIA RESEARCH VIA PARALLELED SUPPORT AND DATA ACQUISITION: AN UPDATE

Craig Newman, PhD, DClinPsych (1), John Hodges, MD (2), Stephen Pearson, MD (3), Rupert Noad, MPhil, DClinPsych (4)

(1) Plymouth University Peninsular Schools of Medicine and Dentistry, Plymouth, UK; (2) Neuroscience Research Australia, New South Wales, Australia; (3) Devon Partnership Trust, Devon, UK; (4) Plymouth Hospital NHS Trust, Plymouth UK

P1-49  THE SKT SHORT COGNITIVE PERFORMANCE TEST: A REGRESSION-BASED SCALING OF A PROVEN NEUROPSYCHOLOGICAL TEST ESPECIALLY FOR PRE-CLINICAL STAGES OF NEUROCOGNITIVE DISORDERS

Brenda L. Plassman, PhD (1,2), Andreas Monsch, PhD (3), Kathleen A. Welsh-Bohmer, PhD (1,2), Heather Romero, PhD (1,2), Kathleen M. Hayden, PhD (1,2,4), Kumar Budur, MD (5), Grant Runyan, PhD (5), Stephen Crawford, PhD, MHS (6), Mark Atkinson, PhD (6), Toyoji Oguri (6), Alexandra Atkins, PhD (7), Nicole Turcotte, MA (7), Richard Keefe, PhD (7), Shyama Brewster (8), Daniel K. Burns, PhD (8), Allen D. Roses, MD (8) for the TOMMOROW study investigators

(1) Joseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC, USA; (2) Department of Psychiatry, Duke University Medical Center, Durham, NC, USA; (3) University of Basel, Basel, Switzerland; (4) Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA; (5) Takeda Development Center Americas, Inc., Deerfield, IL, USA; (6) Covance Inc, Princeton, NJ, USA; (7) NeuroCog Trials Inc., Durham, NC, USA; (8) Zinfandel Pharmaceuticals, Inc., Chapel Hill, NC, USA

P1-50  NORMATIVE STUDY OF THE GERMAN LANGUAGE TOMMOROW NEUROPSYCHOLOGICAL BATTERY

Brenda L. Plassman, PhD (1,2), Andreas Monsch, PhD (3), Kathleen A. Welsh-Bohmer, PhD (1,2), Heather Romero, PhD (1,2), Kathleen M. Hayden, PhD (1,2,4), Kumar Budur, MD (5), Grant Runyan, PhD (5), Stephen Crawford, PhD, MHS (6), Mark Atkinson, PhD (6), Toyoji Oguri (6), Alexandra Atkins, PhD (7), Nicole Turcotte, MA (7), Richard Keefe, PhD (7), Shyama Brewster (8), Daniel K. Burns, PhD (8), Allen D. Roses, MD (8) for the TOMMOROW study investigators

(1) Joseph and Kathleen Bryan ADRC, Duke University Medical Center, Durham, NC, USA; (2) Department of Psychiatry, Duke University Medical Center, Durham, NC, USA; (3) University of Basel, Basel, Switzerland; (4) Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Winston-Salem, NC, USA; (5) Takeda Development Center Americas, Inc., Deerfield, IL, USA; (6) Covance Inc, Princeton, NJ, USA; (7) NeuroCog Trials Inc., Durham, NC, USA; (8) Zinfandel Pharmaceuticals, Inc., Chapel Hill, NC, USA

P1-51  NORMATIVE STUDY OF THE RUSSIAN TOMMOROW NEUROPSYCHOLOGICAL BATTERY

Heather Romero (1,2), Oksana Makeeva (3), Kathleen A. Welsh-Bohmer (1,2), Brenda L. Plassman (1,2), Kathleen M. Hayden (1,2,4), Kumar Budur (5), Grant Runyan (5), Stephen Crawford (6), Mark Atkinson (6), Toyoji Oguri (6), Alexandra Atkins (7), Nicole Turcotte (7), Richard Keefe (7), Shyama Brewster (8), Daniel K. Burns (8), Yuka Matuyama (8), Natalia Zhukova (3), Irina Zhukova (3), Valentina Markova (3), Larisa Mihaycheva (3), Stepan Buikin (3), Zara Melikyan (8), Allen D. Roses (8) for the TOMMOROW study investigators

(1) Joseph and Kathleen Bryan ADRC, Duke University Medical Center (Durham, NC); (2) Department of Psychiatry, Duke University Medical Center (Durham, NC); (3) Center for Clinical Trials, Neubiolo LLC (Tomsk, RU); (4) Department of Social Sciences and Health Policy, Wake Forest School of Medicine (Winston-Salem, NC); (5) Takeda Development Center, Americas, Inc., (Deerfield, IL); (6) Covance Inc (Princeton NJ); (7) NeuroCog Trials Inc. (Durham, NC); (8) Zinfandel Pharmaceuticals, Inc. (Chapel Hill, NC)

P1-52  SOLCOS BASED-MODEL INDIVIDUAL REMINISCENCE FOR OLDER ADULTS WITH MILD TO MODERATE DEMENTIA IN RESIDENTIAL CARE: AN SECOND PILOT STUDY

Peter Van Boogaert RN (1), MSc, PhD, Roel Eerlingen (1) RN, MSc, Daisy Carvers RN (1)

(1) Division of Nursing and Midwifery Sciences, Centre for Research and Innovation in Care (CRIC), Faculty of Medicine and Health Sciences, University of Antwerp, Belgium
POSTER PRESENTATIONS

POSTER SESSION 1: Thursday, November 5th

P1-53  ALZHEIMER’S DISEASE PREVENTION INTO PRIMARY CARE
Bertrand Fouggère, MD, PhD (a,b), Bruno Chicioula, MD (c), Julien Delrieu, MD (a), Nêda Tavassoli, PhD (a,d), Christine Lagourdette (a), Julie Subra, MD (c), Stéphane Oustric, MD (b,c), Bruno Vellias, MD, PhD (a,b,d)
(a) Gérontopôle, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; (b) Inserm UMR1027, Université de Toulouse Paul Sabatier, Toulouse, France; (c) Département de médecine générale, Université de Toulouse, France; (d) Equipe Régionale Vieillissement et Prévention de la Dépendance, Centre Hospitalier Universitaire de Toulouse, France

P1-54  NORMATIVE STUDY OF THE ITALIAN-LANGUAGE TOMMORROW NEUROCOGNITIVE BATTERY
Brenda L. Plissman, PhD (1,2), Samantha Galluzzi, MD (3), Carlo de Lenalena, MD (4), Kathleen A. Welsh-Bohmer, PhD (1,2), Heather Romero, PhD (1,2), Kathleen M. Hayden, PhD (1,2,5), Kumar Budur, MD, MS (6), Grant Runyan, PhD (6), Janet O’Neil, MBA (6), Stephen Crawford, PhD, MHS (7), Mark Atkinson, PhD (7), Toyoko Oguri, MS (7), Alexandra Atkins, PhD (8), Nicole Turcotte, MA (8), Richard Keefe, PhD (2,8), Shyama Brewster, BSc (Hons) (9), Dominic Fitzsimmons, BSc (Hons) (10), Daniel K. Burns, PhD (9), Maura Parapini, MS (3,11), Letizia Imbriano, MSc (4), Giovanni B. Frisoni, MD, PhD (8), Maria Soto, MD, PhD (1), Wouter Detry, MD, PhD (11), Sergio S. Santarelli, MD (1,11), Elena Monari, MD (1), Giuseppe Ferrari, MD (11), Giovanni B. Frisoni, MD (11), and the TOMMORROW Study Investigators

P1-55  CULTURAL ADAPTATION OF THE TOMMORROW NEUROCOGNITIVE BATTERY IN RUSSIA, SWITZERLAND, AND ITALY
Alexandra S. Atkins, PhD (1), Adam W. Vaughan, PhD (1), Nicole M. Turcotte, MA (1), Oksana A. Makeeva, Ph (2), Andreas U. Monsch, PhD (3), Giovanni B. Frisoni, MD (4,10), Maura Parapini, MS (10), Irina Zhukova, MD, PhD (2), Zara Meilikyan, PhD (5), Shyama Brewster, BSc Joint (Hons) (5), Kumar Budur, MD, MS (6), Janet O’Neil, MBA (6), Heather R. Romero, PhD (8), Brenda L. Plissman, PhD (7,8), Kathleen M. Hayden, PhD (7,8,9), Kathleen A. Welsh-Bohmer, PhD (7,8), Richard S.E. Keefe, PhD (7,8).
(1) NeuroCog Trials, Durham, NC, USA; (2) Neuropsychology Testing Center, Neubbo, Llo, Tomsk, RU; (3) University for the TOMMORROW Study Investigators

P1-56  INTERNATIONAL NOMENCLATURE CONSENSUS WORKING PARTY: PERIOPERATIVE NEUROCOGNITIVE DISORDERS (PREVIOUSLY KNOWN AS POSTOPERATIVE DELIRIUM AND POSTOPERATIVE COGNITIVE DYSFUNCTION)
Lis Evered BSC, MBiostat, PhD (1,2), Steven DeKosky (3), Rod Eckenhoff (4), David Scott (1,2), Esther Oh (5), Greg Crosby (6,7), Brendan Silbert (1,2), and the international nomenclature consensus working party
(1) St Vincent’s Hospital, Melbourne; (2) University of Melbourne; (3) University of Florida; (4) University of Pennsylvania; (5) Johns Hopkins Medicine; (6) Brigham and Women’s Hospital, Boston; (7) Harvard Medical School

P1-57  COMPREHENSIVE COGNITIVE TRAINING IN LATER ADULTHOOD LEADS TO A REDUCTION IN ANNUALIZED AGE-RELATED COGNITIVE DECLINE
Daniel Sternberg, PhD1, Michael Scanlon, Glenn Morrison, MSc, PhD1
(1) Lumos Labs. Inc. San Francisco, CA

P1-58  DEMENTIA IN LONG TERM CARE FACILITIES: TELEMEDICINE FOR THE MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS: THE DETECT STUDY, METHODS OF A CLUSTER RANDOMIZED CONTROLLED TRIAL
Maria Soto, MD, PhD (1), Antoine Piau, MD (2), Adelaide de Mauclère, MD (1), Pierre Rumeau, MD, PhD (1), Alsane Sene, PhD (2), Pascal Saidilitz MD (1), Benoit Lepage MD, PhD (3), Maryline Duboué, MSc (1), Bruno Vellias, MD, PhD (1), Fati Nourhashemi, MD, PhD (1)
(1) Gerontopôle, INSERM U 1027, Alzheimer’s Disease Research and Clinical Center, Toulouse University Hospital, France; (2) Gerontopôle, Cand University, France; (3) Department of Epidemiology and Public Health, CHU Toulouse University Hospital, France, INSERM U 1027

P1-59  RATIONALE AND PRELIMINARY DATA FOR THE ADCS MULTICENTER TRIAL: PRAZOSIN FOR AGITATION IN ALZHEIMER’S DISEASE
Murray A. Raskind, MD (1,2), Elaine R. Peskind, MD (1,2), Lucy Wang, MD (1,2)
(1) VA Puget Sound Health Care System, Mental Illness Research, Education and Clinical Center (MIRECC), Seattle/American Lake, WA, USA; (2) University of Washington, Department of Psychiatry and Behavioral Sciences, Seattle, WA, USA
POSTER PRESENTATIONS

POSTER SESSION 1: Thursday, November 5th

P1-60 APATHY AS A DRUG TARGET AND A SURROGATE MARKER IN AD CLINICAL TRIALS
Anton Alvarez, MD, PhD (1,2)
(1) Medinova Institute of Neurosciences, Clinica RehaSalud, A Coruña, Spain; (2) Clinical Research Department, QPS Holdings, A Coruña, Spain

P1-61 RELATIONSHIP BETWEEN “CAREGIVER’S STRESS” AND BPSD IN NURSING HOMES
Alba Maiara, MD (1), Francesco Bettarini MD (1), Francesco Ceravolo, MD (1), Serena Di Cello, MD (1), Francesco Praino, MD (1), Vincenzo Settembrini, MD (1), Giovanni Sgrò, MD (1), Fausto Spadea, MD (1), Vincenzo Rispoli, PhD (1)
Scientific Committee of National Association of Nursing Home for Third Age (ANASTE) Calabria, Lamezia Terme (CZ), Italy

P1-62 DEPRESSION AND COGNITIVE DECLINE: FACTORS RELATED TO DEMOGRAPHICS AND PSYCHO PHARMACOTHERAPY ON ELDERLY IN NURSING HOMES
Edvaldo Soares, PhD, Patrícia de Souza Rossignoli, PhD
Laboratory of Cognitive Neuroscience-LaNeC, Sao Paulo State University, São Paulo, Brazil

THEME 11: Clinical Trials and New Therapies

P1-63 PROTEOTOXIC CONTROL IN ALZHEIMER’S DISEASE MAY BE ATTAINED BY BUBR1: A POSSIBLE TARGET FOR THERAPY?
Vladan Bajic (1), Biljana Spremo-Potparevic (2), Lada Zivkovic (2), Boban Stanojevic (3), Martina Bruckner (4), Thomas Arendt (4)
(1) Department of Radiobiology and Molecular Genetics, “Vinca” Institute; Belgrade, Serbia, (2) Department of Physiology, Faculty of Pharmacy, University of Belgrade, Serbia, (3) Department of Endocrinology and Molecular Biology, “Vinca” Institute; Belgrade, Serbia, (4) Paul-Flechsig-Institute for Brain Research, University of Leipzig, Medical Faculty, Leipzig, German

P1-64 EFFICACY AND SAFETY OF A NOVEL ACETYLCHOLINESTERASE INHIBITOR OCTOHYDROAMINOACRIDINE IN MILD TO MODERATE ALZHEIMER’S DISEASE: A PHASE II MULTICENTER RANDOMIZED CONTROLLED TRIAL
Shifu Xiao (1,2), Tao Wang (1,2), Xia Li, (1,2), Zhongxin Zhao (3), Xueyuan Liu (4), Xiaoping Wang (5), Hengge Xie (6), Qinpu Jiang (7), Li Sun (8), Benyan Luo (9), Lan Shang (10), Wei Xin Chen (11), Yan Bai (12), Muni Tang (13), Maolin He (14), Kaixiang Liu (15), Qilin Ma (16), Zhi Song (17), Yingyi Qin (18), Xiuqiang Ma (18), Jia He (18)
(1) Department of Geriatric Psychiátry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China; (2) Alzheimer’s Disease and Related Disorders Center, Shanghai Jiao Tong University, Shanghai, China; (3) Department of Neurology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China; (4) Department of Neurology, the 10th People’s Hospital, Tongji University, Shanghai, China; (5) Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China; (6) Department of Geriatric Neurology, Chinese PLA General Hospital, Beijing, China; (7) Mental Health Center of Hebei Province, Baoding, Hebei Province, China; (8) Department of Neurology, the First Hospital of Jilin University, Changchun, Jilin Province, China; (9) Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China; (10) Beijing Hui-Long-Guan Hospital, Peking University, Beijing, China; (11) Department of Gerontology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China; (12) First Affiliated Hospital of Kunming Medicine University, Kunming, Yunnan Province, China.; (13) Guangzhou Psychiatric Hospital, Guangzhou, Guangdong Province, China; (14) Department of Neurology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China; (15) Affiliated Hospital of Gulin Medical School, Gulin, Guangxi Province, China; (16) Department of Neurology, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian Province, China; (17) Neurological Department, the Third Xiangya Hospital of Central South University, Hunan Province, China; (18) Department of Health Statistics, Second Military Medical University, Shanghai, China

P1-65 COMBINATION TRIALS WITH AMYLOID MODULATING AGENTS. A QUANTITATIVE SYSTEMS PHARMACOLOGY PERSPECTIVE
Hugo Geerts, PhD, BachMed (1,2); Athan Spiros, PhD (1)
(1) In Silico Biosciences, Berwyn, PA; (2) Perelman School of Medicine, Univ of Pennsylvania, Philadelphia, PA

P1-66 RAMCIP PROJECT: ROBOTIC RESEARCH DEVELOPMENT TO HELP ALZHEIMER’S DISEASE PATIENTS AT HOME
Carla Abdelsout MD (1), Natalia Tantinyá (1), Joan Hernández MSc (1), Eivir Martín MSc (1), Silvia García (1), Joan Carles Ribes (1), Asunción Lafuente MD (1), Isabel Hernández MD, PhD (1), Maitee Rosende MD (1), Ana Mauleón MD (1), Liliana Vargas MD (1), Montserrat Alegret PhD (1), Ana Espinosa MSc (1), Gemma Ortega PhD (1), Domingo Sánchez MD (1), Octavio Rodríguez MD (1), Pilar Canyabate PhD (1), Mariola Moreno (1), Silvia Preckler (1), Ángela Sanabria MSc (1), Alba Pérez-Cordón MSc (1), Lluís Tarragà MSc (1), Agustín Ruiz MD, PhD (1), Mercè Boada MD, PhD (1), RAMCIP group
(1) Research Center and Memory Clinic of Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain
POSTER PRESENTATIONS

POSTER SESSION 1: Thursday, November 5th

P1-67 SAFETY AND PHARMACOKINETICS OF ANTI-PROTOFIBRILLAR MAB SAR228810 IN FIRST-IN-MAN STUDY AFTER SINGLE AND MULTIPLE ASCENDING IV AND SC DOSING IN PATIENTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE
Bruno Pellias, MD (1), Raphael Dahmen, MD (2), Olivier Nicolas, PhD (3), Valerie Martin, MS (4), Caroline Cohen, PhD (4), Laurent Vermet, MSc (3), Jerome Barakos, MD (5), Joyce Suhy, PhD (5), Anne Björklund-Hanson, MD, PhD (6), Henrik Ostlund, MD (7), Geert Jan Groeneveld, MD, PhD (8), Niels Prins, MD, PhD (9), Philip Schellens, MD, PhD (9), Kaj Blennow, MD (10), Niels Andreasen, MD (11)
(1) Gérontopôle, CHU Purpan, Toulouse, France; (2) Sanofi-Aventis R&D, Frankfurt, Germany; (3) Sanofi-Aventis R&D, Montpellier, France; (4) Sanofi-Aventis R&D, Shanghai, China; (5) BioClinica, Medical Imaging, Newark, CA, USA; (6) Department of Neuroradiology, Sahlgrenska University Hospital, Gothenburg, Sweden; (7) Memory Clinic, Skånes University Hospital, Malmö, Sweden; (8) Center for Human Drug Research, Leiden, the Netherlands; (9) Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands; (10) Clinical Neurochemistry Lab, Dept. of Neuroscience and Physiology, Sahlgrenska University Hospital, Gothenburg, Sweden; (11) KI Alzheimer Center, Dept. of Geriatric Medicine, Karolinska University Hospital, Stockholm, Sweden

P1-68 SAFETY OF THE 5-HT6 ANTAGONIST, RVT-101 IN PATIENTS WITH ALZHEIMER’S DISEASE: SUMMARY OF PHASE 2 CLINICAL TRIALS
Ilise Lombardo, MD (1), Geetha Ramaswamy, MD (1), Stephen C. Piscitelli, PharmD (2), Lawrence T. Friedhoff, MD, PhD, FACP (1)
(1) Axovant Sciences, Inc., New York, NY; (2) Roivant Sciences, Inc., New York, NY

P1-69 STEM CELLS FOR ALZHEIMER’S DISEASE: TRANSITION TO CLINICAL TRIALS
Tristan Belmont, PhD (1,2), Theo Lasser (1), Alexei Lukashev, PhD (2), Nikolai Tankovich, MD, PhD (3)
(1) École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland; (2) Steemedica International, Epalinges, Switzerland; (3) Steemedica Cell Technologies, San Diego, CA, USA

P1-70 PHARMACOGENETICS SUPPORTED CLINICAL TRIAL TO DELAY ONSET OF MCI DUE TO AD USING PIOGLITAZONE 0.8 MG SR: TOMMORROW STUDY
Kumar Budur, MD, MS (1), Kathleen A. Welsh-Bohmer, PhD (2), Daniel K. Burns, PhD (3), Carl Chiang, PhD (3), Janet O’Neil, MBA (1), Grant Runyan, PhD (1), Meredith Culp, BS (1), Donna G. Crenshaw, PhD (3,4), Michael W. Lutz, PhD (2), Craig A. Metz, PhD (3), Ann M. Saunders, PhD (2), Deborah Yarbrough, MS, MBA (1), Stephen Haneline, MS (3), David Yarnall, MS (3), Eric Lai, PhD (1), Stephen K. Brannan, MD (1), Allen D. Roses, MD (2,3)
(1) Takeda Development Center Americas, Inc., Deerfield, IL, USA; (2) Duke Bryan ADRC, Durham, NC, USA; (3) Zinfandel Pharmaceuticals, Inc., Research Triangle Park, NC, USA; (4) Department of Medicine, Duke University, Durham, NC, USA

POSTER SESSION 2: Friday, November 6th

THEME 3: Clinical Trials Imaging

P2-1 CORTICAL THINNING PATTERNS IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE
Eun Yo Lim (1), Jung Hee Chi (1), Yong Soo Shin (1), Yun Jeong Hong (2), Bora Yoon (3), Dong Won Yang (1)
(1) Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea; (2) Department of Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea; (3) Konyang University College of Medicine, Daejeon, Korea

P2-2 GRAY MATTER VOLUMES AND TREATMENT RESPONSE OF PSYCHOTIC SYMPTOMS TO RISPERIDONE IN ANTIPSYCHOTIC-NAÍVE ALZHEIMER’S DISEASE PATIENTS
Young Min Lee, PhD; Je-Min Park, MD, PhD, Byung-Dae Lee MD, PhD, Eunsou Moon MD, Hee-Jeong Jeong, MD
Department of Psychiatry, School of Medicine, Pusan National University, Busan, Korea

P2-3 WHITE MATTER MICROSTRUCTURE DISRUPTION IS CORRELATED WITH AMYLOID BURDEN IN SUBJECTS WITH SUBJECTIVE COGNITIVE DECLINE. FUNDACIO ACE HEALTHY BRAIN INITIATIVE
O. Rodríguez-Gómez (1) MD, A. Sanabria (1) Msc, A. Pérez-Cordón (1) Msc, D. Sánchez-Ruiz MD (1), S. Ruiz (1), M. Tarragona (1), J. Pavia (2) PhD, F. Campos (2) Msc, A. Vivas (3) MD, M. Gómez (3) MD, M. Tejero (3) RT, M. Alegret (1) PhD, A. Espinosa (1) Msc, G. Ortega (1) PhD, C. Abdelnour (1) MD, I. Hernández (1) MD PhD, A. Ruiz (1) MD PhD, J. Giménez (3) MD, F. Lomeña (2) MD, L. Tárraga (1) Msc, O. Sotolongo-Grau (1) PhD, M. Boada (1) MD PhD
(1) Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; (2) Servei de Medicina Nuclear, Hospital Clínic i Provincial, Barcelona, Spain; (3) Departament de Diagnòstic per la Imatge, Clínica Coralcan, Barcelona, Spain

P2-4 PET STUDIES WITH RVT-101 IN HEALTHY VOLUNTEERS DEMONSTRATE HIGH OCCUPANCY OF THE 5HT6 RECEPTOR
Ilise Lombardo, MD, (1), Geetha Ramaswamy, MD, (1), Stephen C. Piscitelli, PharmD (2), Lawrence Friedhoff, MD, PhD, FACP (1)
(1) Axovant Sciences, Inc.; (2) Roivant Sciences, Inc.
P2-5
FIRST CLINICAL APPLICATION OF THE AUTOMATIC SEGMENTATION METHOD OF HIPPOCAMPAL SUBFIELDS (ASHS) IN (PRODROMAL) ALZHEIMER’S DISEASE: A POTENTIAL BIOMARKER
Eske Christiane Gerdig, MD (1), John Pluta (2), Sandhitsu Das, PhD (2), Andreas Engelhardt, MD (1), Lauren Mancuso (3), Dasha Kliot (3), Paul Yushkevich, PhD (2), David Wolk, MD (3)
(1) Department of Neurology, University of Oldenburg, Oldenburg, Germany; (2) Penn Image Computing and Science Laboratory, Department of Radiology, University of Pennsylvania, Philadelphia, USA; (3) Penn Memory Center, Department of Neurology, University of Pennsylvania, Philadelphia, USA

P2-6
INTEGRATION OF FLORBETAPIR PET AND CEREBROSPINAL FLUID Aß42 TO DEFINEAMYLID BURDEN IN ALZHEIMER’S DISEASE
Gerald Novak, MD (1), Lisa Ford, MD (1), Mahesh Samtani PhD (1), Mark Forrest Gordon, MD (2), for the Alzheimer’s Neuroimaging Initiative and the European Medical Information Framework Alzheimer’s Disease
(1) Janssen Pharmaceuticals, LLC, Titusville, NJ, USA; (2) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA

P2-7
DIFFERENTIATING THE EFFECTS OF DOWN SYNDROME AND ALZHEIMER’S DISEASE UPON NEURONAL FUNCTION AND BRAIN VOLUME
Dawn Matthews, MS MBA (1), Ana Lukic, PhD (1), Randolph Andrews, MS (1), Boris Marendic, PhD (1), James Brewer, PhD (2), Lisa Mosconi, PhD (3), Stephen Strother, PhD (1,4), Miles Wernick, PhD (1,5), Mark Schmidt, MD (6), Michael Rafi, MD PhD (2), for the Alzheimer’s Disease Neuroimaging Initiative
(1) ADM Diagnostics, Chicago, Illinois, USA; (2) University of California San Diego School of Medicine, San Diego, California, USA; (3) New York University, New York, NY, USA; (4) Baycrest Hospital, Toronto, ON, Canada; (5) Illinois Institute of Technology Chicago, Illinois, USA; (6) Janssen Research and Development, Beerse, Belgium

P2-8
INCREASED UTILIZATION OF IMAGING IN ALZHEIMER DISEASE (AD) TRIALS: IMPACT ON PATIENT RECRUITMENT, RETENTION AND LOGISTICS
Kohkan Shamsi MD, PhD
Principal at RadMD LLC, Pipersville, PA - USA

P2-9
HIPPOCAMPUS VOLUME LOSS IN ALZHEIMER’S DISEASE PATIENTS: EFFECT OF TREATMENT WITH CHOLINE ALPHOSCERATE IN ADDITION TO CHOLINESTERASE INHIBITOR
Enea Traini, PhD (1), Anna Carotenuto, PhD (1,2), Angiola Maria Fasanaro, MD (1,2), Raffaele Rea, PhD (1,2), Francesco Arena, MD (1)
(1) Centro di Ricerca, Telematematica e Telefarmacia, University of Camerino, Camerino, (2) Alzheimer Evaluation Unit, National Hospital, “A. Cardarelli”, Naples, Italy

P2-10
PRESUBICULUM VOLUME CHANGES IN MILD COGNITIVE IMPAIRMENT PATIENTS WITH AD PATHOLOGY
Moria Marizzi, PhD (1), Jorge Jovicich, PhD (2), Elena Rolandi, MSc (1), Samantha Galluzzi, MD (1), Flavio Nobili, MD (3), Mira Didić, MD (4,5), David Bartrès-Faz, MD (6), Ute Fiedler, (7), Peter Schönknecht, MD (8), Pierre Payoux, MD (9,10), Alberto Bellatte, MD (11), Andrea Sorcini, MD (12,13), Lucia Parnetti, MD (14), Magda Tsolaki, MD (15), Paolo Maria Rossini, MD (16,17), Philip Scheltens, MD (18), Gianluigi Fortoni, PhD (19), Regis Bordet, MD (20), Olivier Blin, MD (21), Giovanni Battista Frisoni, MD (1,22), on behalf of the PharmaCog Consortium
(1) Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; (2) Center for Mind/Brain Sciences, University of Trento, Trento, Italy; (3) Department of Neuroscience, Ophthalmology, Genetics and Mother–Child Health (DINOGMI), University of Genoa, Genoa, Italy; (4) APHM, CHU Timone, Service de Neurologie et Neuropsychologie, Marseille, France; (5) Aix-Marseille Université, INSERM U 1106, Marseille, France; (6) Department of Psychiatry and Clinical Psychobiology, Universitat de Barcelona and IDIBAPS, Barcelona, Spain; (7) LVR-Clinic for Psychiatry and Psychotherapy, Institutes and Clinics of the University Duisburg-Essen, Essen, Germany; (8) Department of Neuroradiology, University Hospital Leipzig, Leipzig, Germany; (9) INSERM, Imagerie cérébrale et handicaps neurologiques, UMR 825, Toulouse, France; (10) Université de Toulouse, UPS, Imagerie cérébrale et handicaps neurologiques, UMR 825, CHU Purpan, Toulouse, France; (11) Department of Neuroradiology, General Hospital, Verona, Italy; (12) IRCCS SDN, Naples, Italy; (13) University of Naples Parthenope, Naples, Italy; (14) Section of Neurology, Centre for Memory Disturbances, University of Perugia, Perugia, Italy; (15) 3rd Department of Neurology, Aristotle University of Thessaloniki, Thessaloniki, Greece; (16) Dept. Geriatrics, Neuroscience & Orthopaedics, Catholic University, Policlinic Gemelli, Rome, Italy; (17) IRCSS S. Raffaele Pisana, Rome, Italy; (18) Alzheimer Centre and Department of Neurology, Vrije Universiteit University Medical Center, Amsterdam, The Netherlands; (19) Neuroscience Department, IRCCS Istituto di Ricerche Farmacologiche «Mario Negri», Milan, Italy; (20) Department of Pharmacology, EA1046, University of Lille Nord de France, Lille Cedex, France; (21) Pharmacology, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University-CNRS UMR 7289, Marseille, France; (22) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

P2-11
ROBUSTNESS OF 18F-FLORBETAPIB SUVR CUTOFF QUANTIFICATION ACROSS REFERENCE REGIONS AND STANDARDS OF TRUTH
Santiago Bullich, PhD (1), Susan De Santi, PhD (2), John Seibyl, MD (3), Ana M. Catafau, MD, PhD (1)
(1) Piramal Imaging GmbH, Berlin, Germany; (2) Piramal Pharma Inc, Boston, MA, USA; (3) Molecular Neuroimaging, New Haven, CT, USA
POSTER SESSION 2: Friday, November 6th

P2-12 CLASSIFICATION OF POSITIVE AND NEGATIVE 18F-FLORBETABEN SCANS: COMPARISON OF SUVR CUTOFF QUANTIFICATION AND VISUAL ASSESSMENT PERFORMANCE
Santiago Bullich, PhD (1), Susan De Santi, PhD (2), John Seibyl, MD (3), Ana M. Catalafau, MD, PhD (1)
(1) Piramal Imaging GmbH, Berlin, Germany; (2) Piramal Pharma Inc, Boston, MA, USA; (3) Molecular Neuroimaging, New Haven, CT, USA

P2-13 SINGLE-CASE Voxel-BASED ANALYSIS OF FLORBETAPIR-PET
Altomare Daniele, MS (1), Bosco Paolo, PhD (1), Guerra Ugo Paolo, MD (2), Faghera Barbara, MD (3), Festari Cristina, MS (1), Pasqualetti Patrizio, MS (4), Muscio Cristina, MS (1,5), Pievani Michela, PhD (1), Padovani Alessandro, MD (6), Frisoni Giovanni Battista, MD (1,7), Boccardi Marina, PhD (1)
(1) Laboratory of Alzheimer’s Neuroimaging and Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; (2) Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy; (3) Nuclear Medicine, University of Brescia and Spedali Civili Brescia, Brescia, Italy; (4) Fatebenefratelli Hospital of Isola Tiberina, Roma, Italy; (5) European Foundation Biomedical Research (FERRB), Center of Excellence Alzheimer, Ospedale Briolini di Gazzaniga, Bergamo, Italy; (6) Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy; (7) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland

P2-14 RELATIONSHIPS BETWEEN COGNITIVE ASSESSMENTS AND SPATIAL DISTRIBUTION OF NEUROPATHOLOGICAL IMPAIRMENT (MCI)
Michael D. Devous, Sr., Michael Navitsky, Ian Kennedy, Abhinay D. Joshi, Ming Lu, Michael J. Pontecorvo, Mark A. Mintun
Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

P2-15 LOW DOSE WHOLE BRAIN IRRADIATION AS A POTENTIAL TREATMENT OF ALZHEIMER’S DISEASE
James Fontanesi, MD (1), Daniel B. Michael, MD, PhD (1), Brian Marples PhD (2), George D. Wilson PhD (2), Alvaro A. Martinez MD (3), Scott E. Bowen PhD (4)
(1) Department of Neurosurgery, William Beaumont Hospital/Oakland University School of Medicine, Royal Oak, Michigan USA; (2) Department of Radiation Oncology, William Beaumont Hospital/Oakland University School of Medicine, Royal Oak, Michigan USA; (3) Department of Psychology, Wayne State University, Detroit, Michigan USA; (4) Department of Psychology, Wayne State University, Detroit, Michigan USA

P2-16 SNP PROFILING AS AN APPROACH TO RISK STRATIFICATION FOR FUTURE COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT (MCI)
Valentina Escott-Price, PhD (1), Richard Pither, BSc, PhD (2), Harald Hampel, MD, PhD (3), Julie Davis, BSc, MSc (2), John Hardy, PhD, DSc (4)
(1) Cardiff University, Cardiff, United Kingdom, (2) Cytox Ltd, UK, Oxford, United Kingdom, (3) Université Pierre et Marie Curie, Paris, France, (4) UCL Institute of Neurology, London, United Kingdom

P2-17 IDENTIFICATION OF POTENTIAL TARGETS FOR BRAIN STIMULATION IN AD AND BVFTD: A META-ANALYSIS OF FMRI STUDIES
Michela Pievani, PhD (1), Lorenzo Pini, MS (1), Clarissa Ferrari, PhD (2), Maria Cotelli, PhD (3), Rosa Manenti, PhD (3), Giovanni B. Frisoni, MD (1,4)
(1) Lab Alzheimer’s Neuroimaging & Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; (2) IRCCS Fatebenefratelli, Brescia, Italy; (3) Neuropsychology Unit, IRCCS Fatebenefratelli, Brescia, Italy; (4) University Hospitals and University of Geneva, Geneva, Switzerland

P2-18 DOES HIPPOCAMPAL VOLUMETRY IMPACT ON DIAGNOSTIC CONFIDENCE IN ALZHEIMER’S DISEASE? AN EADC STUDY
Paolo Bosco, PhD (1), Alberto Redolfi, MSc (1), Martina Bocchetta, MSc (1,2), Clarissa Ferrari, PhD (3), Samantha Galluzzi, MD (1,5), Mark Austin, PhD (1), Louis Collins, PhD (5), Andrea Chincarini, PhD (6), Alessio Rui, PhD (7), Francesco Sensi, MSc (6), Robin Wolz, PhD (4), Montserrat Alveret, PhD (8), Msce Balsa, MD (9), Christine Bastin, PhD (10), Anastasia Bougea, PhD (11), Derya Dursus Emek-Sawat MSc, PhD (12,13), Sebastian Engelborghs, MD, PhD (1,2), Timo Grimmer, MD, PhD (16), Ntovas Konstantinos (17), Milica G. Kramberger, MD, PhD (18), Brian Lawlor, MD (19), Gorana Mandic Stojmenovic, MD (20), Patrizia Meccoci, MD (21), Jose Luis Molinuevo, MD (9), Ricardo Moralis, MD (22), Ellis Nienantsverdriet, MSc (14), Flavio Nobili, MD (23), Sarah O’Dwyer, MSc (11), George P. Paraskevaidis, MD (11), Luca Pelini, MD (20), Agnese Picco, MD (23), Eric Salmon, MD (10), Isabel Santana, MD (24), Oscar Solotoung-Grau, PhD (8), Elba Stefanova, MD, PhD (20,25), Katariina Surlan Popovic, MD, PhD (26), Magda Tsalaki, MD (17), Gorsev G. Yener, MD, PhD (12,13,17), Giovanni B. Frisoni, MD (1,28)
(1) IRCCS Fatebenefratelli, Brescia, Italy; (2) University of Brescia, Brescia, Italy; (3) IRCCS Fatebenefratelli, Brescia, Italy; (4) IRCCS Fatebenefratelli, Brescia, Italy; (5) University of Antwerp, Antwerp, Belgium; (6) INFN, Genova, Italy; (7) Siemens, Lausanne, Switzerland; (8) Fundació ACE, Barcelona, Spain; (9) Hospital Clinic, Barcelona, Spain; (10) University of Liége, Belgium; (11) Medical school of Athens, Greece; (12) Dokuz Eylül University, Izmir, Turkey; (13) Department of Dokuz Eylül University, Izmir, Turkey; (14) University of Antwerp, Antwerp, Belgium; (15) Hospital Network Antwerp (ZNA) Hoge Beuken and Middelheim, Antwerp, Belgium; (16) Technische Universität München, Munich, Germany; (17) Aristotle University of Thessaloniki, Greece; (18) University Hospital Medical Center Ljubljana; (19) St. James’s Hospital, Dublin, Ireland; (20) Institute of Neurology, CCS, Belgrade, Serbia; (21) Università degli Studi di Perugia, Perugia, Italy; (22) Hospital Universitário de Coimbra, Coimbra, Portugal; (23) University of Genoa, Italy; (24) Hospital Universitàrio de Coimbra, Coimbra, Portugal; (25) Faculty of Medicine, University of Belgrade, Belgrade, Serbia; (26) University Medical Center Ljubljana; (27) Dokuz Eylül University, Izmir, Turkey; (28) University Hospitals and University of Geneva, Geneva, Switzerland
POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

P2-19 INABILITY OF THREE FUNCTIONAL MRI CONNECTIVITY ENDPOINTS TO DETECT PROGRESSION IN CLINICAL TRIAL PATIENTS WITH ALZHEIMER’S DISEASE
Alexandre Coimbra, PhD (1), David Clayton, PhD (1), Faraji Farshid, PhD (1), Lee Honinberg, PhD (2), Robert Paul, MD, PhD (2), Alex deCrespigny PhD (1)
(1) Genentech, gRed Clinical Imaging Group, South San Francisco, California, USA; (2) Genentech, gRed ITGR, South San Francisco, California, USA

P2-20 CORTICAL THICKENING AND DIFFUSIVITY CHANGES IN PRECLINICAL ALZHEIMER’S DISEASE
Juan Fortea, MD, MD (1)*, Victor Montal, MSc (1)*, Eduard Vilaplana, MSc (1), Daniel Alcolea, MD (1), Jordi Pegueroles, MSc (1), Frederic Sampedro, MSc (1,2), Maria Carmona-Iragui, MD (1), Jordi Clarimon, PhD (1), Sofia Gonzalez, MD (3), Pablo Martinez-Lage, MD, PhD (4), Pascual Sanchez-Juan, MD, PhD (5), Rafael Blesa, MD, PhD (1), Alberto Lieo, MD, PhD (1)
(1) Department of Neurology, IIB Sant Pau - Hospital Sant Pau, Universitat Autónoma de Barcelona, Barcelona, Spain; (2) Department of Nuclear Medicine, IIB Sant Pau - Hospital Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; (3) Department of Radiology, Hospital del Mar, Barcelona, Spain; (4) Fundación CITA-alzheimer Fundazcita, San Sebastián, Spain; (5) Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Santander, Spain- Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED, Spain. The SIGNAL study

P2-21 IDENTIFICATION AND FIRST-IN-HUMAN EVALUATION OF GENENTECH TAU PROBE 1 ([(18F)GTP1]
Sandra Sanabria Bohorquez, PhD (1), Olivier Barret, PhD (2), Gilles Tamagnan, PhD (2), Jeff Tihanow, MS (3), Annie Ogasawara, BS (3), Simon Williams, PhD (3), Alex de Crespigny, PhD (1), Gai Ayalon, PhD (4), Geoffrey Kerchner, MD PhD (5), William Cho, MD PhD (6), Danna Jennings, MD (2), John P. Seibyl, MD (2), Ken Marek, MD (2), Robby Weimer, PhD (3), Jan Marik, PhD (3)
(1) Clinical Imaging Group, (2) Biomedical Imaging, (3) Department of Biomedical Imaging, (4) Department of Neuroscience and (5) Early Clinical Development, Genentech, Inc., North San Francisco, USA; (2) Molecular NeuroImaging LLC, New Haven, CT, USA

P2-22 INTEGRATION OF EADC-ADNI HARMONISED HIPPOCAMPUS LABELS INTO THE LEAP AUTOMATED SEGMENTATION TECHNIQUE
Katherine R. Gray, PhD (1,2), Hoi Kin Kwan, MSc (1), Robin Wolz, PhD (1,2), Derek L.G. Hill, PhD (1)
(1) IXICO plc., London, United Kingdom; (2) Biomedical Image Analysis Group, Imperial College London, United Kingdom

P2-23 LONGITUDINAL FDG-PET CHANGES IN COGNITIVELY NORMAL ADNI SUBJECTS USING TEMPORAL CORRELATION ANALYSIS
Sepideh Shokouhi
Vanderbilt University Institute of Imaging Science, Nashville, TN, USA

THEME 4: Clinical Trials Biomarkers

P2-24 TEST-RETEST REPRODUCIBILITY OF CSF BIOMARKER MEASUREMENTS IN ADNI
Weining Robieson, PhD (1), Deli Wang, MD, PhD (1), Yunzhi Lin, PhD (1), Davis Ryman, MD, PhD (1), Nuno Mendonca, MD (1), Laura Gault, MD, PhD (1)
(1) AbbVie Inc., North Chicago, Illinois, USA; (2) AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

P2-25 CLINICAL DIAGNOSIS AND THE CONGRUENCE OF BIOMARKER CONSTELLATION IN AD
Hermann-Josef Gertz MD (1), David Weise, MD (1,2), Carolin Awissus (1), Solveig Tiepolt MD (3), Henryk Barthel MD (3), Osama Sabir, MD (3), Karl-Titus Hoffmann MD (4), Donald Lobsien MD (4), Thorsten Kaiser MD (5)
(1) Department of Psychiatry, University of Leipzig, Leipzig, Germany; (2) Department of Neurology, University of Leipzig, Leipzig, Germany; (3) Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany; (4) Department of Neuropadiology, University of Leipzig, Leipzig, Germany; (5) Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, University of Leipzig, Leipzig, Germany

P2-26 A FRAGMENT OF BREVICAN AS A NOVEL BLOOD BIOMARKER OF ALZHEIMER’S DISEASE
Dilek Inekci (1), Ditte Joneasco (1), Ole J. Vilholm (2), Morten Karsdal (1), Kim Henrikson (1)
(1) Biomarkers and Research, Nordic Bioscience, Herlev, Denmark; (2) Department of Neurology, Lillebaelt Hospital, Vejle, Denmark

P2-27 ABETA LEVELS IN THE JUGULAR VEIN AND ABETA OLIGOMER LEVELS IN CSF CAN BE CHANGED AFTER THE TREATMENT OF IVIG FOR AD
Takashi Kasai, MD, PhD (1), Masaki Kondo, MD, PhD (1), Ryotarou Ishii, MD, PhD (1), Toshiaki Mizuno, MD, PhD (1), Takahiko Tokuda, MD, PhD (2)
(1) Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto, Japan; (2) Department of Molecular Pathobiology of Brain Diseases, Kyoto Prefectural University of Medicine, Kyoto, Japan

P2-28 APOLIPROTEIN E GENOTYPE IN SUBJECTS WITH SUBJECTIVE MEMORY IMPAIRMENT ASSESSED FOR OBJECTIVE COGNITIVE IMPAIRMENT
Georg Adler, MD, Binder J, Yvonne Lembach, PhD
Institut fuer Studien zur Psychischen Gesundheit (ISPG), Mannheim, Germany
POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

P2-29  
A FAST AND COST-EFFECTIVE METHOD FOR APOLIPOPROTEIN E ISOTYPING AS AN ALTERNATIVE TO APOE GENOTYPING FOR PATIENT STRATIFICATION IN CLINICAL TRIALS
Miguel Calero, PhD (1); Olga Calero, PhD (3); Andrés Rodríguez-Martín (2); Luis Gil-de-Gómez, PhD (2); Sergi Gassó, PhD (4); Luis García-Albert, PhD (5)  
(1) Chronic Disease Programme, CIBERNED, and CIEN Foundation-Queen Sofia Foundation, Instituto de Salud Carlos III, Madrid, Spain; (2) Biocross, S.L., Valladolid, Spain; (3) CIBERNED and Chronic Disease Programme, Instituto de Salud Carlos III, Madrid, Spain; (4) Pragmatic Diagnostics S.L., Bellaterra (Cerdanyola del Vallés), Barcelona, Spain; (5) Chronic Disease Programme, Instituto de Salud Carlos III, Madrid, Spain

P2-30  
TECHNICAL PERFORMANCE OF A NOVEL FULLY AUTOMATED ELECTROCHEMILUMINESCENCE IMMUNOASSAY FOR THE QUANTITATION OF Aß1–42 IN HUMAN CEREBROSPINAL FLUID (CSF)
Tobias Bittner, PhD, Christina Rabe, PhD, Ekaterina Manullova, MSc, and Peter Heiss, PhD  
Roche Diagnostics GmbH, Penzberg, Germany

P2-31  
RETINAL ASSESSMENT WITH OPTICAL COHERENCE TOMOGRAPHY IN ALZHEIMER DISEASE AND MILD COGNITIVE IMPAIRMENT
D. Sánchez-Ruíz (1) MD, M. Castilla (1) MD, O. Rodríguez-Gómez (1) MD, J. Serra (1), A. Ciudin (2) MD, O. Simó-Servat (2) MD, C. Hernández (2) MD PhD, A. Maulué (1) MD, M. Rosende-Roca (1) MD, L. Vargas (1) MD, C. Abelín (1) MD, G. Ortega (1) MS PhD, A. Espinosa (1) MS, L. Hernández (1) MD PhD, M. Alegret (1) MS PhD, R. Simó (2) MD PhD, A. Ruiz (1) MD PhD, L. Tárraga (1) MS, M. Boada (1) MD PhD  
(1) Alzheimer Research Center and Memory Clinic, Fundació ACE, Institut Català de Neurociències Aplicades, Barcelona, Spain; (2) Diabetes and Metabolism Department, Vall d’Hebron Research Institute, VHIR, Barcelona, Spain

P2-32  
ACURATE MEASUREMENT OF TAU IN SERUM AND PLASMA USING A NOVEL TECHNOLOGY WITH FG/ML SENSITIVITY
Galina N. Nikolenko, PhD, Robert Umek, PhD, Laukik Sardesai, MS, Anu Mathew, PhD, John H. Kenter, PhD, Eli N. Giezer, PhD, and Jacob N. Wohlstätter  
Meso Scale Discovery (MSD), Rockville, MD, USA

P2-33  
PREDICTORS OF AMYLOID POSITIVITY IN A STUDY SAMPLE WITH AMNESTIC MILD COGNITIVE IMPAIRMENT
Yuki Mukai, MD (1), Yi Mo, PhD (1), Cyrielle Sur, PhD (1), Tiffany Voss, MD (1), Ying Zhang, PhD (1), James Kost, PhD (1), Gregory Klein, PhD (2), Mehul Sampat, PhD (2), Davis Stawow, BSc (2), Derk Purcell, MD (2,3,4), Jerome Barakos, MD (2,3), Joyce Suhy, PhD (2), David Michelson, MD (1), Michael Egan, MD (1)  
(1) Merck & Co., Inc., Kenilworth, NJ, USA; (2) BioClinica, Newark, CA, USA; (3) California Pacific Medical Center, San Francisco, CA, USA; (4) University of California San Francisco, San Francisco, CA, USA

P2-34  
USE OF STABLE ISOTOPE LABELING AMINO ACID IN-VIVO (SILVA) TO MONITOR CSF PROTEIN METABOLISM IN ALZHEIMER’S DISEASE PATIENTS
S. Lehmann (1), G. Gras Combe (2), J. Vialaret (1), L. Bauchet (2), ML. Tall (3), O. Hanon (4), A. Gabelle (1,5), C. Hirtz (1)  
(1) CHRU de Montpellier and Université de Montpellier, IRMB, Laboratoire de Biochimie Protéomique Clinique, Montpellier, France; (2) Service de Neurochirurgie, CHRU de Montpellier, hôpital Gui de Chauliac, Montpellier, and Université de Montpellier; Montpellier, France; (3) Pharmacie, Groupement Hospitalier Edouard Herriot, Lyon, France; (4) AP-HP Hôpital Broca, Service de Gériatrie, Paris, France. Université Paris Descartes, Sorbonne Paris Cité, Paris, France; (5) Centre Mémoire Ressources Recherche Languedoc-Roussillon, CHRU de Montpellier, hôpital Gui de Chauliac, Montpellier, and Université de Montpellier; Montpellier, France

P2-35  
HEADING FOR SUPERIOR ANALYTICAL PERFORMANCE: FROM INNOTEST TO THE FULLY AUTOMATED CHEMILUMINESCENT &-AMYLOID (1-42) AND TOTAL TAU ASSAYS ON THE LUMIPULSE® G INSTRUMENT SERIES
Annelies Vandersteen, Sandra Pereson, Filip Dekeyser, Tinne Dumont, Katrien De Vuyst, Wim Vandezande, Kathleen Gotteman, Paul Vandeponseele, Pieter Van Hecke, Martine Daveau, Geert Jannes  
Fujirebio Europe N.V., Gent, Belgium

P2-36  
METABOLIC BIOMARKERS OF COGNITIVE DECLINE IN HEALTHY POSTMENOPAUSAL WOMEN
Roberta Diaz Brinton, PhD; Jamaica R. Rettberg, PhD, Howard N. Hodis, MD, Víctor W. Henderson, MD; Wendy J. Mack PhD.  
(1) Pharmacology & Pharmaceutical Sciences, University of Southern California, Los Angeles, CA, USA; (2) 23andMe, Mountain View, CA, USA; (3) Department of Medicine, University of Southern California, Los Angeles, CA, USA; (4) Department of Neurology, Stanford University, Palo Alto, CA, USA; (5) Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA

P2-37  
CHARACTERIZATION OF ALBUMIN OXIDATION STATUS IN ALZHEIMER’S DISEASE PATIENTS
Montserrat Costa (1), Raquel Horrillo (1), Ana Maria Ortiz (1), Alba Pérez (1), Pol Herrero (2,3), Núria Canela (2,3), Mercè Boada (4), Agustín Ruiz (4), Isabel Hernández (4), Natalia Afonso (1), Mireia Torres (1), Salvador Grancha (1), Juan Ignacio Jorquera (1)  
(1) R&D and Clinical Operations, Bioscience Industrial Group, Grifols S.A., Barcelona, Spain; (2) Centre for Omc Sciences (COS), Universitat Rovira i Virgili (URV) Reus, Spain; (3) Centre Tecnològic en Nutrició i Salut (CTNS), Reus, Spain; (4) Fundació ACE (Barcelona Alzheimer Treatment & Research Center), Barcelona, Spain
POSTER PRESENTATIONS

POSTER SESSION 2: Friday, November 6th

P2-38
ALZHEIMER’S DISEASE CSF BIOMARKERS PREDICT COGNITIVE DECLINE IN DLB
Carla Abdelnour (1), Elisabet Londos (2), Milica Kramberger (3), Inger van Steenoven (4), Evelien Lemstra (4), Mercè Boada (1), Dag Aarsland (5, 6) on behalf of the JPND DLB study group
(1) Fundació ACE Barcelona Alzheimer Treatment & Research Center, Barcelona, Spain; (2) Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden; (3) Department of Neurology, University Medical Centre, Ljubljana, Slovenia; (4) Alzheimer Centre, Department of Neurology, VU Medical Centre, Amsterdam, The Netherlands; (5) Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institute, Stockholm, Sweden; (6) Center for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway

P2-39
ANALYSIS OF REST PROTEIN EXPRESSION IN ALZHEIMER’S DISEASE UTILIZING MONOCLONAL ANTIBODIES TO THIS BIOMARKER
Richard J. Kascak (1), Ph.D., Regina B. Kascak (1), B.S., Thomas Wisniewski (2), M.D.
(1) New York State Institute for Basic Research in Developmental Disabilities, Staten Island, NY; (2) New York University School of Medicine, New York, NY

P2-40
MULTIPLEX CSF PHOSPHO-TAU SITE-SPECIFIC QUANTIFICATION BY MASS SPECTROMETRY TO ENABLE EARLIER DIAGNOSIS AND PHARMACODYNAMICS BIOMARKERS
Ian Pike PhD (1), Claire Russell PhD (1), Vikram Mitra (1), Henrik Zetterberg PhD (2, 3), Mikko Hiltunen PhD (4), Malcolm Ward PhD (1)
(1) Proteome Sciences plc, Cobham, UK; (2) University of Gothenburg, Gothenburg, Sweden; (3) UCL, Queen Square, London, UK; (4) University of Eastern Finland, Kuopio, Finland

P2-41
INFLAMMATORY MARKERS IN ALZHEIMER’S DISEASE WITH VARIOUS DEGREES OF DEMENTIA SEVERITY
Tatyana Klyushnik, Lyubov Androsova, Natalia Mikhailyova, Svetlana Zozulya, Alexander Dupin, Svetlana Gavrilova
FSGI “The Mental Health Research Centre”, Moscow, Russia

P2-42
THE ALZHEIMER’S METABOLOME: IDENTIFICATION OF NOVEL MARKERS AND TREATMENT TARGETS
Jon B. Toledo, MD (1), J Will. Thompson, PhD (2), Lisa St. John-Williams (2), Ph.D, Guido Dallmann (4), Xianlin Han, PhD (3), Jessica D. Tenenbaum (2), PhD, Therese Koal (4), Siamak Mahmoudian-Dekhordi (2), Alison Motsinger, PhD (2), Ph.D, Sungeun Kim, Ph.D (5), Vijitha Senanayake, Ph.D (6), Andrew J. Saykin, PsyD (5), Rebecca Baillie, PhD (3), Leslie M. Shaw, PhD (1), John Q. Trojanowski, MD, PhD (1), Dayan B. Goodenowe, PhD (6), Mitchell A. Kling, MD (1), Arthur Moseley (2), Rima Kaddurah-Daouk, PhD (2) For the Alzheimer Disease Neuroimaging Initiative and the Alzheimer’s Disease Metabolomics Consortium
(1) Department of Pathology & Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA; (2) Duke University Medical Center, Durham, NC, USA; (3) Sanford-Burnham Medical Research Institute, Orlando, FL, USA; (4) BIOCRATES Life Sciences AG, Innsbruck, Austria; (5) Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN, USA; (6) Phenomenome Discoveries Inc., Saskatoon, SK, Canada

P2-43
CORRELATION OF LOAD-RELATED APOE4 AND WTGSTO1 VARIANTS WITH MILD COGNITIVE IMPAIRMENT DEPENDS ON THE CLASSIFYING NEUROPSYCHOLOGICAL TEST
Ellen Umlauf (1), Eduard Rappold (1), Bettina Schiller (1), Petra Fuchs (2), Michael Rainer (3), Brigitte Wolf (4), Maria Zeilinger (1)
(1) Medical University of Vienna, Institute of Physiology, Vienna, Austria; (2) SMZ Otto Wagner Spital, 3rd Department of Psychiatry, Vienna, Austria; (3) SMZ Ost, Karl Landsteiner Institut für Gedächtnis- und Alzheimerforschung, Vienna, Austria; (4) Medical University of Vienna, Department of Surgery and Surgical Research, Vienna, Austria

P2-44
PLASMA TAU IN ALZHEIMER’S DISEASE
Niklas Mattsson, MD, PhD (1), Henrik Zetterberg, MD, PhD (2), Shorenna Janelidze, PhD (1), Ulf Andreasson, PhD (2), Erik Stromrud, MD, PhD (3), Sebastian Palmqvist, MD, PhD (3), David Baker, PhD (3), Cristina A. Tan Hehir, PhD (4), Andreas Jeromin, PhD (5), David Hanlon, PhD (5), Leslie M. Shaw, PhD (6), John Q. Trojanowski, MD, PhD (6), Michael W. Weiner, MD (7), Oskar Hansson, MD, PhD (1), Kaj Blennow, MD, PhD (2)
(1) Lund University, Sweden; (2) University of Gothenburg, Sweden; (3) Janssen R&D (J&J); (4) GE Global Research; (5) Quanterix; (6) University of Pennsylvania, USA; (7) University of California San Francisco, USA

P2-45
ULTRA-SENSITIVE SINGLE MOLECULAR ARRAY (SIMOA) TECHNOLOGY FOR THE DETECTION OF TAU IN BLOOD: CNS APPLICATIONS
Amelie Castro, Lei Chang, PhD, David Hanlon, PhD, David Wilson, PhD, Andreas Jeromin, PhD
Quanterix Corporation Lexington, MA, USA

P2-46
olfactory deficits predict response to cholinesterase inhibitors in MCI due to Alzheimer disease
Davangere P. Devanand, MD (1); Seonjoo Lee, Ph.D (2), Yaakov Stern, Ph.D (3); Gregory H. Pelton, M.D. (1)
(1) Division of Geriatric Psychiatry, Columbia University Medical Center; (2) Biostatistics, Mailman School of Public Health, Columbia University; (3) Department of Neurology, Taub Institute, Columbia University Medical Center, New York City, NY, USA
POSTER SESSION 2: Friday, November 6th

P2-47 HEALTH PLAN FOR ADULT SUBJECTS WITH DOWN SYNDROME AND DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI) PROJECT
Sebastian Videl A MD PhD (1); Maria Carmona-Iragui MD PhD (1,2); Laura Videl A BSc (1); Susana Fernández MD (1); Bessy Benejam BSc (1); Daniel Alcolea MD (2); Valie Camacho MD (3); Sandra Giménez MD (4); Sofia González-Ortíz MD (5); Eduard Vilaplana BSc (1); Jordi Clarimon BSc (2); Rafael Blesa MD PhD (2); Alberto Liéb MD PhD (2); Juan Fortea MD PhD (1,2) (1) Fundació Catalana Síndrome de Down, Barcelona, Spain; (2) Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain; (3) Department of Nuclear Medicine, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain; (4) CIN Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain; (5) Radiology Department, Hospital del Mar, Barcelona, Spain

P2-48 SERUM PLASMALOGENS, COGNITION, AND COGNITIVE DECLINE IN ALZHEIMER’S DISEASE
Dayan B. Goodenow, PhD (1)*, Vijitha Senanayake, PhD (1), Mitchell A. Kling, MD (2), Jon B. Toledo, MD (3), Tara Smith, PhD (1), Asuka Mochizuki, MS (1), Jessica Tenenbaum, PhD (4), Emily Burke, BS (4), Xianning Han, PhD (5), Rebecca Baillie, PhD (6), Joseph Lucas, PhD (4), Murali Dora (7), John T. Trojanowski, MD (3), Leslie M. Shaw, PhD (5), Sungeun Kim, PhD (8), Andrew J. Saykin, PsyD (8), Rima Kaddurah-Daouk, PhD (7)*, and the Alzheimer Disease Metabolomics Consortium (1) Phenomenome Discoveries Inc., Saskatoon, Saskatchewan, Canada; (2) Department of Psychiatry and (3) Department of Pathology & Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; (4) Duke University Medical Center, Durham, NC; (5) Sanford-Burnham Medical Research Institute, Orlando, FL; (6) Rosa & Co. LLC, San Carlos, CA; (7) Duke Institute for Brain Sciences, Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC; (8) Indiana Alzheimer Disease Center, Indiana University School of Medicine, Indianapolis, IN

THEME 11: Clinical Trials and New Therapies

P2-49 PERIPHERAL INFLAMMATORY STATUS IN AMYLOID POSITIVE PATIENTS: EFFECTS OF THE GUT MICROBIOTA
Cattaneo A, PhD (1,2), Cattane N, PhD (1), Altomare D, MS (3), Festani C, MS (3), Piviani M, PhD (3), Pasqualetti P, PhD (4), Muscio C, MS (5), Boccardi M, PhD (5), Prella A, MD (6), Villani D, MD (7), Gentile S, MD (8), Bellandi D, MD (9), Turia M, MD (10), Dalla Volta G, MD (11), Manetti O, MD (12), De Fanti C, MD (13), Padovani A, MD (14), Frisoni GB, MD (3), and the INDIANF-FB working group (1) IRCCS Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy; (2) Stress, Psychiatry and Immunology Laboratory, Department of Experimental Medicine, Institute of Psychiatry, King’s College London, London, UK; (3) LENITEM-Laboratory of Epidemiology, Neuroimaging and Telemedicine, IRCCS Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy; (4) SeSMIT, AFeR, Fatebenefratelli Hospital, Isola Tiberina, Rome; and Unit of Clinical and Molecular Epidemiology; (5) Fondazione Europea Ricerca Biomedica (FERRB), Centro Eccellenza Alzheimer, Ospedale Brianzolo, Gazzaniga, Bergamo, Italy; (6) A.O. Ospedale Maggiore di Crema, Italy; (7) Casa dicura Figlie di San Camillo, Crema, Italy; (8) Casa di cura Ancelle della Carità, Crema, Italy; (9) Fondazione Istituto Ospedaliero di Osoppo Onlus, Osoppo, Crema, Italy; (10) Ospedale di Valcaverna Esine, Brescia, Italy; (11) Istituto Clinico Città di Brescia, Brescia, Italy; (12)ATM, IRCCS Centro San Giovanni di Dio, Fatebenefratelli, Brescia, Italy; (13) Centro Alzheimer di Gazzaniga, Bergamo, Italy; (14) Department of Medical and Experimental Sciences, Unit of Neurology, Brescia University, Brescia, Italy; (15) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals of Geneva Genome, Switzerland

P2-50 PHARMACOKINETIC PROFILE OF A NOVEL LOW DOSE EXTENDED RELEASE FORMULATION OF AGB101 (LEVITIRACETAM)
Sharon Rosenweig-Lipson, PhD (1), Steven Mulcahy (1), Ken Payne, PhD (1), Sarah Bullock (2), Elsie Melsopp, PhD (3), Jack James (3), Michelle Gallagher, PhD (1) (1) AgeneBio, Inc, Baltimore, MD, USA; (2) Worldwide Clinical Trials, Early Phase Services, San Antonio, TX, USA; (3) AAI Pharma, Wilmington, NC, USA

P2-51 NEW NEUROPROTECTIVE STRATEGY IN EARLY AD: ARGUMENTS FOR A TRITHERAPY
Jacques Hugon MD PhD, Sarah Gourmaud PhD, Marion Tible PhD, Anne Sophie Carret MD PhD, François Mouton-Liger PhD, Pascal Millet MD PhD, Julien Dumurgier MD PhD, Claire Paquet MD PhD Memory Centre and Inserm UMR 942 Lariboisière Hospital, APHP and University of Paris Diderot, Paris France

P2-52 REPEATED EMOTIONAL STRESS EXACERBATES AMYLOID-B PEPTIDE INDUCED BRAIN PATHOLOGY IN ALZHEIMER’S DISEASE. POTENTIAL NEUROPROTECTIVE EFFECTS OF NANOWIRED DELIVERY OF CEREBROLYSIN
Jacques Hugon MD PhD, Sarah Gourmaud PhD, Marion Tible PhD, Anne Sophie Carret MD PhD, Francois Mouton-Liger PhD, Pascal Millet MD PhD, Julien Dumurgier MD PhD, Claire Paquet MD PhD Memory Centre and Inserm UMR 942 Lariboisière Hospital, APHP and University of Paris Diderot, Paris France
P2-53  TRAUMATIC BRAIN INJURY EXACERBATES AMYLOID B-PEPTIDE INDUCED BRAIN PATHOLOGY IN ALZHEIMER'S DISEASE. SUPERIOR NEUROPROTECTIVE EFFECTS OF TiO2 NANOWIRED MESENCHYMAL STEM CELLS WITH POLY (D,L-LACTIDE-CO-GLYCOLIDE) NANOPARTICLES LOADED CEREBROLYSIN DELIVERY  
(1) Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden; (2) Dept. of Neurosciences, University of Basque Country, Bilbao, Spain; (3) Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania; (4) Dept. Neurology, Bethune Int Peace Hospital Army, Shijiazhuang, Hebei province, China; (5) University of Maryland, Dept. of Pathology, Baltimore, MD, USA; (6) Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA; (7) School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of Technology, Banaras Hindu University, Varanasi, India; (8) Dept. Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA; (9) Pharmaceutical Technology and Nanomedicine, TeFarTI research Center, Department of Life Sciences, University of Modena and Reggio Emilia, Italy; (10) Ever NeuroPharma, Oberburgau, Austria

P2-54  THE EFFECTS OF MUSIC BASED RELAXATION (MUSIC CARE® APP) ON AUTOBIOGRAPHICAL MEMORY AND ANXIETY IN ALZHEIMER’S DISEASE: RANDOMIZED CONTROLLED TRIAL  
Stéphane Guétin (1,3), Julie Destoutz (3), Bérénice Cagnat (2), Florence Ricciardi (2), Claire Cadilhac (1,2), Jacques Touchon (1)  
(1) Service de Neurologie (CMRR), CHRU Montpellier, INSERM U1061, Montpellier, France; (2) Département Universitaire d’Orthophonie, UFR Médecine, Université Montpellier, France; (3) MUSIC CARE, Research & Development, Paris, France

P2-55  ABSOLUTE BIOAVAILABILITY AND SAFETY OF A NOVEL RIVASTIGMINE INTRANASAL SPRAY IN HEALTHY ELDERLY INDIVIDUALS  
Timothy Morgan, PhD (1), Bob Soh, MBBS (2)  
(1) Lachesis Biosciences Pty Ltd, Warrnambool, VIC, AU; (2) Nucleus Network Ltd, Melbourne, VIC, AU

P2-56  NEW ANALOGUES OF 7-METHOXYTACRINE AND A POTENTIAL THERAPEUTIC USE IN ALZHEIMER DISEASE  
Jan Ricny (1), Zdena Kristofikova (1), Jana Sirova (1), Jan Korabecny (2), Kamil Kuca (2), Kamil Musilek (3), Daniela Ripova (1)  
(1) NUDZ, Topolova 748, 250 67 Klecany, Czech Republic; (2) Faculty of Military Health Science, Hradec Kralove, Czech Republic; (3) Faculty of Science, University of Hradec Kralove, Hradec Kralove, Czech Republic

P2-57  APPLICATION OF TAI CHI 6 FORMS IN APPARATUS AND WII FOR BALANCE TRAINING OF ELDERS WITH ALZHEIMER DISEASE  
Alice M.K. Wong, MD (1,2), Yin-Chou Lin, MD,PhD (1), Chia-Wei Wang,MS (1), Albert CK Chen,MD (1), Jean-Lon Chen,MD,PhD (1), Yu-Cheng Pei,MD,PhD (1)  
(1) Department of Physical Rehabilitation medicine, Chang Chung Memorial Hospital,Taiwan,ROC; (2) Institute of Healthy Aging,Chang Gung University,Taiwan,ROC

P2-58  AMYPOSOMES®: A NEW NANOMEDICINE FOR THERAPY OF ALZHEIMER DISEASE, WAITING FOR CLINICAL TRIALS  
Massimo Masserini PhD, Simona Mancini, Francesca Re, PhD  
School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

P2-59  SUVN-502 - SAFETY, TOLERABILITY AND PHARMACOKINETICS OF A POTENT AND SELECTIVE 5-HT6 RECEPTOR ANTAGONIST IN HEALTHY SUBJECTS  
Ramakrishna Nirogi, PhD, Koteswara Mudigonda, PhD, Kiran Kumar Penta, MS, Gopinadh Bhuyrapuneni, PhD, Devender Reddy Ajala, MS, Nageswararao Muddana, MS, Veera Raghava Chowdary Palacharla, MS, Vinod Kumar Goyal, MS, Santosh Kumar Pandey, MS, Renny Abraham, MS, Pradeep Jayarajan, MS, Rajesh Kumar Badange, MS, and Ramasastry Kambhampati, PhD  
Discovery Research, Suven Life Sciences Ltd, Warrnambool, VIC, AU

P2-60  EFFECT OF COMBINATION THERAPY OF CAFFEINATED COFFEE AND SELECTIVE 5-HT4 AGONIST, PRUCALOPRIDE, IN AN ALZHEIMER’S DISEASE MOUSE MODEL: POSSIBLE IMPLICATIONS ON AMYLOID BETA FORMATION  
M.sc Nouran A.H Al Shehaby (1), Ass. Prof. (3,4), Khaled Abou Aisha, PhD (3), Mona Rady, Prof. (1), Laila Mhran and Ass. Prof. (1,2), Nesrine El Sayed  
(1) Pharmacology & Toxicology Department, Faculty of Pharmacy & Biotechnology, German University in Cairo, EG; (2) Pharmacology & Toxicology Department, Faculty of Pharmacy, Cairo University, CAI, EG; (3) Pharmaceutical Biology Department, Faculty of Pharmacy & Biotechnology, German University in Cairo, CAI, EG; (4) Pharmaceutical Biology Department, Faculty of Pharmacy, Cairo University, CAU, EG

P2-61  IN SILICO EVALUATION AND SYNTHESIS OF NEW MOLECULES AS THERAPEUTIC ALTERNATIVES IN THE ALZHEIMER DISEASE  
García Marín Johanan Daniel MS- (3), Hernández Rodríguez Maricarmen,Sc,M (2), Rosales-Hernández Martha Cecilia,Sc,M,ScD (2),Correa-Basurto José,Sc,M,ScD (1), Manuel Jonathan Fragoso Vázquez,Sc,M,ScD (3)  
(1) Laboratorio de Modelado Molecular y Bioinformática; (2) Laboratorio de Biofisica y Biocatalisis, Escuela Superior de Medicina, Instituto Politécnico Nacional, Plan de San Luis y Díaz Miron s/n, México City, D.F., México; (3) Laboratorio de Investigacion Bioquimica. Laboratorio de Investigacion Bioquimica, Seccion de Estudios de Posgreado e Investigacion Plan de San Luis y Diaz Miron s/n, Mexico City, D.F., Mexico
P3-1
MINIMIZING TRIAL COSTS BY ACCELERATING/IMPROVING ENROLLMENT/RETENTION IN AD TRIALS IN GLOBAL CLINICAL TRIALS FOR ALZHEIMER’S DISEASE
Debbie N Coté, RN, Clinical R&D Consultant, San Francisco, California US
Contributing Author of Chapter 12: Minimizing trial costs by Accelerating/Improving Enrollment/Retention in AD trials In Global Clinical Trials for Alzheimer’s Disease, 1st Edition Design, Implementation, and Standardization

P3-2
APPRAISAL OF THE UTILITY OF THE AMYLOID IMAGING TASKFORCE RECOMMENDATIONS FOR AMYLOID-PET ASSESSING THE FINANCIAL BURDEN ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT
Boccardi Marina, PhD (1), Allomare Daniele, MS (1), Guerra Ugo Paolo, MD (2), Pievani Michela, PhD (1), Albanese Emiliano, MD (3), Festari Cristina, MS (1), Antelmi Luigi, MS (1), Pasqualetti Patrizio, MS (4), Muscio Cristina, MS (1,5), Nobili Flavio, MD (6), Padovani Alessandro, MD (7), Frisoni Giovanni Battista, MD (1,8), & the INDIA-FBP Working Group*
(1) Laboratory of Alzheimer’s Neuroimaging and Epidemiology, IRCCS Fatebenefratelli, Brescia, Italy; (2) Department of Nuclear Medicine, Poliambulanza Foundation, Brescia, Italy; (3) Department of Mental Health and Psychiatry, University Hospital of Geneva, Geneva, Switzerland; (4) Fatebenefratelli Hospital of Isola Tiberina, Roma, Italy; (5) European Foundation Biomedical Research (FERB), Center of Excellence Alzheimer, Ospedale Briolini of Gazzaniga, Bergamo, Italy; (6) Clinical Neurology, Department of Neuroscience (DINOOGM), University of Genoa, Genoa, Italy; (7) Centre for Neurodegenerative Disorders, Neurology Unit, University of Brescia, Brescia, Italy; (8) Memory Clinic and LANVIE - Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva, Geneva, Switzerland
*Full list of INDIA-FBP participants:
http://www.centraлиземерзайер.org/site/contenuti/lp_lilly_publications/INDIA-FBP_WORKING_GROUP.pdf
Project link: http://www.centraлиземерзайер.org/site/lp_lilly.php

P3-3
ASSESSING THE FINANCIAL BURDEN ASSOCIATED WITH MILD COGNITIVE IMPAIRMENT
Thang G.N. Ton, PhD (1), Thomas DeLeire, PhD (2), Suepattra G. May, PhD, MPH (1), Ninggi Hou, MHS, PhD (1), Jennifer Benner, BA (1), Er Chen, PhD (3), Joshua Chodosh, MD (4),
(1) Precision Health Economics, Los Angeles, CA, USA; (2) McCourt School of Public Policy, Georgetown University, Washington, DC, USA; (3) Genentech, Inc., San Francisco, CA, USA; (4) Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA

P3-4
MULTICULTURAL DIFFERENCES TOWARD ALZHEIMER’S EDUCATION AND CLINICAL TRIAL PARTICIPATION ON ALZHEIMER’S DISEASE'S UNIVERSITY (WWW.ALZU.ORG)
Vanessa Cooper BS (1), Candace L Haddox MD (2), Jaclyn L. Chen BS (3), Max Pensack BS (3), Ciara Gaglio BA (3), Alon Seifan MD MS (3), Richard S. Isaacson MD (3)
(1) New York Medical College, New York, New York, USA; (2) Mayo Clinic, Rochester, MN, USA; (3) Weill Cornell Medical College, New York, New York, USA

P3-5
USING SOCIAL MEDIA TO EDUCATE ABOUT CLINICAL TRIALS ON ALZHEIMER’S PREVENTION & TREATMENT VIA ALZHEIMER’S DISEASE’S UNIVERSITY (WWW.ALZU.ORG)
Candace L. Haddox, MD,(1) Ciara Gaglio, BA, (2) Jaclyn L. Chen BS,(2) Max Pensack BS (2), Alon Seifan, MD, MS, (2) Richard S. Isaacson, MD, (2)
(1) Mayo Clinic, Rochester, MN, USA; (2) Weill Cornell Medical College, New York, New York, USA

P3-6
MINIMIZING TRIAL COSTS BY ACCELERATING/IMPROVING ENROLLMENT/RETENTION IN AD TRIALS
Global Clinical Trials for Alzheimer’s Disease: Design, Implementation, and Standardization
Edited by Menghis Bairu, M.D., Michael Weiner, M.D.
Chapter 12: Minimizing Trial Costs by Accelerating/Improving Enrollment/Retention in AD Trials Debbie N Coté Cote, RN

P3-7
MODIFIABLE RISK FACTORS FOR DEMENTIA: A STRATEGY TO COUNTERACT THE POOR PROSPECTS?
Jesper Skov Neergaard, MSc (1), Katrine Dragsbaek, MSc (1), Henrik Bo Hansen, MSc(1), Kim Henriksen, PhD(1), Claus Christiansen, MD, DMSc (1), Morten Asser Karsdal, PhD (1)
(1) Nordic Bioscience A/S, Herlev, Denmark

P3-8
GENETIC EPIDEMIOLOGY OF ALZHEIMER’S DISEASE: GWAS SIGNIFICANT RISK FACTORS IN CHROMOSOME 19 AND THE APOE LOCUS CURSE
(1) Research Center and Memory Clinic of Fundació ACE, Institut Catalá de Neurociències Aplicades, Barcelona, Spain. (2) Institute of Human Genetics, University of Bonn, Bonn, Germany. (3) Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany. (4) Department of Psychiatry and Psychotherapy, University of Bonn, Bonn, Germany. (5)German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. (6) Memory Unit, University Hospital La Paz-Cantoblanco, Madrid, Spain. (7) Dementia Unit, University Hospital Virgen de la Arrixaca, Murcia, Spain. (8) Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM) Spain, Hospital Clínico San Carlos, Madrid, Spain

THEME 8: Clinical Trials and Health Economics

THEME 9: Clinical Trials: Epidemiology and miscellaneous
POSTER PRESENTATIONS

POSTER SESSION 3: Saturday, November 7th

P3-9 APOE GENOTYPE MODIFIES THE RELATIONSHIP BETWEEN VASCULAR RISK FACTORS AND COGNITIVE DECLINE
Juarez-Cedillo Teresa, PhD (1), Rosas-Carrasco Oscar, MsC (2), Gutiérrez- Gutiérrez Lidia A., MsC (3)
(1) Instituto Mexicano del Seguro Social, Centro Médico Nacional Siglo XXI, México D.F.; (2) Instituto Nacional de Geriatría, SSA, México, (3) Instituto Nacional de la Nutrición Salvador Zubirán, SSA, México

P3-10 CLINICAL-PATHOLOGICAL CORRELATION IN A DEMENTIA UNIT IN BARCELONA
Isabel Hernández, MD, PhD (1), Ana Mauleon, MD (1), Maitê Rosende, MD (1), Liliana Vargas, MD (1), Montse Alegret, PhD (1), Ana Espinosa, MSc (1), Gemma Cuberas, PhD (1), Pilar Cañabate, PhD (1), Mariola Moreno, SW (1), Ellen Gelpi, MD (2)
(1) Fundació ACE. (ICNA), Barcelona, (2) IDIBAPS. Banc de Teixits Neurològics de Catalunya

P3-11 RESTING-STATE CARDIAC WORKLOAD IS RELATED TO BOTH INCREASED NEOCORTICAL AGGREGATION OF β-AMYLOID PROTEIN AND RELATIVE IMPAIRMENTS IN SPATIAL WORKING MEMORY IN PRE-CLINICAL ALZHEIMER’S DISEASE
Claudia Y. Santos, (1), Yen Yang Lim, (2,3), Wen-Chih Wu, (4), Shahena Polynice, (5), Paul Maruff, (3,6) Peter J. Snyder, (1,2)
(1) Interdisciplinary Neuroscience Program, University of Rhode Island, Kingston, RI, USA; (2) Department of Neurology, Alpert Medical School of Brown University, Providence, RI, USA; (3) The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, Victoria, Australia; (4) Division of Cardiology, Department of Medicine, Alpert Medical School of Brown University, Providence, RI, USA; (5) Department of Neuroscience, Brown University, Providence, RI, USA; (6) Cogstate Ltd., Melbourne, Victoria, Australia

P3-12 BURDEN OF ALZHEIMER’S DISEASE: CLINICAL COMORBIDITIES AND CO-MEDICATIONS
Nawal Bent-Ennakhil, MS (1), Lin Xie, MA, MS (2), Myrleen Sanon, MPH (3), Florence Coste, MS (1), Yuxei Wang, ME (2), M. Furaha Kariburyo, MPH (2), Peter Neumann, ScD (4), Howard Fillit, MD, M, (5,6)
(1) Global Epidemiology, Lundbeck SAS, Issy-Les-Moulineaux, France; (2) StatinMed Research, Ann Arbor, MI, USA; (3) Health Economics and Outcomes Research, Otsuka America Pharmaceuticals, Princeton, NJ, USA; (4) Tufts-New England Medical Center, Boston, Massachusetts, USA; (5) Mount Sinai Medical Center, New York City, USA; (6) Alzheimer’s Drug Discovery Foundation, New York, NY, USA

P3-13 AN UPDATE ON ALZHEIMER’S DISEASE PATIENT & TREATMENT CHARACTERISTICS IN THE UNITED STATES
Myrleen Sanon, MPH (1), Lin Xie, MA, MS, (2) Nawal Bent-Ennakhil, MS (3), Florence Coste, MS,(3) Yuxei Wang, ME (2), M. Furaha Kariburyo, MPH (2), Peter Neumann, ScD, (4) Howard Fillit, MD, M, (5,6)
(1) Health Economics and Outcomes Research, Otsuka America Pharmaceuticals, Princeton, NJ, USA; (2) StatinMed Research, Ann Arbor, MI, USA; (3) Global Epidemiology, Lundbeck SAS, Issy-Les-Moulineaux, France; (4) Tufts New England Medical Center, Boston, Massachusetts, USA; (5) Mount Sinai Medical Center, New York City, USA; (6) Alzheimer’s Drug Discovery Foundation, New York, NY, USA

P3-14 IDENTIFICATION OF A FAST PROGRESSION DEMENTIA PHENOTYPE: A COMPARATIVE EVALUATION OF TWO SHORT COGNITIVE SCREENING INSTRUMENTS
Jesper Skov Neeraard, MSc (1), Katrine Dragsbaek, MSc (1), Henrik Bo Hansen, MSc (1), Kim Henriksen, PhD (1), Claus Christiansen, MD, DMSc (1), Morten Asser Karsdal, PhD (1)
(1) Nordic Bioscience A/S, Herlev, Denmark

P3-15 GENETIC VALIDATION OF DRUG TARGETS FOR SECONDARY PREVENTION OF ALZHEIMER’S DISEASE
(1) Research Center and Memory Clinic of Fundació ACE, Barcelona, Spain; (2) German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; (3) VU University Medical Centre, Amsterdam,The Netherlands; (4) University of Bonn, Bonn, Germany; (5) University of Bonn, Bonn, Germany; (6) University of Bonn, Bonn, Germany; (7) VU University Medical Centre Amsterdam, The Netherlands; (8) Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany; (9) Charité University Medicine, Berlin, Germany; (10) University of Heidelberg, Mannheim, Germany; (11) University of Freiburg, Freiburg, Germany; (12) University of Gottingen, Gottingen, Germany; (13) Medical Centre Hamburg- Eppendorf, Hamburg, Germany; (14) University of Cologne, Cologne, Germany; (15) VU University Medical Centre, The Netherlands; (16) University of Leipzig, Leipzig, Germany; (17) University of Bonn, Bonn, Germany

P3-16 REPRESENTATIVENESS OF CLINICAL TRIAL POPULATIONS IN MILD AD DEMENTIA – A COMPARISON OF 18 MONTH OUTCOMES WITH REAL WORLD DATA FROM THE GERAS OBSERVATIONAL STUDY
Annabel Barrett (1), Mark Belger (1), Grazia Dell’Agnello (2), Kristin K Wroblewski (3), Sethuraman Gopalan (3), David Henley (3), Joel Raskin (3), Catherine Reed (1)
(1) Eli Lilly and Company Limited, Windlesham, UK; (2) Eli Lilly Italia, Sesto Fiorentino, Italy; (3) Eli Lilly and Company, Indianapolis, US
P3-17 THE DEMENTIA OF ALZHEIMER’S DISEASE MAY BE DUE TO A DECLINE IN THE MONOSACCHRIDE TRANSFERASE, ALG7, THAT IS INVOLVED IN THE N-GLYCOSYLATION PATHWAY
Jordan L. Holtzman, M.D., Ph.D.
University of Minnesota, Minneapolis, Minnesota, USA

P3-18 BUTYRYLCHOLINESTERASE K-VARIANT - A GENETIC MARKER OF POOR RESPONSE TO DONEPEZIL IN MILD COGNITIVE IMPAIRMENT.
Sophie Sokolow, RPh, PhD (1), X. Li, PhD (3,4), L. Chen, BSc (1), K. D. Taylor, PhD (3,4), J.I. Rotter, MD (3,4), R.A. Rissman, PhD (5,6), P.S. Aisen, MD (7), L. G. Apostolova, PhD (8)
(1) School of Nursing, University of California at Los Angeles, Los Angeles, CA, USA; (2) Brain Research Institute, University of California at Los Angeles, Los Angeles, CA, USA; (3) Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA; (4) Division of Genomic Outcomes and Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA, USA; (5) Alzheimer’s disease cooperative study, University of California San Diego, San Diego, CA, USA; (6) Department of Neuroscience, School of Medicine at UCSD, University of California San Diego, San Diego, CA, USA; (7) Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, CA, USA; (8) Indiana University School of Medicine, Indiana Alzheimer’s Disease Center, Indianapolis, IN, USA

P3-19 A NEW CLINICAL DIAGNOSTIC FRAMEWORK FOR ASSESSING PRECLINICAL ALZHEIMER’S DISEASE IN HEALTHY AT-RISK ADULTS: A WORK IN PROGRESS
Aron Seifian, MD, MS, (1) Robert Krikorian, PhD, (2) Max Pensack BS (1), Jaclyn L. Chen BS, (1) Josefina Meléndez-Cabrero, PhD, (3) Richard S. Isaacson, MD, (1)
(1) Weill Cornell Medical College, New York, NY, USA; (2) University of Cincinnati College of Medicine, Cincinnati, OH, USA; (3) Geropsychology Memory Clinic, San Juan, PR

THEME 10: Clinical Trials and Animal Models

P3-20 INTRANASAL DELIVERY OF STEM CELL FACTORS DECREASE ABETA AMYLOIDOSIS IN ANIMAL MODELS
Tristan Belmont, PhD (1,2), Theo Lasser (1), Taoufiq Harach, Yuri Kudinov (3) MD, PhD, Alexei Lukashev, PhD (2)
(1) Ecole Polytechnique Federale de Lausanne, Lausanne, Switzerland; (2) Stemedica International, Epalinges, Switzerland; (3) Stemedica Cell Technologies, California, USA

P3-21 BI 409306, A NOVEL PHOSPHODIESTERASE 9A INHIBITOR, INCREASES CGMP IN CSF: RESULTS FROM NON-CLINICAL AND CLINICAL TRANSLATIONAL PROOF-OF-MECHANISM STUDIES
Holger Rosenbrock, PhD (1), Kajja Boland, PhD (2), Viktoria Moschetti, MD (1), Holger Fuchs, PhD (1), Frank Runge, PhD (1), Michael Sand, MPH, PhD (3), Chantaratsamon Dansinkul, PhD (2), Solen Pichereau, PhD (2), Lien Gheyte, MD, PhD (4), Glen Wunderlich, PhD (5)
(1) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; (2) Boehringer Ingelheim Pharm GmbH & Co. KG, Biberach an der Riss, Germany; (3) Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA; (4) SGS Life Science Services – Clinical Research, Antwerpen, Belgium; (5) Boehringer Ingelheim (Canada) Ltd, Burlington, ON, Canada

P3-22 MICRORNA-574 IS INVOLVED IN COGNITIVE IMPAIRMENT IN 5-MONTH-OLD APP/PS1 MOUSE THROUGH REGULATION OF NEURITIN
Fei Li (1), Gang Wei (2), Ye Bai (1), Yunjun Li (1), Fengyuan Huang (1), Jian Lin (1), Qiuke Hou (1), Rudong Deng (1), Jian Hong Zhou (1), Sai Xia Zhang (1), Dong Feng Chen (1)
(1) Department of Anatomy, Guangzhou University of Traditional Chinese Medicine, Guangzhou, China; (2) Research & Development of New Drugs, Guangzhou University of Traditional Chinese Medicine, Guangzhou, China

P3-23 MODULATION OF THE IMPAIRMENT OF NEUROENDOCRINE-IMMUNE SYSTEM IN 3XTG-AD: EFFECTS OF POSTNATAL HANDLING AND NMDA-INDUCED STRESS
Lydia Giménez-Llort, PhD (1), Raquel Baeta-Corral (1), Mónica De la Fuente MD, PhD (2)
(1) Institute of Neuroscience & Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Spain; (2) Department of Physiology (Animals Phsiology II) Complutense University of Madrid, Spain

P3-24 ENRICHED ENVIRONMENT (EE): IMMEDIATE AND LONG TERM EFFECTS ON SPATIAL MEMORY
Edvaldo Soares, PhD
Sao Paulo State University, Laboratory of Cognitive Neuroscience-LaNec, Marilia, São Paulo, Brazil

P3-25 SUNV-502, A NOVEL 5-HT6 RECEPTOR ANTAGONIST: PRECLINICAL EVIDENCE FOR THE DESIGN OF PHASE II STUDIES FOR ALZHEIMER’S DISEASE
Ramakrishna Nirogi, PhD, Pradeep Jayarajan, MS, Renny Abraham, MS, Gopinadh Bhypurupeni, PhD, Vijay Benade, MS, Rajesh babu Medapatti, MS, Nageswararao Muddana, MS, Saivishal Daripelli, MS, Ramasastry Kambhampati, PhD.
Discovery Research, Suven Life Sciences Ltd, Hyderabad, India

P3-26 MODULATION OF THE IMPAIRMENT OF NEUROENDOCRINE-IMMUNE SYSTEM IN 3XTG-AD: EFFECTS OF POSTNATAL HANDLING AND NMDA-INDUCED STRESS
Lydia Giménez-Llort, PhD (1) Raquel Baeta-Corral (1), Mónica De la Fuente MD, PhD (2)
(1) Institute of Neuroscience & Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Spain; (2) Department of Physiology (Animals Phsiology II) Complutense University of Madrid, Spain

P3-27 AN AUTOPHAGY-INDUCING HERBAL EXTRACT IMPROVES COGNITIVE FUNCTION IN AN AB42-INJECTION MOUSE MODEL OF ALZHEIMER’S DISEASE
Yung-Feng Liao, PhD (1), Rita P.-Y. Chen, PhD (2), Chang-Jen Huang, PhD (2)
(1) Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, TAIWAN, (2) Institute of Biological Chemistry, Academia Sinica, Taipei, TAIWAN
This year 3 different poster sessions are presented during the event:

- **POSTER SESSION 1**: Thursday, November 5th
  P1-1 to P1-70
- **POSTER SESSION 2**: Friday, November 6th
  P2-1 to P2-61
- **POSTER SESSION 3**: Saturday, November 7th
  P3-1 to P3-26

**Welcome Reception**

**Thursday, November 5th**
From 8 to 10:45 pm

The reception is for pre-registered attendees only.

**Mercat Princesa**
Flassaders 21,
08003 Barcelona

---

**Practical details:**

**Pre-registration**

Wednesday, November 4th 3 - 6 pm

To avoid the rush at the registration desk on Thursday morning we recommend you come pick up your badge and attendee’s bag the day before.

**Registration desk opening hours:**

- Thursday, November 5th
  6:30 am - 6:30 pm
- Friday, November 6th
  6:30 am - 6:15 pm
- Saturday, November 7th
  7:00 am - 12:30 pm

**Meeting Room**: Catalunya

**Coffee Breaks, Lunches and Poster Sessions**: Gaudi Mezzanine Level
Clinical Trials on Alzheimer’s Disease (CTAD) would like to thank the following companies for their ongoing support helping CTAD meet its mission and goals.